Library › Clinical bacteriology: specimens, identification, antimicrobial susceptibility testing and bacterial pathogens
Clinical bacteriology: specimens, identification, antimicrobial susceptibility testing and bacterial pathogens
Last reviewed 2026-11-10 by a board-certified pathologist. 305 references.
Microbiology Specimens, Stains, Culture Media and Blood Cultures
Definition. Bacterial diagnosis begins with the specimen. Collection site, volume, container, transport time and temperature determine whether culture recovers the pathogen or the resident microbiota. The IDSA and ASM guide to utilization of the microbiology laboratory was updated in 2024 (Miller 2024) and replaced the 2018 edition (Miller 2018).
Related page: Bacterial Identification: Biochemical Tests, MALDI-TOF Mass Spectrometry, Sequencing and Rapid Molecular Panels (biochemical tests, MALDI-TOF mass spectrometry, sequencing and syndromic panels) Related page: Antimicrobial Susceptibility Testing, Breakpoints and Resistance Mechanisms (susceptibility testing, breakpoints and resistance mechanisms) Related page: Gram-Positive Bacteria and Anaerobes: Staphylococci, Streptococci, Enterococci, Gram-Positive Rods and Clostridioides difficile (anaerobe culture and rule-out tests for gram-positive select agents) Related page: Gram-Negative Bacteria: Enterobacterales, Nonfermenters, Neisseria, Haemophilus and Fastidious Gram-Negative Rods (enteric pathogens and rule-out tests for gram-negative select agents) Related page: Mycobacteria, Nocardia, Spirochetes, Mycoplasma, Chlamydia and Other Intracellular Bacteria (modified acid-fast stains for Nocardia, treponemal serology and syphilis testing algorithms) Related page: Respiratory specimen types, sputum adequacy, inhaled particles, storage disease and alveolar hemorrhage (sputum adequacy criteria in cytology) Related page: Infections in Cerebrospinal Fluid Cytology (CSF cell counts and chemistry in bacterial and tuberculous meningitis) Related page: Synovial fluid cell counts and cytology: septic, rheumatoid and traumatic effusions (septic arthritis and prosthetic joint infection in synovial fluid) Related page: Organisms in Cervical Cytology (clue cells and shift in flora in cervical cytology) Related page: Stains in Cytology (special stains for fungi and mycobacteria in aspirates) Related page: Transfusion Reactions (septic transfusion reactions) Related page: Method Validation, Statistical Quality Control and Proficiency Testing in Clinical Chemistry (QC statistics, method verification and proficiency testing)
Specimen collection, transport and rejection
Transport conditions in the 2024 IDSA/ASM guide
A specimen held at room temperature for the interval specified in its section of the guide (for example, 2 hours) is refrigerated after that interval unless the section states otherwise (Miller 2024). Anaerobic culture of lower respiratory specimens is performed only on specimens collected with a protected brush or catheter, and the brush is transported in an anaerobic container or in prereduced broth (Miller 2024). Pleural fluid is delivered immediately or placed in anaerobic transport medium, and the guide lists an anaerobic transport vial at room temperature for up to 72 hours (Miller 2024).
Periprosthetic tissue compared with swabs. In 117 revision arthroplasties, tissue cultures were positive in 28 of 30 septic cases (93%) and swab cultures in 21 of 30 (70%). Tissue cultures were positive in 2 of 87 aseptic cases (2%) and swab cultures in 10 of 87 (12%) (Aggarwal 2013). Sensitivity, specificity, positive predictive value and negative predictive value were 93%, 98%, 93% and 98% for tissue and 70%, 89%, 68% and 90% for swabs (Aggarwal 2013).
Urine transport. Unpreserved urine stored at room temperature showed statistically significant increases in uropathogen colony counts when recultured at 2, 4, 24 and 48 hours. Refrigerated urine and urine in a boric acid preservative tube at room temperature differed only slightly, and those differences were not statistically significant (Eisinger 2013). Preservative tubes are used when prompt processing or refrigeration is not feasible (Eisinger 2013).
Specimens and situations that do not yield interpretable cultures
| Specimen or situation | Rule or evidence | Source |
|---|---|---|
| Poor-quality specimen of any type | Rejected; the microbiologist contacts the physician | Miller 2024 |
| Expectorated sputum heavily contaminated with oropharyngeal microbiota | Screened for acceptability and excluded | Miller 2024 |
| Bronchial wash for routine bacterial culture | Not appropriate | Miller 2024 |
| Intravenous catheter tip sent routinely at removal | No diagnostic value; not cultured | Miller 2024 |
| Stool for bacterial culture after 3 days of hospitalization | Yield 3 of 1,511 (0.2%) after day 3 compared with 97 of 3,751 (2.59%) within 3 days; 39.8% of inpatient requests rejected once the rule was applied | Seyler 2007 |
| Stool for Clostridioides difficile testing | Performed only in patients with ≥3 unformed stools within 24 hours who are not receiving laxatives | Miller 2018; Miller 2024 |
Wound specimens: superficial swab compared with deep tissue. In 56 patients with clinically infected diabetic foot ulcers, a superficial swab and a deep tissue punch biopsy were taken from each wound after cleansing with sterile saline and debridement. The swab recovered every organism isolated from the paired tissue specimen in 9 of 10 PEDIS grade 2 wounds (90.0%), and in 12 of 29 grade 3 (41.4%) and 7 of 17 grade 4 wounds (41.2%) (p = 0.02). Sensitivity of swab culture for gram-negative organisms was 33.3%, and Serratia and Ralstonia pickettii were recovered from tissue alone. Tissue culture is therefore used for wounds of grade 3 or higher, in which swab culture misses pathogens (Huang 2016).
Biosafety practices, sentinel laboratory rule-out and specimen shipping
Biosafety reference. The CDC and NIH reference for laboratory biosafety practice is Biosafety in Microbiological and Biomedical Laboratories, 6th edition (CDC 2026). Several bacteria require handling in a biological safety cabinet once they are suspected. A case of Brucella suis bacteremia initially identified as Ochrobactrum anthropi by an automated system showed that timely recognition of Brucella allows safe handling in biological safety cabinets and prevents laboratory-acquired infection (Vila 2016). Inactivation of suspected agents before MALDI-TOF analysis is covered in Bacterial Identification: Biochemical Tests, MALDI-TOF Mass Spectrometry, Sequencing and Rapid Molecular Panels.
Laboratory Response Network. Sentinel laboratories provide routine diagnostic services and determine whether specimens are sent to an LRN reference laboratory (CDC 2024). Their role is to rule out a suspected agent and to refer isolates they cannot exclude (Wagar 2016). Reference laboratories investigate or refer specimens. National laboratories, including those operated by CDC, perform specialized characterization, bioforensics and select agent activities and handle highly infectious agents (CDC 2024). In the College of American Pathologists Laboratory Preparedness Exercise, participating laboratories improved in reaching the required level of diagnosis and in referring isolates to a reference laboratory. The agents that proved most difficult for sentinel laboratories were the more fastidious gram-negative organisms, especially Francisella tularensis and Burkholderia species (Wagar 2016).
Bacterial agents on the Federal Select Agent Program list (page last reviewed January 14, 2025).
| Agent | List | Tier 1 | Source |
|---|---|---|---|
| Bacillus anthracis | Overlap | Yes | FSAP 2025 |
| Bacillus anthracis Pasteur strain | Overlap | No | FSAP 2025 |
| Bacillus cereus biovar anthracis | HHS | Yes | FSAP 2025 |
| Botulinum neurotoxin–producing Clostridium species | HHS | Yes | FSAP 2025 |
| Burkholderia mallei | Overlap | Yes | FSAP 2025 |
| Burkholderia pseudomallei | Overlap | Yes | FSAP 2025 |
| Francisella tularensis | HHS | Yes | FSAP 2025 |
| Yersinia pestis | HHS | Yes | FSAP 2025 |
| Coxiella burnetii | HHS | No | FSAP 2025 |
| Rickettsia prowazekii | HHS | No | FSAP 2025 |
Brucella species are absent from the current select agent list page (FSAP 2025).
Classification of infectious substances for transport. Category A infectious substances (UN2814 for substances affecting humans, UN2900 for substances affecting animals) are transported in a form that, on release and physical contact, can cause permanent disability or life-threatening or fatal disease in humans or animals. Category B infectious substances (UN3373) are those for which the likely consequences of exposure are neither permanent disability nor fatality (Transport Canada 2026). Category A material is shipped in a triple packaging system with a leakproof primary receptacle, a leakproof secondary packaging and a UN-specification outer box (Transport Canada 2026).
Gram stain, acid-fast stains and fluorescent direct examinations
Gram stain error rates and interpretation by specimen
Four tertiary medical centers evaluated Gram stains on 6,115 nonblood specimens with standardized criteria. Results were discrepant from culture in 5% of specimens (Samuel 2016). Of the discrepant results, 58% showed no organisms on the smear with significant growth in culture, and 42% reported organisms that culture did not recover (Samuel 2016). Review of available slides attributed 24% of discrepancies (63 of 263) to reader error, with a range of 9% to 45% across sites, and the overall Gram stain error rate ranged from 0.4% to 2.7% by site (Samuel 2016). The study identified specimen quality, smear preparation and smear interpretation as the contributing factors (Samuel 2016).
The sensitivity of the CSF Gram stain for bacterial meningitis is 60%–80% in patients who have not received antimicrobial therapy (Miller 2024).
Sputum screening by Gram stain.
| Squamous epithelial cells per low-power field (×100) | Mean number of species isolated | Flora recovered | Interpretation | Source |
|---|---|---|---|---|
| More than 10 | More than 4 | Oropharyngeal flora in nearly all specimens; potential pathogens in under 15% | Specimen is unsuitable for bacterial culture | Murray 1975 |
| Fewer than 10 | 2.7 | Flora resembling that of transtracheal aspirates | Specimen is suitable for bacterial culture | Murray 1975 |
| Transtracheal aspirate (reference) | 2.4 | Reference comparison | Not applicable | Murray 1975 |
The Bartlett system scores neutrophils per low-power field (fewer than 10, 0; 10–25, +1; more than 25, +2), mucus (+1) and squamous cells per low-power field (10–25, −1; more than 25, −2) (Mahale 2024). Among 391 expectorated sputa, the Murray-Washington criteria rejected 25% of specimens and the Bartlett criteria 17%, and the Bartlett criteria missed fewer potential pathogens (Wong 1982).
Stains and the organisms they demonstrate
| Stain | Principle | Organisms demonstrated | Source |
|---|---|---|---|
| Gram stain | Crystal violet–iodine complex retained by thick peptidoglycan after decolorization | Most aerobic and anaerobic bacteria and yeast | Miller 2018 |
| Ziehl-Neelsen and Kinyoun carbol fuchsin | Mycolic acid–rich cell wall retains carbol fuchsin after acid decolorization | Mycobacterium species | Steingart 2006 |
| Auramine and auramine-rhodamine fluorochrome | Fluorochrome binds mycolic acids and fluoresces | Mycobacterium species, with higher sensitivity than conventional carbol fuchsin microscopy at similar specificity | Steingart 2006 |
| Calcofluor white | Binds chitin and cellulose and fluoresces | Fungal elements; sensitivity 92% and specificity 95% for dermatophytes in skin scrapings compared with 88% and 95% for potassium hydroxide | Haldane 1990 |
| Acridine orange | Intercalates nucleic acid and fluoresces | Bacteria in CSF and other fluids, with higher sensitivity than Gram stain against culture | Sharma 2020 |
Gram-variable and misread morphotypes. On vaginal Gram stain, Gardnerella-like small gram-variable rods and curved gram-variable rods are the morphotypes scored in the Nugent system (Nugent 1991). The curved-rod morphotype corresponds more often to BV-associated bacterium 1 than to Mobiluncus, and the Bacteroides morphotype to Prevotella and Porphyromonas species (Srinivasan 2013). In positive blood cultures, Acinetobacter baumannii can appear as large gram-positive oval cocci and Brucella as pleomorphic gram-positive rods; a repeat Gram stain from early growth on the plate, an oxidase test and a urease test prevent the error (Bazzi 2017).
Darkfield microscopy of lesion exudate is a morphology- and motility-based examination that depends on live treponemes and is performed within 20 minutes of specimen collection (Papp 2024). Where CDC recommends darkfield microscopy, and its sensitivity by lesion stage, are covered in Mycobacteria, Nocardia, Spirochetes, Mycoplasma, Chlamydia and Other Intracellular Bacteria.
Culture media and their purposes
| Medium | Type | Purpose and selective principle | Source |
|---|---|---|---|
| Sheep blood agar | Enriched, nonselective | Growth of most aerobic bacteria; also the plate used for semiquantitative roll culture of catheter segments | Maki 1977 |
| Chocolate agar | Enriched, nonselective | Lysed or heated blood or hemoglobin with a growth supplement provides hemin (X factor) and nicotinamide adenine dinucleotide (V factor), which supports Haemophilus and Neisseria species that grow poorly or not at all on sheep blood agar | BD 2026a; Tebbutt 1983 |
| Columbia colistin-nalidixic acid (CNA) agar with 5% sheep blood | Selective | Colistin and nalidixic acid inhibit gram-negative bacteria and give luxuriant growth of gram-positive organisms from mixed flora | BD 2026b |
| Phenylethyl alcohol (PEA) agar with 5% sheep blood | Selective | Phenylethyl alcohol inhibits DNA synthesis in gram-negative bacteria and is bacteriostatic for them, which isolates gram-positive organisms, particularly cocci, from mixed flora | BD 2026c |
| MacConkey agar | Selective and differential | Bile salts and crystal violet suppress gram-positive organisms; lactose and a pH indicator separate lactose fermenters from nonfermenters | March 1986 |
| Sorbitol-MacConkey agar (SMAC) | Selective and differential | Sorbitol replaces lactose; Escherichia coli O157:H7 is a non-sorbitol fermenter and forms colorless colonies against pink fecal flora, with 100% sensitivity and 85% specificity in stool culture | March 1986 |
| Xylose-lysine-deoxycholate (XLD) agar | Selective and differential | Recovered 83% of salmonellae and 90% of shigellae relative to four media combined, with fewer false-positive plates than Hektoen enteric agar | Taylor 1971 |
| Hektoen enteric agar | Selective and differential | Recovered 80% of salmonellae and 80% of shigellae, with more than twice the false-positive plates of XLD | Taylor 1971 |
| Gram-negative broth and selenite F broth | Enrichment | Gram-negative broth recovered 87% of salmonellae and 100% of shigellae; selenite F recovered 97% of salmonellae and 77% of shigellae; direct streaking alone recovered 54% and 59% | Taylor 1971 |
| Cefsulodin-irgasan-novobiocin (CIN) agar | Selective and differential | Antibiotics suppress Pseudomonas aeruginosa, E. coli, Klebsiella pneumoniae and Proteus mirabilis; mannitol fermentation separates Yersinia enterocolitica, with quantitative recovery in 24 hours at 32 °C or 48 hours at 22 °C | Schiemann 1979 |
| Thiosulfate-citrate-bile salts-sucrose (TCBS) agar | Selective and differential | Recovery of Vibrio cholerae, V. parahaemolyticus, V. vulnificus and V. fluvialis; recovery and quality of growth varied significantly among manufacturers' formulations, which supports lot quality control | West 1982 |
| Modified Thayer-Martin medium | Selective | Antimicrobial supplementation for the cultivation of Neisseria gonorrhoeae and Neisseria meningitidis from specimens with competing flora | Thayer 1966 |
| Buffered charcoal yeast extract with antimicrobial agents (BMPA-alpha) | Selective | Charcoal yeast extract base with cefamandole, polymyxin B and anisomycin plus alpha-ketoglutarate; recovery of Legionella pneumophila from contaminated respiratory specimens, with acid wash for water specimens | Edelstein 1981 |
| Regan-Lowe medium | Transport and enrichment | Semisolid charcoal agar with cephalexin and horse blood; of 567 specimens received in Amies transport medium, 290 (51%) were culture-positive only by enrichment | Regan 1977 |
| Burkholderia cepacia selective agar (BCSA) | Selective | Recovered 94% of B. cepacia complex from cystic fibrosis respiratory specimens and was significantly more selective than two comparator cepacia media | Marrs 2021 |
| Löwenstein-Jensen and Middlebrook 7H11 solid media | Selective, enriched | Sensitivity for Mycobacterium tuberculosis 79.6% and 76.1%, compared with 93% for the MGIT 960 liquid system | Idigoras 2000 |
| Media supplying X factor (hemin) and V factor (nicotinamide adenine dinucleotide) | Enriched | Growth of Haemophilus influenzae; satellitism and the porphyrin test are covered in Bacterial Identification: Biochemical Tests, MALDI-TOF Mass Spectrometry, Sequencing and Rapid Molecular Panels | Tebbutt 1983 |
Blood cultures
Blood culture volume, number of sets and incubation
For adults, 20–30 mL of blood per culture set is recommended, with 2–4 sets per septic episode (Miller 2018; Miller 2024). Among 629 unimicrobial episodes in which at least 3 cultures were drawn in 24 hours, the first culture detected 460 (73.1%), the first two detected 564 (89.7%), the first three detected 618 (98.2%) and the fourth brought the total to 628 (99.8%) (Lee 2007). An earlier analysis of 37,568 cultures on an automated instrument found that the percentage increase in pathogen recovery per milliliter of blood was smaller than with manual broth systems, that more consecutive sets over 24 hours were needed, and that a shorter incubation sufficed (Cockerill 2004). In a tertiary center using a continuous-monitoring system, only 23 of 13,103 bottles (0.18%) flagged positive after 4 days of incubation; 16 (69.6%) grew contaminants, 7 (30.4%) grew clinically significant organisms, and only 1 changed management (Tron 2026).
Blood volume also governs pediatric yield. Among 121 pediatric septic episodes with a measurable concentration of organisms, 73 (60.3%) represented low-level bacteremia at 10 CFU/mL or less, and 28 (23.1%) were detected at 1.0 CFU/mL or less. Among 144 episodes in which two or more culture devices were inoculated, 85 (59%) had a false-negative result from at least one device, and the total volume cultured was set by patient weight and total blood volume (Kellogg 2000).
Blood culture contamination: definition, rates and reduction
Blood culture contamination is the growth of specified commensal and environmental organisms from a single blood culture set within a series, without true bacteremia (Palavecino 2024). The laboratory calculates the rate with preset criteria that are not universally defined and that depend on the institution's patient population and practices (Palavecino 2024). Coagulase-negative staphylococci were the most frequently isolated organisms in a prospective study of 843 positive-culture episodes, and only 12.4% were clinically significant (Weinstein 1997).
Blood culture contamination rate.
| Element | Definition | Source |
|---|---|---|
| Numerator | Blood culture sets growing a designated commensal or environmental organism from a single set within a series, without true bacteremia | Palavecino 2024 |
| Denominator | All blood culture sets collected in the same period and population | Palavecino 2024 |
| Contamination rate | Numerator ÷ denominator, expressed as a percentage | Palavecino 2024 |
| Commensal organism list | CAP, CLSI and National Healthcare Safety Network lists differ; CAP (65%), CLSI (17%) and NHSN (17%) criteria were in use among surveyed hospitals, and rates increased with the NHSN list | Fabre 2025 |
| Benchmark | CLSI recommends a threshold below 3%, with 1% or less considered optimal | Fabre 2025 |
| Observed United States rates | Mean CAP-defined rate 1.38% in intensive care units and 0.96% on wards across 362,078 cultures from 48 hospitals | Fabre 2025 |
Earlier guidance from CLSI, CAP and others promoted a limit of 3% or less as acceptable, and that limit rested on expert opinion and surveys (Sautter 2024). Lower rates are achievable (Sautter 2024). In the ASM evidence-based guideline, the interventions that significantly reduced contamination were chlorhexidine skin antisepsis, a diversion device, sterile technique, a dedicated phlebotomy team and education or training programs. Diversion devices reduced contamination by an average of 64%, and cultures drawn by trained phlebotomists showed an average 41% decrease (Sautter 2024). In a controlled emergency department trial, an initial specimen diversion device that sequestered the first 1.5–2 mL of blood reduced contamination from 16 of 904 cultures (1.78%) to 2 of 904 (0.22%), and true bacteremia was detected in 65 of 904 compared with 69 of 904 with standard practice (Rupp 2017). Blood culture contamination was associated with higher central line–associated bloodstream infection rates in intensive care units, and sharing contamination data outside the laboratory, measuring additional quality indicators and limiting catheter-drawn cultures were associated with lower rates (Fabre 2025).
Catheter-related bloodstream infection and endocarditis criteria
The semiquantitative roll-plate method distinguishes infection from contamination at a threshold of 15 or more colonies: septicemia arose from 4 of the 25 catheters with 15 or more colonies and from none of the 225 with fewer (Maki 1977). A high probability of catheter-associated infection exists when the catheter-drawn culture becomes positive more than 2 hours before the peripheral venipuncture culture and both grow the same organism (Miller 2024). In the original prospective study of differential time to positivity, 16 of 17 patients whose hub culture turned positive at least 2 hours before the peripheral culture had definite catheter-related bacteremia, and catheter-related infection was excluded in 10 of the 11 patients with a differential below 2 hours (Blot 1999).
The 2023 Duke-ISCVID criteria updated the modified Duke criteria for infective endocarditis. The microbiologic changes are new diagnostics (enzyme immunoassay for Bartonella species, polymerase chain reaction, amplicon and metagenomic sequencing, in situ hybridization), an expanded list of typical organisms that includes pathogens counted as typical only when an intracardiac prosthesis is present, and removal of the requirements for timing and separate venipunctures for blood cultures (Fowler 2023). Previous rule: the modified Duke criteria defined possible infective endocarditis as 1 major plus 1 minor criterion or 3 minor criteria, eliminated the minor echocardiographic criterion, made Staphylococcus aureus bacteremia a major criterion regardless of nosocomial acquisition or a removable source, and made positive Coxiella burnetii serology a major criterion (Li 2000). The exclusion of Enterococcus faecium from the list of typical organisms in the 2023 criteria was challenged in correspondence (Lindberg 2023).
Urine culture interpretation by specimen type
In 202 paired specimens from premenopausal women with acute cystitis, growth of Escherichia coli in voided midstream urine predicted bladder bacteriuria measured in catheter urine even at low counts, with a positive predictive value of 93% at 10² CFU/mL (Spearman r = 0.944). Enterococci (10% of cultures) and group B streptococci (12%) in midstream urine did not predict bladder bacteriuria at any colony count (r = 0.322 and 0.272) (Hooton 2013).
Urine culture interpretation.
| Specimen and organism | Threshold or finding | Interpretation | Source |
|---|---|---|---|
| Voided midstream urine, E. coli | 10² CFU/mL | Positive predictive value 93% for bladder bacteriuria | Hooton 2013 |
| Voided midstream urine, enterococci or group B streptococci | Any colony count | No prediction of bladder bacteriuria | Hooton 2013 |
| Catheter-collected urine | Reference standard in the paired study | Defines bladder bacteriuria | Hooton 2013 |
| Urine held unpreserved at room temperature | Recultured at 2, 4, 24 and 48 hours | Uropathogen colony counts rose significantly | Eisinger 2013 |
| Any urine refrigerated or in boric acid preservative | Up to 48 hours | Counts stable; differences from immediate culture not significant | Eisinger 2013 |
Lower respiratory and upper respiratory cultures
Ventilator-associated and hospital-acquired pneumonia. In a prospective study of 311 patients undergoing bronchoalveolar lavage for suspected ventilator-associated pneumonia, the diagnosis was defined by 2% or more of lavage cells containing intracellular organisms or a quantitative lavage culture yielding 10⁴ CFU/mL or more of potentially pathogenic organisms. The most accurate threshold for endotracheal aspirate semiquantitative culture was moderate or heavy growth, and the incidence of pneumonia varied from 15% to 68% depending on the threshold and modality used (Scholte 2014).
Pharyngitis. Group A streptococci cause 10%–15% of pharyngitis in adults and 15%–30% in children (Miller 2024). Rapid antigen tests, molecular tests and backup culture for group A streptococcal pharyngitis are covered in Gram-Positive Bacteria and Anaerobes: Staphylococci, Streptococci, Enterococci, Gram-Positive Rods and Clostridioides difficile.
Prosthetic joint infection specimens
Bayesian latent class analysis of 1,437 periprosthetic tissue samples from 499 revision arthroplasties found the greatest accuracy with 4 specimens by conventional culture (91%; 95% credible interval 77–100) and with 3 specimens when tissue was inoculated into blood culture bottles (92%; 95% credible interval 79–100) (Peel 2017). Sonication of the explanted prosthesis dislodges adherent organisms from biofilm. In 331 patients, sensitivity was 78.5% for sonicate fluid culture and 60.8% for periprosthetic tissue culture (P<0.001), with specificities of 98.8% and 99.2%, and 14 infections were detected by sonicate fluid culture alone (Trampuz 2007).
Cerebrospinal fluid and stool workup
Cerebrospinal fluid. Molecular testing has replaced viral culture for enteroviral meningitis and is not routinely relied on for the detection of bacteria in CSF (Miller 2024). The highest yields for acid-fast bacillus smear and culture occur when large volumes of CSF (≥5 mL) are used, and CSF of 5 mL or more is listed as the optimum specimen for Mycobacterium species in shunt infection (Miller 2024).
Stool. Most laboratories routinely detect Salmonella, Shigella and Campylobacter in stools submitted for culture, and a test for the detection of Shiga toxin is recommended as part of routine testing (Miller 2024). The CDC rule for Shiga toxin–producing E. coli testing of every stool is covered in Gram-Negative Bacteria: Enterobacterales, Nonfermenters, Neisseria, Haemophilus and Fastidious Gram-Negative Rods.
Genital tract specimens and the Nugent score
Clinical diagnosis of bacterial vaginosis by Amsel criteria requires at least 3 of 4 findings: a homogeneous, thin discharge that smoothly coats the vaginal walls; clue cells on microscopy; vaginal fluid pH above 4.5; and a fishy odor before or after addition of 10% potassium hydroxide (the whiff test). Against the Nugent score, the Amsel criteria have a sensitivity of 37%–70% and a specificity of 94%–99% (Workowski 2021). The criteria derive from a study of 397 university students (Amsel 1983). Nugent and colleagues then derived a Gram stain score that improved interexaminer reliability: the standardized score reached a Spearman correlation of 0.82 between centers compared with 0.61 for the Spiegel criteria (Nugent 1991). The score omits gram-positive cocci because of their poor interexaminer agreement (0.23), combines the G. vaginalis and Bacteroides morphotypes, and weights curved gram-variable rods most heavily, which had the best agreement (0.85) (Nugent 1991).
Nugent score (natural order by morphotype).
| Morphotype | Score range | Direction | Source |
|---|---|---|---|
| Lactobacillus-like large gram-positive rods | 0 to 4 | Score increases as the morphotype decreases | Nugent 1991 |
| Gardnerella-like short gram-variable rods | 0 to 4 | Score increases with abundance | Nugent 1991 |
| Mobiluncus-like curved gram-variable rods | 0 to 2 | Score increases with abundance | Nugent 1991 |
| Total 0–3 | Not applicable | Lactobacillus-predominant flora | Workowski 2021 |
| Total 4–6 | Not applicable | Intermediate flora | Workowski 2021 |
| Total 7–10 | Not applicable | Consistent with bacterial vaginosis | Nugent 1991; Workowski 2021 |
In transfeminine people with neovaginas the score does not correlate with the abundance of the targeted bacteria and does not predict local inflammation or symptoms, so its validity is limited to the population in which it was derived (Parmar 2026).
Laboratory quality and test utilization in bacteriology
Each new lot of medium and each stain is verified before use, and the statistical tools for quality control and the regulatory requirements for method verification under 42 CFR 493.1253 are covered in Method Validation, Statistical Quality Control and Proficiency Testing in Clinical Chemistry. Lot-to-lot variation is measurable: recovery and quality of growth of Vibrio species differed significantly among four commercial brands of TCBS agar prepared according to the manufacturers' instructions, and components of the inoculation procedure also contributed significant variance (West 1982).
Diagnostic stewardship is the practice of influencing test ordering, processing and reporting so that the result changes management appropriately (Morgan 2017). The rejection rules above are its most direct application: a three-day rule for inpatient stool cultures rejected 5,744 of 14,439 requests (39.8%) over three years with a post-day-3 pathogen yield of 0.2% (Seyler 2007), and sputum screening removes specimens in which oropharyngeal flora would be reported as a result (Murray 1975).
Bacterial Identification: Biochemical Tests, MALDI-TOF Mass Spectrometry, Sequencing and Rapid Molecular Panels
Definition. Identification assigns a cultured isolate, or an organism detected directly in a specimen, to a genus and species. Four approaches are in routine use: phenotypic reactions read manually or on an automated instrument, protein profiling by matrix-assisted laser desorption ionization–time of flight (MALDI-TOF) mass spectrometry, sequencing of conserved genes or whole genomes, and nucleic acid amplification in multiplexed syndromic panels. MALDI-TOF is an accurate and inexpensive method for identifying cultured bacteria and fungi from the mass distribution of their proteins, and it is automated and high throughput (Patel 2015).
Related page: Microbiology Specimens, Stains, Culture Media and Blood Cultures (specimen handling, Gram stain, culture media and blood cultures) Related page: Antimicrobial Susceptibility Testing, Breakpoints and Resistance Mechanisms (phenotypic and genotypic resistance detection and reporting) Related page: Analytical Methods and Immunoassays in Clinical Chemistry (mass spectrometry ion sources and time-of-flight analyzers; immunoassay formats) Related page: Method Validation, Statistical Quality Control and Proficiency Testing in Clinical Chemistry (verification of a new identification or molecular assay, and contamination control) Related page: Infections in Cerebrospinal Fluid Cytology (cerebrospinal fluid findings in bacterial meningitis)
Phenotypic identification: key tests and their reactions
| Test | Principle | Positive result and organisms | Negative result and organisms | Source |
|---|---|---|---|---|
| Catalase | Decomposition of hydrogen peroxide to oxygen and water | Staphylococci | Streptococci and enterococci | Facklam 1995 |
| Tube coagulase and clumping factor | Conversion of fibrinogen to fibrin | Staphylococcus aureus | Most coagulase-negative staphylococci | Mateo 2005 |
| Pyrrolidonyl arylamidase (PYR) disk | Hydrolysis of a pyrrolidonyl substrate | Enterococci | Leuconostoc species | Facklam 1995 |
| Leucine aminopeptidase (LAP) disk | Hydrolysis of a leucine substrate | Enterococci and Pediococcus species | Leuconostoc species | Facklam 1995 |
| Vancomycin screen disk | Intrinsic glycopeptide resistance | Leuconostoc and Pediococcus species | Most enterococci | Facklam 1995 |
| Optochin susceptibility and bile solubility | Lysis of pneumococci by ethylhydrocupreine and bile salts | Streptococcus pneumoniae | Other mitis group streptococci | Ing 2012 |
| Spot indole | Tryptophanase cleaves tryptophan to indole | Escherichia coli | Most other Enterobacterales | Jagtap 1985 |
| Hippurate hydrolysis | Hydrolysis of sodium hippurate to glycine and benzoate | Campylobacter jejuni | Campylobacter coli | Adzitey 2011 |
| X and V factor requirement by satellitism | Dependence on hemin and nicotinamide adenine dinucleotide | Haemophilus influenzae requires both factors | V-dependent Haemophilus species | Tebbutt 1983 |
Disk satellitism misidentified 6% of H. influenzae strains as H. parainfluenzae, and the porphyrin test reliably demonstrated the X factor requirement; the indole test discriminated poorly in that comparison (Tebbutt 1983). Three disk tests used together with the Gram stain and catalase (vancomycin, PYR and LAP) presumptively separate vancomycin-resistant enterococci, Leuconostoc species and Pediococcus species among 734 catalase-negative, non-beta-hemolytic gram-positive cocci (Facklam 1995). Organism-specific reactions and their clinical significance are covered in Gram-Positive Bacteria and Anaerobes: Staphylococci, Streptococci, Enterococci, Gram-Positive Rods and Clostridioides difficile and Gram-Negative Bacteria: Enterobacterales, Nonfermenters, Neisseria, Haemophilus and Fastidious Gram-Negative Rods.
Limits of phenotypic reactions. Optochin susceptibility, bile solubility and the Quellung reaction are the standards for pneumococcal identification, and strains give inconsistent results with one or more of these tests. Of 52 isolates labeled nontypeable pneumococci, 38 (73%) were optochin susceptible, psaA and ply positive and serotypeable, and 14 required molecular analysis (Ing 2012). The clumping factor test was negative in 35.3% of 17 Staphylococcus lugdunensis isolates confirmed by rpoB sequencing, and species misidentification rates were 5.9%, 23.5% and 29.4% with three commercial systems, usually as Staphylococcus haemolyticus (Mateo 2005). Hippurate hydrolysis agreed with multiplex PCR for 17 of 18 Campylobacter strains, and occasional C. jejuni strains are misidentified as C. coli (Adzitey 2011).
Automated phenotypic identification systems
A meta-analysis of 29 studies with 6,635 isolates for the BD Phoenix 100 and 19 studies with 4,363 isolates for the colorimetric Vitek 2 found no significant difference between the systems at the genus level (97.70% compared with 97.59%, P = 0.919) or the species level (92.51% compared with 88.77%, P = 0.149) (Chatzigeorgiou 2011). Speciation of S. aureus was significantly more accurate than speciation of coagulase-negative staphylococci on both systems (99.78% compared with 88.42% on Phoenix, P < 0.00001) (Chatzigeorgiou 2011). Studies that used conventional comparator methods reported significantly better results than studies that used molecular reference methods, which indicates that reported accuracy depends on the reference standard (Chatzigeorgiou 2011).
Automated systems also misidentify organisms whose phenotype overlaps that of a common species. Brucella suis bacteremia was reported as Ochrobactrum anthropi by the Vitek 2 system, and the two genera share 98.8% rRNA similarity (Vila 2016; Gopalsamy 2021). Ochrobactrum has been transferred to Brucella (Brucella anthropi, formerly O. anthropi), so a report naming either organism prompts a check for a true Brucella pathogen (Hördt 2020).
MALDI-TOF mass spectrometry for bacterial identification
MALDI-TOF workflow, score thresholds and specimen types
The instrument desorbs and ionizes proteins from an intact colony or an extract embedded in a matrix, separates the ions by time of flight and compares the resulting mass spectrum with a database of reference spectra. The ion source and the time-of-flight analyzer are covered in Analytical Methods and Immunoassays in Clinical Chemistry. MALDI-TOF identifies aerobic and anaerobic bacteria, mycobacteria and fungi from culture, and it is also applied to urine and to positive blood culture bottles (Patel 2015). Identification scores define the level of the result on the Bruker Biotyper system: species-level identification at a score of 2.0 or above and genus-level identification in the range 1.70–1.99 in the standard module, with a species-level threshold of 1.8 in the Sepsityper module (Karadağ 2024).
Direct identification from a positive bottle depends on the preparation method. Among 240 positive bottles, species-level identification in the standard module was achieved in 46.7% with sodium dodecyl sulfate lysis, 44.2% with differential centrifugation and protein extraction and 25.4% with a commercial separation kit; in the Sepsityper module the proportions were 74.2%, 74.2% and 55% (Karadağ 2024).
Extraction also changes the result for organisms with resistant cell walls and for agents that must be handled safely. Ethanol and formic acid tube extraction left none of the tested highly pathogenic strains viable, which permitted analysis in a biosafety level 2 laboratory, and the ASM sentinel laboratory protocols recommend tube extraction followed by filtration through a filter of 0.2 µm or smaller pore size whenever MALDI-TOF is applied to a suspected biological threat agent (Rudrik 2017). For Nocardia, an updated Bruker database raised identification with scores above 1.7 from 59 of 76 isolates to 72 of 76 and species accuracy from 84.2% to 98.7% against multigene sequencing, and a simplified extraction separately raised species-level calls from 18 of 29 to 25 of 29 (Liu 2024).
Organism pairs and groups that commercial databases do not reliably separate
| Organism or group | Behavior on MALDI-TOF | Consequence | Source |
|---|---|---|---|
| Shigella species and Escherichia coli | Not distinguishable with commercial databases; a custom database, biomarker assignment and machine-learning classifiers all failed, and most E. coli isolates were assigned to Shigella by the classifier | Reported as the Shigella/E. coli complex, with other tests used for separation | van den Beld 2022 |
| Streptococcus mitis and Streptococcus oralis compared with S. pneumoniae | S. mitis and S. oralis can be reported erroneously as S. pneumoniae with commercial databases | Pneumococcal identification requires confirmation by phenotypic or molecular tests | Ikryannikova 2013 |
| Streptococcus bovis group | No single platform identified all eight type strains of the seven species and subspecies; Vitek MS identified 7 of 8 and sodA sequencing 6 of 8 | Reflex to Vitek MS or sodA sequencing when the species matters | Putnam 2023 |
| Bacillus anthracis and the B. cereus group | No reliable identification with in vitro diagnostic databases, and some laboratories reported B. cereus or the B. cereus group; with the Security-Relevant library, the near neighbors B. cereus and B. thuringiensis were misidentified as B. anthracis | Sentinel laboratories rule out and refer; the identification is not made on a clinical database | Rudrik 2017 |
| Yersinia pestis | Misidentified as Y. pseudotuberculosis by the in vitro diagnostic software in 73.8% of extracts | A Y. pseudotuberculosis result in a compatible case is ruled out and referred | Rudrik 2017 |
| Brucella species | No reliable identification with in vitro diagnostic databases; research-use software gave the genus only, and the Security-Relevant library called all species B. melitensis, the only species it contained | Same referral rule | Rudrik 2017 |
| Burkholderia pseudomallei and B. thailandensis | B. pseudomallei was reported with a high score as B. thailandensis without the Security-Relevant library | Melioidosis can be missed in nonendemic areas | Merlino 2026 |
| Burkholderia pseudomallei on a system without the organism in its diagnostic database | Custom reference spectra built in one region identified 54 of 55 Asian isolates but only 35 of 75 Australian isolates; combining 11 spectra identified all isolates | Database geography affects performance | Watthanaworawit 2021 |
| Mycobacterium tuberculosis complex species | Discrimination of complex members required optimized peptide extraction and a peak-based algorithm, which classified 70 of 80 isolates (88%) correctly against whole-genome sequencing | Complex members are separated by molecular methods in routine practice | Robinne 2022 |
| Salmonella serotypes | Serotypes cannot be differentiated by mass spectrometry; a machine-learning model was developed to address this | Serotyping is performed by agglutination or sequencing | Ren 2025 |
Organism-specific consequences of these limitations are covered in Gram-Positive Bacteria and Anaerobes: Staphylococci, Streptococci, Enterococci, Gram-Positive Rods and Clostridioides difficile, Gram-Negative Bacteria: Enterobacterales, Nonfermenters, Neisseria, Haemophilus and Fastidious Gram-Negative Rods and Mycobacteria, Nocardia, Spirochetes, Mycoplasma, Chlamydia and Other Intracellular Bacteria.
Sequence-based identification
16S rRNA gene sequencing
Sanger sequencing of the first approximately 500 bp of the 16S rRNA gene identifies bacteria whose biochemical profiles or mass spectra are ambiguous. When sequence diversity does not occur within that region, genus- or species-level identification may be impossible, and CLSI MM18 states that a longer segment of the gene or an alternative target is then required (Campodónico 2025). The review of 16S cycle sequencing in the clinical laboratory describes the method, the limits of 16S similarity for separating closely related clinically relevant pathogens, the incompleteness of public sequence databases, and direct broad-range 16S PCR followed by sequencing on appropriate specimens (Church 2020).
Interpretation uses identity thresholds with a margin to the next closest match. For aerobic actinomycetes, CLSI MM18 requires 99.6% identity or higher to the top match plus a distance of more than 0.4% to the next closest species for a species-level result, and Mycobacterium species require 100% identity; the study laboratory assigned family level to a top match of 95% or more when the CLSI cutoffs were not met (Campodónico 2025). A result can change with read depth: one specimen was identified as Mycobacterium paragordonae at 99.00% identity with 68 reads and as Mycobacterium gordonae at 99.12% identity after resequencing yielded 920 reads (Campodónico 2025).
Full-length (approximately 1,500 nt) long-read sequencing of 153 clinical isolates gave higher taxonomic resolution at the genus level than the 500-nt Sanger approach (P < 0.01), with concordance of 100% for the best-matching genus and 91% for the best-matching species when both methods reached that level (Campodónico 2025). Whole-genome sequencing has the potential to replace 16S sequencing for routine identification, and the barriers to full implementation in clinical microbiology are described in the same review (Church 2020).
Nucleic acid amplification methods used in bacteriology
| Method | Principle | Output | Source |
|---|---|---|---|
| Polymerase chain reaction | Thermostable DNA polymerase extends primers through repeated thermal cycles; genomic single-copy sequences were amplified more than 10 million-fold | Qualitative detection of a DNA target | Saiki 1988 |
| Real-time (kinetic) PCR | Fluorescence is monitored during cycling; the cycle at which signal becomes detectable is related to the starting copy number | Qualitative or quantitative | Higuchi 1993 |
| Loop-mediated isothermal amplification | Four primers recognizing six target sequences drive strand-displacement synthesis at one temperature, forming stem-loop products | Qualitative detection without thermal cycling | Notomi 2000 |
| Reverse transcription–based amplification of bacterial RNA (RT-PCR and RT-LAMP) | A bacterial RNA transcript is reverse transcribed and amplified; the assay cannot distinguish the transcript from the DNA that encodes it, so control material must discriminate the two templates | Qualitative detection with evidence of organism viability | Lewis 2024 |
Verification of a molecular assay before clinical use, and the contamination controls that amplification requires, are covered in Method Validation, Statistical Quality Control and Proficiency Testing in Clinical Chemistry.
Syndromic multiplex panels
Blood culture identification panels
The BIOFIRE Blood Culture Identification 2 panel tests 43 targets in approximately 1 hour from a positive bottle, and an antimicrobial resistance gene result is reported only when a potential carrier organism is also detected (Rhoads 2023). The panel's resistance targets are mecA/C, mecA/C with MREJ for methicillin-resistant S. aureus, vanA/B, CTX-M, IMP, KPC, NDM, OXA-48-like, VIM and mcr-1 (Rhoads 2023). In the FDA submission study of 1,074 positive blood culture samples, overall sensitivity was 98.9% (1,712 of 1,731) and specificity 99.6% (33,592 of 33,711) for organism targets, with positive percent agreement of 97.9% (325 of 332) and negative percent agreement of 99.9% (2,465 of 2,767) for resistance determinants (Rhoads 2023). Off-panel organisms that the panel is not designed to detect were identified by standard of care in 114 of 1,074 samples (10.6%), which is the central limitation of any closed panel (Rhoads 2023).
A rapid phenotypic system that reports identification in about 90 minutes and susceptibility in about 7 hours achieved identification sensitivities of 94.6%–100% for 14 bacteria and 2 Candida species. For gram-positive cocci, essential and categorical agreement were 97.6% and 97.9%; for gram-negative rods, 95.4% and 94.3%, with very major error rates of 1.0% and 0.5% (Pancholi 2018).
Effect of rapid blood culture identification on management. In a randomized trial of 617 patients with positive bottles, rapid multiplex PCR shortened the time from Gram stain to organism identification from 22.3 hours to 1.3 hours (P < .001), reduced piperacillin-tazobactam use, increased narrow-spectrum beta-lactam use and reduced treatment of contaminants from 25% to 11% without stewardship review and to 8% with it (Banerjee 2015). In a second randomized trial in gram-negative bacteremia, rapid identification and phenotypic susceptibility testing shortened median time to first antibiotic modification from 14.9 to 8.6 hours (P = .02) and time to escalation in resistant infections from 61.7 to 18.4 hours (P = .01), with no difference in patient outcomes (Banerjee 2021). A meta-analysis of 31 studies with 5,920 patients found lower mortality with molecular rapid diagnostic testing (odds ratio 0.66; 95% CI 0.54–0.80), a significant reduction in studies with an antimicrobial stewardship program (odds ratio 0.64; 95% CI 0.51–0.79) and no significant reduction without one (odds ratio 0.72; 95% CI 0.46–1.12) (Timbrook 2017).
Meningitis, gastrointestinal and pneumonia panels
In the multicenter evaluation of the meningitis and encephalitis panel on 1,560 prospectively collected cerebrospinal fluid specimens, sensitivity or positive percentage of agreement was 100% for 9 of 14 analytes, and specificity or negative percentage of agreement was 99.2% or greater for all analytes other than Streptococcus agalactiae, which had one false-positive and one false-negative result (Leber 2016). Listeria monocytogenes and Neisseria meningitidis were not encountered in the study, so their performance was not measured (Leber 2016). Panel results that contradict the clinical picture require confirmation: a term neonate with late-onset group B streptococcal bacteremia had Haemophilus influenzae reported in cerebrospinal fluid, with negative confirmatory PCR for H. influenzae, negative 16S rRNA PCR and negative culture, and the manufacturer's investigation found borderline amplification of one of two targets that the algorithm called positive (Yokoyama 2025).
The gastrointestinal panel detects 22 enteric targets with a turnaround as short as 1 hour. Sensitivity was 100% for 12 of 22 targets and 94.5% or higher for 7 more, and specificity was 97.1% or higher for all targets, with sensitivity incalculable for 3 targets because of low prevalence (Buss 2015). The pneumonia panel reports bacterial targets in semiquantitative bins. In 190 bronchial washing specimens, culture positivity was 41.6% and panel positivity 51.1%; 21 specimens (11.0%) were positive by the panel alone, and the panel detected 72 additional bacterial targets (Jo 2025). Detection of an organism that culture does not recover requires correlation with the clinical picture and the specimen's quality, since colonization and prior antimicrobial therapy both separate nucleic acid detection from viable growth.
Antigen detection in bacteriology
Urinary antigen tests and rapid antigen tests complement culture when the organism grows slowly or not at all. In a meta-analysis of 21 studies with 5,772 patients, the pooled sensitivity of Legionella urinary antigen testing was 0.79 (95% CI 0.71–0.85) and specificity 1.00 (95% CI 0.99–1.00); for Legionella pneumophila serogroup 1 the sensitivity was 0.86 (95% CI 0.78–0.91) (Kawasaki 2022). The sensitivity of the pneumococcal urinary antigen test in nonbacteremic pneumococcal pneumonia is 52%–78% (Miller 2024). Rapid antigen and molecular tests for group A streptococcal pharyngitis are covered in Gram-Positive Bacteria and Anaerobes: Staphylococci, Streptococci, Enterococci, Gram-Positive Rods and Clostridioides difficile. Immunoassay formats and their interferences are covered in Analytical Methods and Immunoassays in Clinical Chemistry.
Metagenomic sequencing for infection diagnosis
Metagenomic next-generation sequencing of cerebrospinal fluid in 204 hospitalized patients identified 13 of 58 nervous system infections (22%) that clinical testing at the source hospital did not identify, made concurrent diagnoses in 19 of the remaining 45. It missed 26 infections: 11 were diagnosed by serology alone, 7 from tissue other than CSF, and 8 were missed because of low pathogen titers in CSF. Eight of the 13 diagnoses made solely by sequencing had a likely clinical effect (Wilson 2019). Plasma microbial cell-free DNA sequencing of 1,250 organisms showed 93.7% agreement with blood culture in 350 patients with a sepsis alert and identified an adjudicated cause more often than all other microbiological testing combined (169 compared with 132 determinations). Among 166 samples with no adjudicated cause, sequencing identified microbial cell-free DNA in 62, likely from commensal organisms and incidental findings unrelated to the alert (Blauwkamp 2019).
Selection of an identification method in practice
Throughput and cost make MALDI-TOF the first-line method for cultured isolates, and the organism groups that commercial databases do not reliably separate require a second method. Sequencing resolves isolates with ambiguous spectra and organisms absent from the database, and it carries its own interpretive thresholds (Church 2020; Campodónico 2025). Panels answer a defined question quickly from a specimen or a positive bottle, and their closed target lists, semiquantitative output and occasional false-positive results require correlation with culture (Rhoads 2023; Yokoyama 2025).
Antimicrobial Susceptibility Testing, Breakpoints and Resistance Mechanisms
Definition. Antimicrobial susceptibility testing detects resistance in common pathogens and confirms susceptibility to the agents of choice for a given infection. The methods in routine use are broth microdilution and automated instruments based on it, disk diffusion and gradient diffusion. Some methods give a quantitative result as a minimal inhibitory concentration (MIC), and all assign the categories susceptible, intermediate or resistant. Current methods detect common resistance mechanisms accurately, and newer mechanisms require continuous assessment of whether each method still detects resistance (Jorgensen 2009). The interpretive criteria are published annually in CLSI M100, whose current edition is the 36th, published January 26, 2026 (CLSI 2026). As of February 5, 2026, FDA fully recognizes the 36th edition standards unless specific exceptions and additions are identified, and the 35th edition is no longer recognized (FDA 2026).
Related page: Microbiology Specimens, Stains, Culture Media and Blood Cultures (specimen handling, culture media and blood cultures) Related page: Bacterial Identification: Biochemical Tests, MALDI-TOF Mass Spectrometry, Sequencing and Rapid Molecular Panels (identification, rapid panels and resistance gene targets) Related page: Method Validation, Statistical Quality Control and Proficiency Testing in Clinical Chemistry (verification requirements, quality control statistics and proficiency testing)
Antimicrobial classes, targets and resistance mechanisms
| Class | Principal target | Main resistance mechanisms | Source |
|---|---|---|---|
| Penicillins and cephalosporins | Penicillin-binding proteins in cell wall synthesis | Beta-lactamase hydrolysis (classes A, C and D serine enzymes, class B metalloenzymes); altered penicillin-binding proteins | Bush 2010; Tristram 2007 |
| Beta-lactam and beta-lactamase inhibitor combinations | As above, with inhibition of the enzyme | Inhibitor-resistant TEM and SHV variants; enzymes outside the inhibitor's spectrum | Castanheira 2021 |
| Carbapenems | Penicillin-binding proteins | Serine carbapenemases (KPC, OXA-48-like) and metallo-beta-lactamases (NDM, VIM, IMP); porin loss with AmpC or ESBL | Yigit 2001; Yong 2009; Poirel 2004 |
| Monobactams (aztreonam) | Penicillin-binding protein 3 | Hydrolysis by ESBLs and serine carbapenemases; stability against metallo-beta-lactamases | Castanheira 2021; Tamma 2026 |
| Glycopeptides | D-alanyl-D-alanine terminus of peptidoglycan precursors | van operons that replace the binding target; thickened cell wall with restricted access to the division septum | Clark 1998; Howden 2010 |
| Lipopeptides (daptomycin) | Cell membrane, calcium dependent | Reduced susceptibility in enterococci | Satlin 2020a |
| Aminoglycosides | 30S ribosomal subunit; activity is oxygen dependent | Enzymatic modification by acetylation, phosphorylation or adenylation; ribosomal methylation; reduced permeability | Schuetz 2025 |
| Macrolides and lincosamides | 50S ribosomal subunit | Ribosomal methylation by erm, constitutive or inducible; efflux by msrA | Fiebelkorn 2003 |
| Tetracyclines | 30S ribosomal subunit | Efflux and ribosomal protection proteins | Tristram 2007 |
| Fluoroquinolones | DNA gyrase and topoisomerase IV | Target mutations and efflux | Humphries 2019 |
| Folate antagonists (trimethoprim-sulfamethoxazole) | Sequential steps of folate synthesis | Altered or acquired dihydrofolate reductase and dihydropteroate synthase | Tristram 2007 |
| Oxazolidinones | 50S ribosomal subunit | Ribosomal mutation and cfr; linezolid results predict tedizolid susceptibility | Humphries 2021 |
| Polymyxins (colistin, polymyxin B) | Lipopolysaccharide of the outer membrane | Lipid A modification by addition of phosphoethanolamine or 4-amino-L-arabinose through two-component systems, and plasmid-borne mcr genes | Gogry 2021; Liu 2016 |
| Siderophore cephalosporin (cefiderocol) | Penicillin-binding proteins after iron transporter–mediated entry | Reduced iron uptake | Schuetz 2025 |
Intrinsic resistance. Enterococci are intrinsically resistant to cephalosporins, and this trait is conserved across Enterococcus faecalis and E. faecium; it depends on penicillin-binding proteins of low reactivity toward cephalosporins, including Pbp4 or Pbp5 and PbpA (Djorić 2020). Stenotrophomonas maltophilia carries two inducible chromosomal beta-lactamases: L1, a metallo-beta-lactamase that hydrolyzes carbapenems, and L2, a clavulanate-sensitive serine cephalosporinase; L1 gives intrinsic carbapenem resistance (Yang 2014; Walsh 1997). Proteus mirabilis is intrinsically resistant to colistin, as are Neisseria meningitidis and Burkholderia species (Gogry 2021). Enterococcus gallinarum and Enterococcus casseliflavus carry vanC-1 and vanC-2, which confer intrinsic low-level vancomycin resistance (Clark 1998). Aminoglycosides have no activity against anaerobes because their uptake is oxygen dependent, and they show gaps in activity against Salmonella, Shigella, Stenotrophomonas, Burkholderia, Streptococcus and Enterococcus (Schuetz 2025).
Susceptibility testing methods
Reference and routine methods
| Method | Conditions and principle | Output and limits | Source |
|---|---|---|---|
| Broth microdilution | Serial twofold dilutions in cation-adjusted Mueller-Hinton broth, final inoculum about 5×10⁵ CFU/mL per well, incubation at 35 ± 2 °C for 16–20 hours; the MIC is the lowest concentration with no visible growth | Reference method for MIC determination; manual and labor intensive | Dhavale 2026 |
| Disk diffusion | Standardized single-disk method on Mueller-Hinton agar; a 0.5 McFarland suspension is applied within 15 minutes, and plates are incubated at 35 ± 2 °C in ambient air overnight before zone measurement | Categorical result | Bauer 1966; Wang 2026 |
| Gradient diffusion (MIC test strip) | A concentration gradient on a strip applied to agar inoculated with the same suspension | Quantitative MIC; agreement with broth microdilution is organism and agent specific | Wang 2026 |
| Automated instrument systems | Miniaturized dilution panels or cards read photometrically | Categorical agreement above 94% for Enterobacterales against broth microdilution, with agent-specific exceptions | Richter 2025 |
| Direct disk diffusion from positive blood culture broth | Introduced in M100 in 2021 for Enterobacterales, with early (8–10 hours) and overnight (16–18 hours) reading breakpoints and separate tables for Enterobacterales and Pseudomonas aeruginosa | Earlier categorical result; the organism identification must be known before interpretation, because intrinsic resistance rules apply and fluoroquinolone breakpoints do not apply to Salmonella species | Schuetz 2025 |
Testing conditions for each organism and agent are specified in M100 Table 2, and a laboratory using an FDA-cleared device follows the manufacturer's instructions for test conditions (Schuetz 2025). Cefiderocol requires iron-depleted cation-adjusted Mueller-Hinton broth, and its endpoints are difficult to read because of trailing growth in broth and inner colonies in disk diffusion. Cefiderocol disk zones below 15 mm for Acinetobacter baumannii are uninterpretable and are followed by MIC testing (Schuetz 2025). Mueller-Hinton Fastidious medium (Mueller-Hinton with 5% mechanically defibrinated horse blood and 20 µg/mL nicotinamide adenine dinucleotide) is an approved alternative to Haemophilus test medium for selected agents and an option for disk diffusion of Streptococcus pneumoniae (Schuetz 2025). Agar dilution is the reference method for anaerobes, covered in Gram-Positive Bacteria and Anaerobes: Staphylococci, Streptococci, Enterococci, Gram-Positive Rods and Clostridioides difficile. Mycobacterial susceptibility testing is covered in Mycobacteria, Nocardia, Spirochetes, Mycoplasma, Chlamydia and Other Intracellular Bacteria.
Interpretive categories
| Category | Meaning | Source |
|---|---|---|
| Susceptible (S) | Standard dosing is expected to be effective | Jorgensen 2009 |
| Susceptible dose-dependent (SDD) | Effectiveness depends on an increased dosing regimen | Schuetz 2025 |
| Intermediate (I) | Covers an MIC that may predict success where the agent concentrates physiologically (denoted I^ in M100, for example in urine) or where higher exposure is achievable; also serves as a buffer for technical variability and indicates uncertain activity, as with colistin | Schuetz 2025 |
| Resistant (R) | Standard or increased dosing is not expected to be effective | Jorgensen 2009 |
| Epidemiological cutoff value (ECV) | The high end of the wild-type MIC distribution, at or below which resistance mechanisms are not detectable | Schuetz 2025 |
EUCAST redefined the intermediate category in 2019 as "susceptible, increased exposure", which states that efficacy may be achieved through dose adjustment (Ali 2025).
Breakpoint setting and the three breakpoint-setting bodies
Breakpoints are derived from the wild-type MIC distribution and its epidemiological cutoff value, pharmacokinetic and pharmacodynamic target attainment, and clinical outcome data. In the aminoglycoside revision, the ratio of area under the concentration-time curve to MIC was most predictive of activity, and a 1-log reduction in colony-forming units was unachievable at safe exposures for isolates with MICs at or below the ECV, while net bacterial stasis was achievable. The revised breakpoints therefore apply to infections where stasis suffices: a low bacterial burden with good source control and combination therapy (Schuetz 2025).
CLSI, FDA and EUCAST set criteria independently, and their breakpoints differ for some organism-agent pairs. Gentamicin breakpoints for P. aeruginosa still exist for FDA while CLSI and EUCAST have none, and the three bodies have different P. aeruginosa breakpoints for amikacin and tobramycin (Schuetz 2025). The current EUCAST breakpoint tables are version 16.1, valid from June 24, 2026 (EUCAST 2026). When FDA has not recognized a revised CLSI breakpoint, manufacturers cannot obtain clearance for it, and the laboratory may adopt it off label after a validation study if the system includes low enough dilutions; interim measures include suppressing a result or categorizing it as resistant (Schuetz 2025).
CLSI breakpoint revisions, 2006–2023
| Organism and agent | Previous rule | Current rule | Edition | Source |
|---|---|---|---|---|
| Enterobacterales, cephalosporins and carbapenems | Higher breakpoints with mechanism testing for ESBL or carbapenemase production required before reporting | Lowered breakpoints; mechanism testing no longer required for reporting, because the lower breakpoints were considered sufficient to detect isolates without acquired mechanisms | M100-S20 (2010) | Schuetz 2025 |
| S. aureus, vancomycin | Susceptible ≤4, intermediate 8–16, resistant ≥32 µg/mL | Susceptible ≤2, intermediate (VISA) 4–8, resistant (VRSA) ≥16 µg/mL | 2006 | Howden 2010 |
| S. pneumoniae, parenteral penicillin | Single low breakpoint applied to all infections | Nonmeningeal infection ≤2 µg/mL susceptible with 12–24 million units per day; meningitis ≤0.06 µg/mL unchanged (≥18 million units per day) | January 2008 | Weinstein 2009 |
| Enterococcus species, daptomycin | Susceptible-only breakpoint of ≤4 µg/mL | E. faecium susceptible dose-dependent ≤4 µg/mL with 8–12 mg/kg/day and resistant ≥8 µg/mL; E. faecalis and other species susceptible ≤2, intermediate 4, resistant ≥8 µg/mL | 29th (2019) | Satlin 2020a |
| Enterobacterales and P. aeruginosa, fluoroquinolones | Higher ciprofloxacin and levofloxacin breakpoints | Lowered breakpoints | 29th (2019) | Humphries 2019 |
| Colistin and polymyxin B | Susceptible category existed | Susceptible category eliminated by CLSI; EUCAST retained it | 30th (2020) | Satlin 2020b |
| Enterobacterales and P. aeruginosa, piperacillin-tazobactam | Enterobacterales breakpoints unchanged since 1993 | Enterobacterales susceptible ≤8/4, susceptible dose-dependent 16/4 with extended infusion, resistant ≥32/4 µg/mL (FDA categorizes 16/4 as intermediate); P. aeruginosa susceptible ≤16/4, intermediate 32/4, resistant ≥64/4 µg/mL | 32nd (2022); 33rd (2023) | Tamma 2023a; Tamma 2023b; Schuetz 2025 |
| Enterobacterales and P. aeruginosa, aminoglycosides | Higher breakpoints from 1979, applied to all isolates | Enterobacterales gentamicin and tobramycin susceptible ≤2 µg/mL and amikacin ≤4 µg/mL; P. aeruginosa tobramycin susceptible ≤1 µg/mL, amikacin restricted to urinary isolates, gentamicin breakpoints removed without classifying the organism as intrinsically resistant | 33rd (2023) | Schuetz 2025 |
Obsolete breakpoints on commercial systems. Clearance of a commercial system for a revised breakpoint can take years (Schuetz 2025). Commercial systems applying the revised piperacillin-tazobactam breakpoints for Enterobacterales showed unacceptable error rates (Manuel 2023). The laboratory's options are an alternative method for the affected organism-agent pairs, validation for off-label reporting, or suppression of the result, and a CDC and FDA Antimicrobial Resistance Bank isolate panel is available for validation studies (Schuetz 2025).
Reporting structure in M100 Table 1 and cascade reporting
M100 Tables 1 list the agents for testing and reporting. In the 33rd edition the three groups A, B and C became four tiers: tier 1 agents are appropriate for routine primary testing and reporting; tier 2 agents are appropriate for routine primary testing and may be reported under institutional cascading rules; tier 3 was created for institutions with high levels of multidrug-resistant organisms and follows institution-specific cascade rules; tier 4 agents are tested and reported on request. The layout changed from vertical to horizontal so that cascade reporting reads from narrow-spectrum tier 1 agents to broad-spectrum tier 3 agents (Schuetz 2025).
Selective reporting withholds or reports results according to criteria unrelated to the isolate's susceptibility profile, such as organism identity, body site, clinical setting or patient demographics; withholding aminoglycoside results for Salmonella and Shigella species is an example. Cascade reporting depends on the profile itself: results for broader-spectrum agents are released only when the isolate is resistant to primary or narrow-spectrum agents of the same class, either within a tier (carbapenems reported when cefepime tests resistant) or between tiers (a newer beta-lactam combination reported when cefepime and the carbapenems test resistant) (Schuetz 2025). Testing and reporting strategies aligned with antimicrobial stewardship are reviewed in Pierce 2023.
Beta-lactamases and their detection
Ambler classes and the extended-spectrum beta-lactamases
The molecular classification divides beta-lactamases into classes A, C and D, which use an active-site serine, and class B metalloenzymes, which require divalent zinc. The functional classification groups them as group 1 (class C) cephalosporinases, group 2 (classes A and D) broad-spectrum, inhibitor-resistant and extended-spectrum enzymes and serine carbapenemases, and group 3 metallo-beta-lactamases (Bush 2010).
ESBLs are class A enzymes that hydrolyze expanded-spectrum beta-lactams and are strongly inhibited by clavulanate; inhibition by clavulanate remains a requirement of the definition. They confer resistance to expanded-spectrum cephalosporins and monobactams and do not hydrolyze carbapenems or cephamycins (Castanheira 2021). TEM- and SHV-type enzymes predominated in the past, and CTX-M enzymes are now the most common type worldwide, with CTX-M-15 dominant, followed by CTX-M-14, and CTX-M-27 emerging in some regions. Inhibitor-resistant TEM and SHV derivatives (functional group 2br) resist clavulanate and sulbactam and mostly remain susceptible to tazobactam and avibactam (Castanheira 2021).
Reporting rules for ESBLs. The MERINO trial and the development of agents directed at specific mechanisms returned mechanism identification to practice, and the 33rd edition added comments in Tables 2A directing the laboratory to consult its stewardship program when deciding whether to perform phenotypic or genotypic ESBL testing for therapeutic management; laboratories may also report ESBLs for infection control (Schuetz 2025). Phenotypic ESBL testing gives false-negative results when AmpC enzymes are coproduced and false-positive results in isolates with multiple mechanisms (Schuetz 2025). IDSA guidance states that routine ESBL testing is not performed by most clinical microbiology laboratories and is not considered compulsory by CLSI (Tamma 2026). Suppression of a susceptible piperacillin-tazobactam result when an ESBL is detected is an institutional decision, because M100 contains no treatment recommendations (Schuetz 2025).
The combination disk method places a cephalosporin disk beside an amoxicillin-clavulanate disk at a center-to-center distance of 20–30 mm; expansion of the cephalosporin zone toward the inhibitor disk is a positive result (Dhavale 2026).
AmpC beta-lactamases
Certain species of Enterobacterales undergo derepression of an inducible chromosomal AmpC within days of therapy with certain third-generation cephalosporins, so an isolate that initially tests susceptible can become resistant. Derepression is most common in the Citrobacter freundii complex, the Enterobacter cloacae complex and Klebsiella aerogenes, formerly Enterobacter aerogenes, and M100 Table 1A lists cefepime as a tier 1 agent for these organisms (Schuetz 2025). IDSA guidance names the E. cloacae complex, K. aerogenes and C. freundii as the Enterobacterales most frequently at moderate risk of clinically significant inducible AmpC production (Tamma 2026; Tamma 2024). M100 comments state that these isolates may initially test susceptible to ceftriaxone, cefotaxime, ceftazidime and ceftaroline (Schuetz 2025).
Carbapenemases and carbapenem-resistant Enterobacterales
KPC-1 was described in K. pneumoniae, and its carbapenemase activity was inhibited by clavulanic acid (Yigit 2001). NDM-1 was characterized in K. pneumoniae from a patient who acquired a urinary tract infection in India, on a transferable region that conferred resistance to all antibiotics except fluoroquinolones and colistin (Yong 2009). OXA-48, identified in K. pneumoniae from Turkey, hydrolyzed penicillins and imipenem but not expanded-spectrum cephalosporins (Poirel 2004). CDC and IDSA define carbapenem-resistant Enterobacterales as organisms resistant to at least one carbapenem (imipenem, ertapenem, doripenem or meropenem) or producing a carbapenemase (Dhavale 2026; Tamma 2026).
| Detection method | Procedure | Interpretation | Source |
|---|---|---|---|
| Modified carbapenem inactivation method (mCIM) | A meropenem 10-µg disk is incubated with a 1-µL loopful of the test organism in 2 mL of tryptic soy broth for 4 hours ± 15 minutes at 35 °C, then transferred to Mueller-Hinton agar seeded with E. coli ATCC 25922 and incubated 18–24 hours | Positive: 6–15 mm, or pinpoint colonies within a 16–18 mm zone; indeterminate: 16–18 mm; negative: 19 mm or more with a clear zone | Pierce 2017; Dhavale 2026 |
| EDTA-modified carbapenem inactivation method (eCIM) | mCIM performed in parallel with EDTA-containing broth | An increase of at least 5 mm in the zone compared with mCIM indicates a metallo-beta-lactamase; sensitivity and specificity were 100% in the development study | Sfeir 2019; Dhavale 2026 |
| Carba NP and commercial colorimetric variants | Imipenem hydrolysis produces acid and a color change | Sensitivity 96.8% and specificity 100% for the in-house test and 99% and 100% for a commercial version; an OXA-244 producer was missed by all three tests evaluated | Dortet 2015 |
| Boronic acid combination disk | Phenylboronic acid inhibits KPC-type enzymes | Zone expansion with the inhibitor indicates a class A carbapenemase | Dhavale 2026 |
| Molecular detection | Amplification of carbapenemase genes, within a syndromic panel or as a stand-alone assay, in 2–3 hours | Identifies the gene family, which directs therapy; targets are listed in Bacterial Identification: Biochemical Tests, MALDI-TOF Mass Spectrometry, Sequencing and Rapid Molecular Panels | Dhavale 2026 |
Previous method. The modified Hodge test used E. coli ATCC 25922 as the indicator strain and read a cloverleaf indentation at the intersection of the indicator and test organisms as positive. It was displaced by the carbapenem inactivation methods because of poorer sensitivity, particularly for metallo-beta-lactamases (Dhavale 2026).
Multidrug-resistant gram-negative organisms and the agents tested against them
Difficult-to-treat resistance in P. aeruginosa is defined by nonsusceptibility to all of aztreonam, cefepime, ceftazidime, ciprofloxacin, imipenem, levofloxacin, meropenem and piperacillin-tazobactam (Tamma 2026). Selection among the newer agents is guided primarily by the carbapenemase mechanism identified together with susceptibility results, so identification of the mechanism (KPC, NDM or OXA-48-like) directs the choice among them (Tamma 2026).
Sulbactam-durlobactam was compared with colistin, each with imipenem-cilastatin, in a randomized phase 3 noninferiority trial in carbapenem-resistant A. baumannii-calcoaceticus complex infection (Kaye 2023). Testing panels therefore include the agents matched to each mechanism.
Resistance in gram-positive organisms and its phenotypic detection
Methicillin resistance in staphylococci
Methicillin resistance is mediated by mecA, which encodes the low-affinity penicillin-binding protein PBP2a. A divergent homologue, now designated mecC, was found in phenotypically resistant, mecA PCR-negative Staphylococcus aureus from cattle and humans; it is 70% identical to mecA and lies in a type XI SCCmec element (García-Álvarez 2011). Syndromic panels target mecA/C with MREJ (Bacterial Identification: Biochemical Tests, MALDI-TOF Mass Spectrometry, Sequencing and Rapid Molecular Panels).
Cefoxitin serves as the surrogate agent for mecA-mediated resistance. In 100 Staphylococcus epidermidis isolates, oxacillin broth microdilution and cefoxitin disk diffusion interpreted with coagulase-negative staphylococcal breakpoints separated mecA-positive from mecA-negative isolates reliably, and cefoxitin interpreted with the S. aureus and S. lugdunensis breakpoints gave 97.6% categorical agreement by disk (Naccache 2019). This is the basis for separate breakpoints for S. aureus and S. lugdunensis and for other coagulase-negative staphylococci. Revised oxacillin MIC breakpoints for selected staphylococci were introduced in the 31st edition (Humphries 2021).
Vancomycin-nonsusceptible staphylococci
Vancomycin-intermediate and heterogeneous vancomycin-intermediate S. aureus arose during the 2000s, are reported globally and are in many cases associated with glycopeptide treatment failure. Sequential point mutations in global regulatory genes produce the phenotype, which is associated predominantly with cell wall thickening and restricted access of vancomycin to its site of action in the division septum, and the phenotypic features vary because the responsible mutations vary (Howden 2010). Vancomycin-intermediate S. aureus is defined by a vancomycin MIC of 4–8 µg/mL under the categories CLSI set in 2006 (Howden 2010). Vancomycin-resistant S. aureus, defined by a vancomycin MIC of 16 µg/mL or more, emerged in the United States in 2002 and arises when vancomycin resistance genes such as the vanA operon transfer from vancomycin-resistant enterococci; every isolate reported to 2015 arose from methicillin-resistant S. aureus (Walters 2015). Detection of these phenotypes requires a dilution-based method, and the public health report follows the institution's reporting requirements.
Inducible clindamycin resistance
Macrolide resistance in staphylococci results from active efflux encoded by msrA or from ribosomal methylation encoded by ermA or ermC, and methylation-mediated resistance is constitutive or inducible. The induction test places erythromycin and clindamycin disks in adjacent positions, and flattening of the clindamycin zone adjacent to the erythromycin disk indicates inducible resistance. Of 114 erythromycin-resistant S. aureus isolates, 33 showed induction at all three disk distances tested, and none of the isolates carrying msrA alone showed induction (Fiebelkorn 2003). An isolate with a positive induction test is reported as clindamycin resistant.
Vancomycin resistance in enterococci
vanA and vanB are acquired determinants, and vanC-1 and vanC-2 are intrinsic (Clark 1998). High-level gentamicin resistance, defined by an MIC of 500 µg/mL or more, is mediated predominantly by aac(6')-Ie-aph(2'')-Ia, which encodes a bifunctional modifying enzyme and eliminates the synergy between gentamicin and a cell wall–active agent; other modifying enzyme genes also occur (Manoharan 2022). The screen for high-level aminoglycoside resistance therefore predicts whether combination therapy is possible.
Genotypic resistance detection and its discordance with phenotype
A resistance gene result and a susceptibility result answer different questions. Detection of a gene predicts a phenotype only for the mechanisms the assay targets, and a negative result does not exclude resistance by an untargeted mechanism (Rhoads 2023). M100 contains guidance on the handling of genotypic and phenotypic resistance discrepancies (Schuetz 2025). The comment introduced in the 32nd edition states that organisms testing susceptible to a beta-lactam alone are also considered susceptible to the corresponding beta-lactam combination agent, while organisms testing susceptible to the combination agent cannot be assumed susceptible to the beta-lactam alone (Schuetz 2025).
Susceptibility testing of fastidious organisms
Penicillin breakpoints for S. pneumoniae separate meningeal from nonmeningeal infection (Weinstein 2009). In H. influenzae, beta-lactamase production causes resistance to ampicillin and amoxicillin. Strains with altered penicillin-binding protein 3 (beta-lactamase negative ampicillin resistant, and beta-lactamase positive amoxicillin-clavulanate resistant) are increasing and resist ampicillin, amoxicillin, amoxicillin-clavulanate and many cephalosporins. Most strains remain susceptible to carbapenems and quinolones (Tristram 2007). For Neisseria gonorrhoeae, agar dilution is the reference method for susceptibility testing and resolves discrepant results obtained by disk diffusion or gradient strips (Kuipers 2025). A gentamicin quality control range for N. gonorrhoeae ATCC 49226 and azithromycin disk breakpoints were added in recent M100 editions (Schuetz 2025; Humphries 2021). Organism-level detail is covered in Gram-Positive Bacteria and Anaerobes: Staphylococci, Streptococci, Enterococci, Gram-Positive Rods and Clostridioides difficile and Gram-Negative Bacteria: Enterobacterales, Nonfermenters, Neisseria, Haemophilus and Fastidious Gram-Negative Rods.
Cumulative antibiograms
Rules for a cumulative susceptibility report (CLSI M39, 5th edition, 2022).
| Rule | Specification | Source |
|---|---|---|
| Isolate selection | Clinical or diagnostic isolates with final verified results | Bamford 2025 |
| Duplicate isolates | Only the first isolate of a species per patient in the analysis period, regardless of source or susceptibility profile | Bamford 2025 |
| Minimum number | At least 30 isolates per organism or organism group, reported with 95% confidence intervals | Bamford 2025 |
| Agents included | Agents tested routinely against all isolates | Bamford 2025 |
| Statistic reported | Percentage susceptible, calculated from results for all isolates whether or not they were released on patient reports | Bamford 2025 |
| Treatment of the intermediate category | Intermediate results are not grouped with susceptible under CLSI methods | Bamford 2025 |
The first-isolate rule removes the bias introduced by repeated isolates from sicker or longer-stay patients (Bamford 2025).
Verification of a new system or a new breakpoint
A validation study following CLSI M52 allows a laboratory to report results with a new breakpoint when the required dilutions are available on its commercial panel, and the preferred approach in the United States is a test with FDA clearance for the updated breakpoint (Richter 2025). Agreement is measured as essential agreement, meaning an MIC within one doubling dilution of the reference, and categorical agreement, meaning the same interpretive category; discrepancies are classified as very major errors (false susceptible), major errors (false resistant) and minor errors (Richter 2025). Acceptability criteria used in FDA device evaluations against broth microdilution are essential and categorical agreement of 90% or more, major errors of 3.0% or less and very major errors of 1.5% or less (Wang 2026). Very major errors appeared for aztreonam and ceftazidime on one commercial system despite overall categorical agreement above 94% (Richter 2025). The general verification framework is covered in Method Validation, Statistical Quality Control and Proficiency Testing in Clinical Chemistry.
Quality control of susceptibility testing
Quality control organisms and acceptable ranges are published in M100 Tables 4 and 5. Some quality control strains have unstable susceptibility characteristics, and a fresh subculture from frozen or freeze-dried stock every 2 weeks is specified for P. aeruginosa ATCC 27853, S. pneumoniae ATCC 49619 and Enterococcus faecalis ATCC 51299 (Schuetz 2025). Colistin results, including those of quality control strains, are significantly affected by testing materials when methods other than the CLSI reference methods are used (Schuetz 2025). Quality control statistics and proficiency testing are covered in Method Validation, Statistical Quality Control and Proficiency Testing in Clinical Chemistry.
Antimicrobial class resistance mechanism lookup
Gram-Positive Bacteria and Anaerobes: Staphylococci, Streptococci, Enterococci, Gram-Positive Rods and Clostridioides difficile
Definition. The gram-positive bacteria of clinical bacteriology comprise the catalase-positive cocci (staphylococci), the catalase-negative cocci (streptococci, enterococci and related genera), the aerobic gram-positive rods (Listeria, Corynebacterium, Bacillus, Erysipelothrix and others) and the anaerobes, which include Clostridioides difficile, the clostridia, Actinomyces and the anaerobic gram-negative rods recovered from the same specimens. Laboratory separation of these groups uses colony morphology and hemolysis, the catalase reaction, the coagulase reaction, a small set of hydrolytic and growth tests, and protein-based identification by mass spectrometry (Becker 2014; Bernard 2012; Alcalá 2021).
Related page: Microbiology Specimens, Stains, Culture Media and Blood Cultures (Gram stain technique, culture media, anaerobic transport, blood culture systems and contamination) Related page: Bacterial Identification: Biochemical Tests, MALDI-TOF Mass Spectrometry, Sequencing and Rapid Molecular Panels (biochemical identification tests, automated systems, MALDI-TOF mass spectrometry, select-agent database limits, syndromic panels and antigen tests) Related page: Antimicrobial Susceptibility Testing, Breakpoints and Resistance Mechanisms (breakpoints, cefoxitin screening for mecA, the D-zone test, vancomycin testing in staphylococci, VRE and high-level aminoglycoside screens, anaerobe susceptibility methods) Related page: Mycobacteria, Nocardia, Spirochetes, Mycoplasma, Chlamydia and Other Intracellular Bacteria (the Nocardia–Actinomyces comparison table and modified acid-fast staining) Related page: Respiratory Infections in Lung Cytology (filamentous bacteria in respiratory cytology) Related page: Organisms in Cervical Cytology (Actinomyces and shift in flora in cervical cytology) Related page: Synovial fluid cell counts and cytology: septic, rheumatoid and traumatic effusions (septic arthritis and prosthetic joint infection) Related page: Infections in Cerebrospinal Fluid Cytology (cerebrospinal fluid findings in bacterial meningitis) Related page: Analytical Methods and Immunoassays in Clinical Chemistry (MALDI-TOF mass spectrometry principles)
Staphylococcus aureus: coagulase and the superantigen toxins
Staphylococcus aureus is a catalase-positive gram-positive coccus in clusters and a leading cause of bacteremia, infective endocarditis, osteoarticular infection, skin and soft tissue infection and device-related infection (Tong 2015).
Production of secreted (free) coagulase separates S. aureus from the coagulase-negative staphylococci. The distinction is operational, because it was defined to separate S. aureus from staphylococci formerly regarded as less pathogenic (Becker 2014). Membrane-bound coagulase (clumping factor) is detected by slide agglutination and gives discordant results in some species (Frank 2008).
Superantigenic exotoxins cause toxic shock syndrome through unconventional polyclonal lymphocyte activation, with rapid shock and multiple organ failure. The principal staphylococcal superantigens are toxic shock syndrome toxin-1 and the staphylococcal enterotoxins, and staphylococcal toxic shock syndrome occurs in menstrual and nonmenstrual forms. Streptococcal toxic shock syndrome is mediated by streptococcal pyrogenic exotoxins A, B and C and streptococcal superantigen A, and accompanies severe group A streptococcal infection (Atchade 2024).
Coagulase-negative staphylococci: species identification and clinical significance
Coagulase-negative staphylococci are among the major nosocomial pathogens, with S. epidermidis and S. haemolyticus the most significant species in foreign body-related infection and in infection of preterm newborns. A large proportion of strains are methicillin resistant. Findings that support true infection include isolation in pure culture from the infected site and repeated isolation of the same strain over the course of the illness (Becker 2014).
Staphylococcus lugdunensis has a distinct profile. It lacks secreted coagulase, and a membrane-bound form present in some isolates produces a positive slide agglutination result and misidentification as S. aureus (Frank 2008). Infections caused by S. lugdunensis resemble those caused by S. aureus, including acute destructive native valve endocarditis that often requires surgery, and the species shares CLSI antimicrobial susceptibility breakpoints with S. aureus (Frank 2008). Isolates are positive for acetoin production, nitrate reduction, ornithine decarboxylase and pyrrolidonyl arylamidase (PYR), negative for oxidase and alkaline phosphatase, and susceptible to novobiocin (Frank 2008).
Staphylococcus saprophyticus subsp. saprophyticus colonizes the rectum and genitourinary tract and has been associated with acute urethritis (Becker 2014). Novobiocin disk testing on Mueller-Hinton agar or tryptic soy sheep blood agar with a 5-µg disk separates the intrinsically resistant S. saprophyticus subsp. saprophyticus from other clinically important coagulase-negative staphylococci of the S. epidermidis group, and this test is applied to urinary isolates (Becker 2014).
Identification of staphylococci relevant to reporting.
| Organism | Tube coagulase | Slide agglutination (clumping factor) | Novobiocin | Other features | Source |
|---|---|---|---|---|---|
| Staphylococcus aureus | Positive | Positive | Susceptible | Secreted coagulase present; protein A present | Becker 2014; Frank 2008 |
| Staphylococcus lugdunensis | Negative | Positive in a variable proportion of strains | Susceptible | PYR positive, ornithine decarboxylase positive, no protein A | Frank 2008 |
| Staphylococcus epidermidis group | Negative | Negative | Susceptible | Most frequent device-associated species | Becker 2014 |
| Staphylococcus saprophyticus subsp. saprophyticus | Negative | Negative | Resistant | Urinary isolates; novobiocin disk 5 µg | Becker 2014 |
Streptococcus pyogenes and the laboratory diagnosis of pharyngitis
Clinical features alone do not reliably separate group A streptococcal pharyngitis from viral pharyngitis, except where overt viral features such as rhinorrhea, cough, oral ulcers or hoarseness are present, so a throat swab is tested by rapid antigen detection test, culture, or both (Shulman 2012). In children and adolescents a negative rapid antigen result is confirmed by throat culture, because the sensitivity of rapid antigen tests is below 90% in most studied pediatric populations (Shulman 2012). Routine back-up culture is not recommended for adults in usual circumstances, given the low incidence of group A streptococcal pharyngitis in adults and the exceptionally low risk of subsequent acute rheumatic fever (Shulman 2012). Antistreptococcal antibody titers reflect past events and are not recommended for the diagnosis of acute pharyngitis (Shulman 2012).
Streptococcus dysgalactiae subsp. equisimilis causes infection ranging from skin and soft tissue infection to streptococcal toxic shock syndrome and necrotizing fasciitis, at a crude invasive incidence approaching that of S. pyogenes, and the two species share virulence factors and mobile genetic elements (Xie 2024).
Streptococcus agalactiae: prenatal screening and susceptibility testing
Group B streptococcus is the leading cause of newborn infection, and maternal genitourinary and gastrointestinal colonization is the primary risk factor. About 50% of colonized patients transmit the organism to the newborn, and without intrapartum prophylaxis 1%–2% of those newborns develop early-onset disease (ACOG 2020). ACOG recommends universal screening by vaginal-rectal culture at 36 0/7 to 37 6/7 weeks of gestation (ACOG 2020). Previous rule: CDC recommended screening at 35–37 weeks of gestation (Verani 2010). Shifting collection one week later extends the 5-week predictive window of the screening test to 41 0/7 weeks (Filkins 2020).
Culture remains the basis of detection. Biochemical testing and latex agglutination are acceptable for identification, protein-based identification by mass spectrometry is preferred where an instrument is available, and mass spectrometry separates S. agalactiae from group B antigen-agglutinating strains of Streptococcus halichoeri and Streptococcus pseudoporcinus (Filkins 2020). Nucleic acid amplification tests performed after broth enrichment are acceptable for detection and identification, and laboratories performing them maintain culture so that susceptibility testing can be performed on isolates that require it (Filkins 2020). Direct-from-specimen group B streptococcal amplification tests without enrichment have poor sensitivity and a low negative predictive value, and the 2020 laboratory guideline does not endorse them (Filkins 2020).
Group B streptococcus is predictably susceptible to penicillin and ampicillin, the agents used for intrapartum prophylaxis. Clindamycin is the preferred agent for patients with severe penicillin allergy, and resistance of S. agalactiae to macrolides and lincosamides can exceed 40%, so susceptibility testing is performed on isolates from patients with severe penicillin allergy (Filkins 2020).
Streptococcus pneumoniae and the mitis group
Reliable separation of S. pneumoniae from the viridans group streptococci has been difficult even with 16S rRNA gene sequencing and mass spectrometry, and database version and interpretation algorithm determine performance, with misidentification of mitis group isolates as S. pneumoniae falling from the majority of isolates to none across database and algorithm updates (Harju 2017). The phenotypic and molecular confirmation rules are covered in Bacterial Identification: Biochemical Tests, MALDI-TOF Mass Spectrometry, Sequencing and Rapid Molecular Panels.
Pneumococcal urinary antigen testing provides rapid identification. Among patients with acute respiratory failure and suspected pneumonia, pooled sensitivity was 0.66 (95% CI 0.62–0.69) and pooled specificity was 0.90 (95% CI 0.85–0.93) against culture or smear methods (Yasuo 2022).
Viridans streptococci, Granulicatella and other catalase-negative gram-positive cocci
The Streptococcus anginosus group comprises S. anginosus, S. intermedius and S. constellatus, which are oral commensals and opportunistic pathogens identified to species level by molecular methods (Pilarczyk-Zurek 2022). Streptococcus gallolyticus (S. bovis biotype I) is associated with colorectal neoplasia: the pooled odds ratio for colorectal cancer was 7.26 (95% CI 3.94–13.36) and for infective endocarditis 16.61 (95% CI 8.85–31.16) compared with S. bovis biotype II infection (Boleij 2011).
Granulicatella and Abiotrophia species were originally classified as nutritionally variant streptococci. They are oral flora and cause invasive infection, most often bacterial endocarditis, which is managed as enterococcal endocarditis is (Cargill 2012). Aerococcus urinae grows from the urine of predominantly elderly patients and behaved as a relatively avirulent organism in a review of 54 patients (Sierra-Hoffman 2005).
Several non-enterococcal gram-positive genera are intrinsically glycopeptide resistant, including Lactobacillus, Leuconostoc, Pediococcus and Weissella, and erythromycin was the most active agent against them (Vay 2007). Lactobacillus bacteremia occurs in patients with severe or fatal comorbidity after immunosuppression, prolonged hospitalization or surgery, with 1-month mortality of 26% (Salminen 2004). Rothia mucilaginosa is part of the oral and upper respiratory flora and is a rare cause of bacteremia in pediatric oncology patients (Poyer 2019).
Enterococcus faecium: intrinsic and acquired resistance
The ratio of E. faecalis to E. faecium infection has shifted toward E. faecium. The shift is attributed to intrinsic and acquired resistance and to the spread of hospital-adapted strains of clonal complex 17 (Cattoir 2014). Enterococcus faecium is naturally resistant to cephalosporins and, at low level, to aminoglycosides; most modern isolates are highly resistant to ampicillin, and a substantial proportion are glycopeptide resistant, particularly in the United States (Cattoir 2014). Resistance to linezolid, daptomycin and tigecycline remains uncommon, and isolates with reduced susceptibility have been reported (Cattoir 2014).
Listeria monocytogenes in pregnancy and in older adults
Listeria monocytogenes is a gram-positive, facultative intracellular rod that survives cold temperatures, and infection is mainly foodborne. Bacteremia is the most common invasive form and is difficult to recognize. Neurolisteriosis affects mainly older or immunosuppressed patients; L. monocytogenes caused 16% of community-acquired bacterial meningitis in patients older than 80 years, with a case fatality rate of 13%–36% (Koopmans 2023). Maternal-fetal listeriosis presents mostly in the third trimester and manifests as maternal fever, premature delivery, fetal loss and neonatal systemic and central nervous system infection; clonal complexes 1, 4 and 6 are most often implicated (Charlier 2020).
Penicillin and the aminopenicillins ampicillin and amoxicillin are the first-choice agents, and clinically significant acquired resistance to first-line drugs is rare, with 1.27% of isolates resistant in a large collection, mostly to tetracycline or ciprofloxacin (Koopmans 2023). Listeria monocytogenes is naturally resistant to antibiotics that bind penicillin-binding protein 3 poorly, including the cephalosporins, and complete blockade of penicillin-binding proteins 1, 2 and 4 does not compensate, because PBP3 is the critical listerial target and acts in the late stages of peptidoglycan synthesis (Koopmans 2023). Empiric cephalosporin therapy for meningitis therefore does not cover Listeria, and ampicillin is added when listeriosis is a consideration (Koopmans 2023).
Corynebacterium diphtheriae and the other coryneform bacteria
Catalase-positive gram-positive bacilli called diphtheroids or coryneform bacteria were formerly reported as contaminants and are increasingly implicated as the cause of significant infection, antimicrobial susceptibility data are limited, and identification uses phenotypic methods, genetic methods and mass spectrometry (Bernard 2012). Potentially toxigenic corynebacteria are recovered on selective tellurite-containing media as part of the laboratory diagnosis of diphtheria (Efstratiou 1999). Detection of toxigenicity in C. diphtheriae and C. ulcerans is the confirmatory test, and a modified Elek immunoprecipitation test gives an accurate result after 16 hours of incubation (Engler 1997). Toxin gene detection by real-time PCR is performed in reference and public health laboratories (Efstratiou 1999).
Among the nondiphtherial species, C. jeikeium is a skin commensal that causes left-sided endocarditis and is characteristically resistant to penicillin, cephalosporins and aminoglycosides (Gupta 2021). Corynebacterium striatum is an emerging nosocomial multidrug-resistant pathogen reported in pacemaker endocarditis (Fernández Guerrero 2013). Clinical relevance of a coryneform isolate is assessed against the specimen type, the purity of growth and repeated isolation (Funke 1997).
Arcanobacterium haemolyticum causes pharyngotonsillitis in children and young adults, with a median age of 16.5 years among 191 reported patients (Sayad 2021). Isolates are catalase negative and reverse CAMP positive and carry the phospholipase D gene, and identification is confirmed by commercial biochemical panels and mass spectrometry (Miyamoto 2015).
Bacillus anthracis rule-out, Bacillus cereus and Erysipelothrix rhusiopathiae
Bacillus anthracis is a large, aerobic, spore-bearing gram-positive bacillus measuring 1–1.5 × 3–10 µm and is the only obligate pathogen of the genus (Spencer 2003). Direct Gram stain of vesicle or eschar material, blood or cerebrospinal fluid shows encapsulated large gram-positive bacilli in short chains, blood agar grows grey-white flat colonies with irregular edges after 18–24 hours, and any presumptive colony is referred to a reference laboratory for confirmation (Spencer 2003). Mass spectrometric identification of highly pathogenic organisms requires both a safe inactivating preparation method and a security-relevant or research-use database, because the diagnostic databases alone are insufficient (Rudrik 2017); the platform limits are covered in Bacterial Identification: Biochemical Tests, MALDI-TOF Mass Spectrometry, Sequencing and Rapid Molecular Panels.
Sentinel laboratory rule-out uses a short set of features and stops short of identification. A large gram-positive rod that is nonhemolytic on sheep or horse blood agar and nonmotile cannot be ruled out as B. anthracis and is referred to a Laboratory Response Network reference laboratory, whereas β-hemolysis or motility rules it out. Motility is most reliably detected on a wet mount read after a 2-hour incubation in trypticase soy broth, and a B. anthracis-selective agar such as PLET (polymyxin, lysozyme, EDTA, thallous acetate) is used to screen isolates (Papaparaskevas 2004). The capsule is seen in smears from blood or tissue with the polychrome methylene blue (McFadyean) stain and is not formed on plates unless the medium contains bicarbonate or serum and the plate is incubated in 5%–10% carbon dioxide (Spencer 2003).
Bacillus cereus is a motile, spore-forming aerobic or facultatively anaerobic rod whose pathogenicity depends on tissue-destructive exoenzymes, including four hemolysins, three phospholipases, three pore-forming enterotoxins and an emetic toxin that is formed in the contaminated food (Bottone 2010). Beyond food poisoning it causes severe eye infection, fulminant sepsis and central nervous system infection in neonates and immunosuppressed patients, and isolates from these patients are misreported as insignificant contaminants (Bottone 2010).
Erysipelothrix rhusiopathiae is a facultative, non-spore-forming, non-acid-fast small gram-positive bacillus (Wang 2010). It is distinguished from other gram-positive bacilli by nonmotility, hydrogen sulfide production and negative oxidase and catalase reactions, and it is intrinsically vancomycin resistant, with a vancomycin MIC of 64 µg/mL in a reported bloodstream isolate (Lo 2024). Human infection is occupationally acquired through contact with animals, animal products, wastes or soil and takes three forms: localized cutaneous infection (erysipeloid), diffuse cutaneous infection and septicemia often with endocarditis (Wang 2010). Underdiagnosis is attributed to the resemblance to other infections and to the difficulty of isolation and identification (Brooke 1999).
Anaerobe culture, identification and susceptibility testing
Mass spectrometry is a reliable identification method for anaerobes, because it requires little biomass and these organisms grow slowly and are difficult to isolate. With an updated database, 95.7% of anaerobic isolates were identified to species level, against 16S rRNA gene sequencing as the reference method (Alcalá 2021).
Bacteroides fragilis is a pleomorphic, nonpigmented, nonmotile, encapsulated anaerobic gram-negative rod. It is catalase positive, which is uncommon among anaerobes, and indole negative, it grows well in the presence of 20% bile, and it is resistant to the vancomycin, kanamycin and colistin special-potency disks; these four features give a presumptive identification (Gajdács 2017; Wexler 2007). Growth on Bacteroides bile-esculin agar is distinctive and is the selective step used to recover the group from polymicrobial specimens, because 20% bile inhibits most other anaerobes apart from Bilophila (Wexler 2007; Gajdács 2017).
Susceptibility testing of anaerobes is performed on organisms recovered from sterile body sites, isolated in pure culture, or clinically important with variable susceptibility patterns, and individual isolate testing is considered for Bacteroides, Prevotella, Fusobacterium and Clostridium species (Brook 2013). In a national survey of 1,957 Bacteroides fragilis group isolates over 2006–2009, clindamycin resistance reached 60% and moxifloxacin resistance exceeded 80%, tigecycline resistance remained low at 5.4%, and carbapenem resistance in B. fragilis was 1.1%–2.5%, with the cfiA gene detected in isolates with elevated carbapenem MICs (Snydman 2011).
Gram-positive anaerobic cocci account for about 25%–30% of anaerobic isolates from clinical specimens and are mostly recovered from polymicrobial infection (Murphy 2013). Cutibacterium acnes recovered from revision shoulder arthroplasty requires attention to the time to growth: among 46 cases cultured anaerobically for a mean of 13.1 ± 3 days, time to growth was significantly shorter in probable true-positive cultures than in probable contaminant cultures (p = 0.002) (Frangiamore 2015). Prosthetic joint infection criteria and synovial fluid thresholds are covered in Synovial fluid cell counts and cytology: septic, rheumatoid and traumatic effusions.
Actinomyces species are anaerobic gram-positive bacteria that colonize the mouth and the digestive and genital tracts, and the disease resembles malignancy at several anatomic sites. Prolonged anaerobic culture is required for identification, and histopathology is the other basis of diagnosis (Valour 2014). Cervicofacial, pelvic and pulmonary presentations and the cytologic and tissue findings are covered in Organisms in Cervical Cytology and Respiratory Infections in Lung Cytology. Actinomyces is not acid fast; the comparison with Nocardia is given in Mycobacteria, Nocardia, Spirochetes, Mycoplasma, Chlamydia and Other Intracellular Bacteria.
Clostridium and Fusobacterium species in blood cultures
Among 81 patients with at least one blood culture positive for any Clostridium species over 8 years, 70 (86.4%) met criteria for clinically relevant bacteremia, and 30-day mortality in clinically relevant bacteremia was 31.4% (Stabler 2020). Clostridium septicum bacteremia occurs with malignancy or immunosuppression: associated malignancy was found in four of five patients with blood culture-proven infection in a 10-year series, two with colorectal cancer and two with hematologic malignancy (Chew 2001).
Clostridium perfringens grows anaerobically on sheep blood agar as grey-white colonies with a double zone of hemolysis, and the organism carries plc, encoding the α-toxin phospholipase C, and pfoA, encoding the θ-toxin perfringolysin (Ben Saïd 2024). The α-toxin is a lecithinase that destroys the membranes of red cells, leukocytes and surrounding tissue cells, and its production is detected by the Nagler reaction on egg-yolk agar (Gajdács 2017). Spore position aids clostridial identification: C. perfringens forms central oval spores, C. tetani round terminal spores, and C. botulinum and C. difficile oval subterminal spores (Gajdács 2017).
Botulism is caused by botulinum neurotoxin types A, B, E and F produced by Clostridium botulinum groups I and II, Clostridium butyricum and Clostridium baratii. Routine laboratory diagnosis uses detection of neurotoxin in the patient by the mouse lethality assay, and molecular methods targeted to the neurotoxin genes do not detect biologically active neurotoxin and are not used alone (Lindström 2006).
Fusobacterium necrophorum is the most common cause of Lemierre syndrome, which comprises bacteremia, internal jugular vein thrombophlebitis and metastatic septic emboli after acute pharyngeal infection; pharyngitis or tonsillitis is the source in more than 85% of cases (Lee 2020).
Clostridioides difficile: testing criteria and test combinations
Clostridioides difficile infection is defined by symptoms, usually diarrhea, together with a stool test positive for C. difficile toxins or detection of toxigenic C. difficile, or colonoscopic or histopathologic findings of pseudomembranous colitis (McDonald 2018). Toxins A (TcdA) and B (TcdB), and in some strains the binary toxin CDT, are the primary mediators of inflammation (Smits 2016). The hypervirulent ribotype 027 lineage remains one of the most commonly identified strains in the United States (McDonald 2018; Tickler 2025).
Current guideline. The IDSA/SHEA 2017 guideline specifies the following laboratory rules (McDonald 2018):
- Patients with unexplained and new-onset 3 or more unformed stools in 24 hours are the preferred target population for testing.
- Where there are no preagreed institutional criteria for stool submission, a stool toxin test is used as part of a multistep algorithm (glutamate dehydrogenase [GDH] plus toxin; GDH plus toxin arbitrated by nucleic acid amplification test [NAAT]; or NAAT plus toxin) in preference to NAAT alone for all specimens received.
- Where preagreed institutional criteria for stool submission exist, NAAT alone or a multistep algorithm is used in preference to a toxin test alone.
- Repeat testing within 7 days during the same episode of diarrhea is not performed, and stool from asymptomatic patients is not tested except for epidemiologic studies.
- Testing is never routinely recommended for neonates or infants 12 months of age or younger with diarrhea, because asymptomatic carriage of toxigenic C. difficile is highly prevalent; carriage rates among asymptomatic infants can exceed 40%, and toxin is still detectable in about 15% of 12-month-old infants.
- Testing is not routinely performed in children 1–2 years of age with diarrhea unless other infectious and noninfectious causes have been excluded. By 2–3 years of age about 1%–3% of children are asymptomatic carriers, a rate similar to healthy adults.
Previous rule. The SHEA/IDSA 2010 guideline used a literature search cutoff of 2009, and the first US cleared molecular platform for C. difficile did not become available until 2009, so the 2010 recommendations were written before NAATs were in general use (Cohen 2010; McDonald 2018). That guideline already held that toxin enzyme immunoassay alone is not an adequate stand-alone test and supported toxigenic culture as the reference method for method comparison, and the multistep approach then in use screened with GDH and confirmed positives with a cytotoxicity assay or toxigenic culture (Burnham 2013). The 2017 update retains the clinical definition and manifestations of infection unchanged and refers the reader to the 2010 document for them; what it adds is the set of NAAT-containing algorithms above and the dependence of the recommendation on whether preagreed institutional criteria for stool submission exist (McDonald 2018).
The 2021 IDSA/SHEA focused update addresses the use of fidaxomicin and bezlotoxumab for treatment and does not revise the diagnostic recommendations (Johnson 2021). The ACG guideline covers prevention, diagnosis and treatment of C. difficile infection in adults (Kelly 2021).
Laboratory methods for C. difficile. Toxigenic culture and cell culture cytotoxicity neutralization assay are the two reference methods. Specificity in this table is specificity for C. difficile infection; analytic detection of the organism or its toxin genes is specific, and the limitation is that carriage is common (McDonald 2018).
| Test | Sensitivity | Specificity | Substance detected | Source |
|---|---|---|---|---|
| Toxigenic culture | High | Low; must be combined with a toxin test | Vegetative cells or spores | McDonald 2018 |
| Nucleic acid amplification test | High | Low to moderate | Nucleic acid (toxin genes) | McDonald 2018 |
| Glutamate dehydrogenase immunoassay | High | Low; must be combined with a toxin test | Common antigen | McDonald 2018 |
| Cell culture cytotoxicity neutralization assay | High | High | Free toxins | McDonald 2018 |
| Toxin A and B enzyme immunoassay | Low | Moderate | Free toxins | McDonald 2018 |
Toxigenic culture uses prereduced cycloserine-cefoxitin-fructose agar or a variant, anaerobic incubation for several days and a heat or alcohol spore-selection step applied to the stool, followed by organism identification and a toxin test on the isolate (McDonald 2018). The cytotoxicity neutralization assay applies a stool filtrate to a cell monolayer and reads cytopathic effect for up to 48 hours, with parallel neutralizing antibody to confirm that the effect is toxin mediated; the method is cumbersome and unstandardized (McDonald 2018). Glutamate dehydrogenase is present in toxigenic and nontoxigenic isolates, so the immunoassay is combined with a toxin test or a molecular test (McDonald 2018). Molecular platforms detect targets including tcdA and tcdB, and their positive predictive value for infection is low to moderate depending on disease prevalence and the limit of detection (McDonald 2018). Asymptomatic colonization reaches 3%–26% among adult inpatients, and diarrhea in hospitalized patients is attributable to C. difficile in fewer than 30% of patients (McDonald 2018).
TOOL CANDIDATE: C. difficile multistep algorithm result interpretation (IDSA/SHEA 2017).
| GDH | Toxin A/B enzyme immunoassay | NAAT | Interpretation under the IDSA/SHEA 2017 algorithm | Source |
|---|---|---|---|---|
| Negative | Negative | Not performed | Toxigenic C. difficile not detected | McDonald 2018 |
| Positive | Positive | Not performed | Toxigenic C. difficile with detectable free toxin | McDonald 2018 |
| Positive | Negative | Positive | Toxigenic C. difficile detected without detectable free toxin; detection of the organism without free toxin does not separate infection from colonization, so the result is interpreted against the clinical criteria. Use of molecular tests alone is likely to lead to overdiagnosis and overtreatment, and in one cohort the positive predictive values of GDH and NAAT were below 50% in a population in which 36% of patients tested did not have clinically significant diarrhea | McDonald 2018 |
| Positive | Negative | Negative | C. difficile antigen detected and a toxigenic strain not detected (nontoxigenic strain or false-positive screen); reported as negative for C. difficile infection | McDonald 2018 |
| Not performed | Positive | Positive | Toxigenic C. difficile with detectable free toxin (NAAT-plus-toxin algorithm) | McDonald 2018 |
| Not performed | Negative | Positive | Toxigenic C. difficile detected without detectable free toxin (NAAT-plus-toxin algorithm); the same colonization caveat applies, and the result is interpreted against the clinical criteria | McDonald 2018 |
Gram-Negative Bacteria: Enterobacterales, Nonfermenters, Neisseria, Haemophilus and Fastidious Gram-Negative Rods
Definition. The aerobic and facultatively anaerobic gram-negative bacteria of clinical bacteriology fall into three laboratory groups: the oxidase-negative, glucose-fermenting Enterobacterales; the nonfermenters, including Pseudomonas, Acinetobacter, Stenotrophomonas and Burkholderia; and the fastidious organisms that need enriched or selective media, increased carbon dioxide, defined growth factors, altered temperature or prolonged incubation, among them Neisseria, Haemophilus, the HACEK group, Bordetella, Legionella, Brucella, Francisella and Bartonella. Group assignment uses the Gram stain, the oxidase reaction, growth on MacConkey agar, lactose fermentation and carbohydrate utilization, with species-level identification by automated panels, mass spectrometry or sequencing (Adeolu 2016; Saiman 2024; Papp 2014).
Related page: Microbiology Specimens, Stains, Culture Media and Blood Cultures (culture media, selective and differential agars, blood culture systems, biosafety and specimen rejection) Related page: Bacterial Identification: Biochemical Tests, MALDI-TOF Mass Spectrometry, Sequencing and Rapid Molecular Panels (biochemical identification, automated systems, mass spectrometry limitations and select-agent databases, syndromic panels and urinary antigen tests) Related page: Antimicrobial Susceptibility Testing, Breakpoints and Resistance Mechanisms (extended-spectrum β-lactamases, AmpC, carbapenemases, DTR Pseudomonas aeruginosa, β-lactamase and BLNAR testing in Haemophilus influenzae, gonococcal agar dilution) Related page: Gram-Positive Bacteria and Anaerobes: Staphylococci, Streptococci, Enterococci, Gram-Positive Rods and Clostridioides difficile (anaerobe culture, identification and susceptibility testing) Related page: Mycobacteria, Nocardia, Spirochetes, Mycoplasma, Chlamydia and Other Intracellular Bacteria (serology, nucleic acid amplification and special culture for organisms that routine culture does not detect) Related page: Transfusion Reactions (septic transfusion reactions, including Yersinia enterocolitica in red cell components) Related page: Infections in Cerebrospinal Fluid Cytology (cerebrospinal fluid findings in bacterial meningitis) Related page: Granulomatous Lymphadenitis (Cytology) (histologic workup of cat-scratch lymphadenitis) Related page: Organisms in Cervical Cytology (cervical cytology findings in genital tract infection)
Neisseria gonorrhoeae: extragenital amplification testing and resistance
Nucleic acid amplification tests increased detection of extragenital gonococcal and chlamydial infection. In a sexually transmitted disease clinic that moved from culture to amplification testing for men who have sex with men, rectal gonococcal test positivity rose from 9.0% to 9.7% and pharyngeal positivity from 5.8% to 6.5%, while rectal chlamydial positivity rose from 7.4% to 11.9% (Barbee 2014). Amplification testing outperforms every other available test for overall sensitivity, specificity and ease of specimen transport, and CDC recommends it for urogenital infection; the tests are not FDA cleared for rectal and oropharyngeal specimens, and CDC recommends them for those sites on the basis of increased sensitivity and easier transport (Papp 2014).
Neisseria gonorrhoeae has developed resistance to every first-line therapy, and azithromycin resistance rose rapidly after 2015. The 2020 treatment recommendations and the 2021 CDC sexually transmitted infections treatment guidelines are built on treating the individual, protecting the population and limiting further resistance (Barbee 2022; Workowski 2021). Culture is necessary for susceptibility testing, because a viable isolate is required, and culture remains the method used when treatment failure is suspected (Papp 2014).
Culture and identification. Specimens from normally nonsterile sites are streaked on a selective medium such as Thayer-Martin or Martin-Lewis, and specimens from sterile sites on nonselective chocolate agar. The media use a base supplemented with chocolatized (heated) equine or bovine blood, and the selective versions add vancomycin, colistin and nystatin or another antifungal agent to suppress other bacteria and fungi; some gonococcal strains are themselves inhibited on selective media. Inoculated media are incubated at 35 °C–36.5 °C in an atmosphere supplemented with 5% carbon dioxide, supplied by an incubator, a candle-extinction jar or carbon dioxide-generating tablets, and are examined at 24 and 48 hours. Nonnutritive swab transport systems may maintain gonococcal viability for up to 48 hours at ambient temperature, and local environmental conditions affect viability. A gram-negative, oxidase-positive diplococcus growing on selective medium from a genital specimen may be reported as a presumptive identification, which is enough to start therapy, and a confirmed identification requires additional biochemical tests, because any Neisseria species, Moraxella catarrhalis and coccobacilli such as Kingella denitrificans can give the same presumptive picture. Neisseria gonorrhoeae produces acid from glucose and not from maltose, lactose or sucrose (Papp 2014).
Neisseria meningitidis: serogroups and laboratory-acquired infection
Serogroups. The capsular polysaccharide is the basis of meningococcal serogrouping, and at least 13 groups have been defined by the immunologic reactivity and structure of the capsule: A, B, C, E-29, H, I, K, L, W-135, X, Y, Z and Z' (29E). Only six groups, A, B, C, W-135, X and Y, cause life-threatening disease. The capsules associated with invasive disease are composed of sialic acid derivatives, apart from the group A capsule, which consists of repeating units of N-acetyl-mannosamine-1-phosphate. The group B capsule is an α(2→8)-linked sialic acid homopolymer identical in structure to human fetal neural cell adhesion molecule, which accounts for the poor immune response to it and for the exclusion of group B from the licensed polysaccharide and conjugate-polysaccharide vaccines. Serogroup identification is performed by slide agglutination or PCR (Rouphael 2012).
Neisseria meningitidis is an uncommon but documented laboratory-acquired infection. Sixteen probable cases in laboratory workers occurring worldwide between 1985 and 2001 were identified, including six United States cases between 1996 and 2000, and the cases followed occupational exposure to an isolate of the same serogroup within 14 days of illness onset (Sejvar 2005). Eight of the 16 cases were fatal, nine were serogroup B and seven serogroup C, isolate manipulation had been performed without respiratory protection in 15 of 16 cases, and the attack rate among microbiologists was 13 per 100,000 against 0.2 per 100,000 in United States adults; prevention is stated as a class II biological safety cabinet or additional respiratory protection (Sejvar 2005). Manipulation of suspected N. meningitidis isolates takes place in a certified biological safety cabinet.
Enterobacterales: the 2016 taxonomy
Comparative genomic analysis of 1,548 core proteins, 53 ribosomal proteins and four multilocus sequence analysis proteins supported seven distinct monophyletic groups within the former 'Enterobacteriales' and led to the proposal of the order Enterobacterales, divided into the families Enterobacteriaceae, Erwiniaceae, Pectobacteriaceae, Yersiniaceae, Hafniaceae, Morganellaceae and Budviciaceae (Adeolu 2016). The earlier family-level name Enterobacteriaceae now covers a narrower set of genera, and reports and susceptibility tables that use the order name follow the 2016 taxonomy (Adeolu 2016).
Escherichia coli pathotypes and Shiga toxin detection
Escherichia coli is both a commensal of the gastrointestinal tract and the cause of diarrheal and extraintestinal disease. The diarrheagenic pathotypes share features of mucosal colonization and differ in course, onset and complications. Several have low infectious doses, and all are transmitted through food and water (Croxen 2013).
Current recommendation. All stools submitted for routine testing from patients with acute community-acquired diarrhea, regardless of patient age, season or the presence or absence of blood in the stool, are simultaneously cultured for E. coli O157:H7 and tested with an assay that detects Shiga toxins, so that non-O157 Shiga toxin-producing strains are detected (Gould 2009). The same report gives procedures for specimen selection, handling and transport and reviews culture and nonculture methods (Gould 2009). Previous guidance: laboratory recommendations published in 2006, which the 2009 report replaced (Gould 2009).
Culture-independent diagnostic tests have displaced culture for several enteric pathogens, and the loss of the isolate removes the material needed for whole-genome sequencing-based outbreak detection. Among the clinical laboratories surveyed in 10 FoodNet sites during 2012–2019, between 664 and 723 per year, the proportion using only culture fell, with the largest declines for Vibrio (99% to 57%) and Yersinia (99% to 60%); in 2019 the proportion using only culture-independent tests was highest for Shiga toxin-producing E. coli (43%), Campylobacter (34%) and Vibrio (34%); and from 2015 to 2019 the proportion performing reflex culture after a positive culture-independent test fell, with the largest declines for Shigella (75% to 42%) and Salmonella (70% to 38%) (Ray 2022).
Klebsiella pneumoniae, Enterobacter cloacae and Klebsiella aerogenes
Hypervirulent Klebsiella pneumoniae infects people in the community, including healthy people. Infection presents at several sites or spreads metastatically, requires source control, and causes central nervous system infection and endophthalmitis more often than infection with classical strains (Russo 2019). The genetic determinants are carried on a large virulence plasmid, and integrative conjugal elements are also implicated; increased capsule production and aerobactin production are established virulence factors, and infection is more common in the Asian Pacific Rim and occurs globally (Russo 2019).
Enterobacter aerogenes was reclassified as Klebsiella aerogenes on the basis of its genotypic similarity to Klebsiella (Álvarez-Marín 2021). In a 3-year multicenter prospective cohort of 285 patients with bacteremia, 196 (68.8%) were caused by Enterobacter cloacae and 89 (31.2%) by K. aerogenes, and the clinical profiles were more similar than different (Álvarez-Marín 2021). Chromosomal inducible AmpC β-lactamase in these organisms is covered in Antimicrobial Susceptibility Testing, Breakpoints and Resistance Mechanisms.
Proteus mirabilis in urinary tract infection
Proteus mirabilis is most often a urinary pathogen, particularly in patients with long-term catheterization. Its virulence factors include urease with stone formation, fimbriae and other adhesins, iron and zinc acquisition, proteases, toxins and biofilm formation, and swarming motility produces the concentric growth seen on culture media (Schaffer 2015).
Salmonella and Shigella
Blood culture is the standard diagnostic method for enteric fever, and bone marrow culture is more sensitive. In a prospective study of 64 patients with proven typhoid fever, 44% yielded Salmonella Typhi on blood culture and 59% on bone marrow culture; among the 31 patients tested by both methods the yields were 35% and 61% respectively (p < 0.05) (Akoh 1991). Enteric fever caused by S. Typhi and S. Paratyphi remains a major global cause of febrile illness, and antimicrobial resistance shapes current management (Kuehn 2025). Serotype information is the basis of food safety and public health action, and whole-genome sequencing provides serovar prediction with in silico tools such as SISTR, SeqSero and in silico 7-gene multilocus sequence typing; in 1,041 isolates typed by both methods, SeqSero and traditional serology agreed in 86.4%, differed in 7.7% and gave no prediction in 5.9% (Ibrahim 2018).
Shigella sonnei is a major cause of diarrhea worldwide and is increasing in prevalence relative to other Shigella species; genomic surveillance has clarified its antimicrobial resistance, evolution and transmission (Scott 2025). Shigella species and E. coli share many phenotypic characteristics, and confirmation requires a molecular approach; whole-genome sequencing analyzed for k-mers and single-nucleotide polymorphisms has high discriminatory power, and among nonmolecular methods mass spectrometry is applicable only under defined conditions (Devanga Ragupathi 2018). The mass spectrometry limitation is covered in Bacterial Identification: Biochemical Tests, MALDI-TOF Mass Spectrometry, Sequencing and Rapid Molecular Panels.
Yersinia enterocolitica and Cronobacter
Yersinia enterocolitica is recovered on a selective agar developed for the organism and containing cefsulodin, irgasan and novobiocin (Schiemann 1979). In a systematic review of 55 published post-transfusion cases the overall fatality rate was 54.5%, and the mechanism involves transfusion of preformed endotoxin in stored red cell preparations (Guinet 2011). Septic transfusion reactions are covered in Transfusion Reactions.
Cronobacter species (formerly Enterobacter sakazakii) cause invasive neonatal infection. Among 67 invasive infections published between 2000 and 2008, overall lethality was 26.9%, and lethality was 41.9% for meningitis, below 10% for bacteremia and 19.0% for necrotizing enterocolitis (Friedemann 2009).
Pseudomonas aeruginosa and the other nonfermenters
Cystic fibrosis respiratory cultures require both nonselective and selective media for all specimen types, including specimens obtained after lung transplantation, in order to detect Pseudomonas aeruginosa, Staphylococcus aureus, Haemophilus influenzae and Burkholderia cepacia complex together with less common nonlactose-fermenting gram-negative bacilli such as Stenotrophomonas maltophilia, Inquilinus, Achromobacter, Ralstonia and Pandoraea species, and yeasts and filamentous fungi (Saiman 2024). Modulator therapy has reduced spontaneous sputum production, so oropharyngeal and bronchoalveolar lavage samples now make up a larger share of specimens, and there are no consensus recommendations for detecting, characterizing and reporting small colony variants of S. aureus (Saiman 2024).
Stenotrophomonas maltophilia is a multidrug-resistant global opportunistic pathogen found in aqueous habitats, including plant rhizospheres, animals, food and water sources, and it is recovered most often from respiratory tract infection and from polymicrobial infection. Its intrinsic resistance mechanisms include the L1 metallo-β-lactamase, which hydrolyzes carbapenems, and the L2 cephalosporinase. Infection in immunocompromised patients has a high fatality ratio (Brooke 2012).
Laboratory separation of the common nonfermenters.
| Organism | Growth on MacConkey agar | Features used in identification | Source |
|---|---|---|---|
| Pseudomonas aeruginosa | Positive | Pigment production; mucoid phenotype in cystic fibrosis airways | Saiman 2024 |
| Acinetobacter baumannii-calcoaceticus complex | Positive | Gram-negative rods that become coccoid and resemble diplococci; nonmotile | Saiman 2024 |
| Stenotrophomonas maltophilia | Positive | Intrinsic carbapenem resistance through the L1 metallo-β-lactamase and the L2 cephalosporinase | Brooke 2012 |
| Burkholderia cepacia complex | Positive | Selective media recommended for cystic fibrosis cultures | Saiman 2024 |
| Achromobacter species | Positive | Less common nonlactose fermenter in cystic fibrosis cultures | Saiman 2024 |
| Burkholderia pseudomallei | Variable | Tier 1 select agent; phenotypic identification preferred over mass spectrometry | Gassiep 2020 |
Burkholderia pseudomallei and Burkholderia mallei
Burkholderia pseudomallei, the cause of melioidosis, is a tier 1 select agent endemic in Southeast Asia and northern Australia, with incidence that rises with rainfall. Culture of clinical material is the basis of laboratory diagnosis. Identification is performed by phenotypic methods, although mass spectrometric methods have been described. Serology has a limited diagnostic role, and direct molecular and antigen detection methods have limited availability and sensitivity. Presentations range from acute bacteremic pneumonia to disseminated visceral abscesses and localized infection, risk factors include male sex, diabetes mellitus, alcohol use and immunosuppression, and transmission is by direct inoculation, inhalation or ingestion (Gassiep 2020). Mass spectrometric identification of B. pseudomallei and B. mallei depended on which database was used, including the research-use and security-relevant databases, and sentinel laboratory rule-out and referral are covered in Microbiology Specimens, Stains, Culture Media and Blood Cultures and Bacterial Identification: Biochemical Tests, MALDI-TOF Mass Spectrometry, Sequencing and Rapid Molecular Panels (Rudrik 2017; Wagar 2010).
Vibrio and Aeromonas
Thiosulfate-citrate-bile salts-sucrose agar is the selective medium used for Vibrio species, and its selectivity is limited: of 188 strains of 31 species tested, 177 grew, nine species produced yellow colonies that can be confused with Vibrio cholerae and nine produced green colonies that can be confused with V. parahaemolyticus or V. vulnificus, so colony color on the medium does not identify the species (Lotz 1983). Vibrio vulnificus septicemia is the most common cause of death related to seafood consumption in the United States, occurs predominantly in patients with chronic liver disease, begins abruptly and progresses rapidly to septic shock with high mortality (Haq 2005).
The genus Aeromonas has expanded with species described on a phylogenetic basis. Beyond established disease associations, Aeromonas causes infection after natural disasters and has been linked to near-drowning events, prostatitis and hemolytic uremic syndrome, and the role of the genus in bacterial gastroenteritis and the appropriate extent of species identification in the clinical laboratory remain unsettled (Janda 2010). Aeromonas hydrophila infection is a recognized complication of postoperative medicinal leech application: among 18 reviewed and unreported cases the infections ranged from minor wound complications to extensive tissue loss and sepsis. Onset ranged from within 24 hours to 10 days or more after application, and infection followed application to tissue with questionable arterial perfusion (Lineaweaver 1992).
Campylobacter: culture, identification and the consequences of culture-independent testing
Culture and identification. Campylobacter organisms are gram-negative spiral, rod-shaped or curved bacteria measuring about 0.2–0.8 by 0.5–5 µm, with a single polar flagellum, bipolar flagella or none depending on the species, and they do not form spores. Most species grow under microaerobic conditions, and several require hydrogen or formate as an electron donor for microaerobic growth (Kaakoush 2015). No single method isolates all species: several selective blood-based or blood-free agars are used for the thermotolerant species, and the Cape Town protocol filters homogenized specimens through 0.45-µm or 0.65-µm membranes onto blood agar incubated at 37 °C under about 5% oxygen enriched with carbon dioxide and hydrogen. Incubation temperature, incubation time and atmosphere are manipulated to favor the organism, including growth at 42 °C and a hydrogen-enriched atmosphere (Kaakoush 2015). Hippurate hydrolysis is the only biochemical test that separates the two commonest isolates: C. jejuni hydrolyzes hippurate and C. coli does not. The 16S rRNA gene does not separate these two species, and the internal transcribed spacer region is the most discriminatory target (Kaakoush 2015).
Campylobacter jejuni infection is one of the most widespread infectious diseases, and incidence and prevalence have increased in developed and developing countries. Poultry is a major reservoir and source of transmission, and other risk factors include consumption of animal products and water, animal contact and international travel; Campylobacter concisus and Campylobacter ureolyticus are increasingly recognized as clinically important (Kaakoush 2015). Campylobacter jejuni is the microorganism most notably associated with Guillain-Barré syndrome, in which autoantibodies are triggered by molecular mimicry between peripheral nerve components and bacterial structures (Shahrizaila 2021). In 2019, 34% of surveyed clinical laboratories used only culture-independent tests for Campylobacter, and reflex culture after a positive culture-independent test declined across pathogens, which shifted isolate recovery to public health laboratories (Ray 2022).
Helicobacter pylori: noninvasive tests and susceptibility testing
Current guideline. For treatment-naive patients in whom antibiotic susceptibility is unknown, the ACG 2024 guideline prefers 14-day bismuth quadruple therapy, with 14-day rifabutin triple therapy or potassium-competitive acid blocker dual therapy as empiric alternatives in patients without penicillin allergy; for persistent infection, optimized 14-day bismuth quadruple therapy is preferred, and salvage regimens containing clarithromycin or levofloxacin are used only when susceptibility is confirmed. The guideline also addresses whom to test, universal post-treatment test of cure, and the role of susceptibility testing in selecting initial and salvage treatment (Chey 2024). Previous rule. ACG 2017 chose the regimen by previous antibiotic exposure and confined clarithromycin triple therapy to patients with no previous macrolide exposure in areas of known low clarithromycin resistance, with bismuth quadruple or concomitant therapy for most other patients; universal post-treatment testing to prove eradication and the option of culture or molecular resistance testing were already recommended in 2017 (Chey 2017).
Molecular mechanisms differ by antibiotic, and advances in sequencing have broadened susceptibility testing for H. pylori; susceptibility-guided therapy is compared with empiric therapy based on current resistance patterns (Ng 2023). Among noninvasive tests, the urea breath test is the most accurate: at a fixed specificity of 0.90, sensitivity was 0.94 for the ¹³C-urea breath test and 0.92 for the ¹⁴C test, against 0.84 for serology and 0.83 for stool antigen, with endoscopic biopsy and histopathologic examination as the confirmatory standard (Best 2018).
Haemophilus influenzae, Moraxella catarrhalis and the HACEK organisms
Growth factor requirements separate Haemophilus species, and the satellitism, porphyrin and sucrose tests are covered in Bacterial Identification: Biochemical Tests, MALDI-TOF Mass Spectrometry, Sequencing and Rapid Molecular Panels (Tebbutt 1983). After conjugate vaccine introduction, type b disease in young children fell markedly and the epidemiology of invasive H. influenzae changed: estimated mean annual incidence during 2009–2015 was 1.70 cases per 100,000 population, highest in adults 65 years and older (6.30) and in children younger than 1 year (8.45), and many infant cases occurred in the first month of life in preterm or low-birth-weight infants (Soeters 2018). Nontypeable strains carry the highest incidence (1.22 per 100,000) and case fatality (16%), against type b (0.03 per 100,000; 4%) and non-b encapsulated serotypes (0.45 per 100,000; 11%), with overall case fatality of 14.5% (Soeters 2018).
More than 90% of Moraxella catarrhalis isolates are β-lactamase positive, which is reported with the identification (Verduin 2002). The organism is an established pathogen in sinusitis, otitis media, bronchitis, pneumonia and ocular infection in children, and in laryngitis, bronchitis and pneumonia in adults (Verduin 2002).
Kingella kingae is recovered from pediatric osteoarticular infection when osteoarticular samples are inoculated into blood culture bottles and tested by broad-range 16S rRNA PCR and organism-specific PCR assays. In a prospective pediatric orthopedic series of 98 septic arthritis, 70 osteomyelitis, 23 osteoarthritis and six spondylodiscitis cases, PCR increased the yield of bacteriologic diagnosis by 54%, and among documented infections K. kingae was the leading pathogen (52%), ahead of Staphylococcus aureus (28%) (Ferroni 2013). In one study addressing the question, prolonged blood culture incubation did not improve the microbiologic diagnosis of HACEK and other slow-growing organisms in infective endocarditis (Lourtet-Hascoët 2019).
Bordetella: amplification targets and their cross-reactivity
Amplification of the IS481 target is more sensitive than culture for Bordetella pertussis, and the target cross-reacts with Bordetella holmesii. In an evaluation of 808 nasopharyngeal specimens, an assay directed at the separate insertion sequence IS1001 was used to assess B. holmesii, which was not detected in any specimen, and an assay against the pertussis toxin promoter was designed as the confirmatory target for B. pertussis (Knorr 2006). An IS481-positive result therefore requires a species-specific confirmatory target before B. pertussis is reported.
Legionella: urinary antigen, culture and molecular testing
Culture of patient specimens remains the standard for diagnosis of legionellosis, and selective buffered charcoal yeast extract medium with added antibiotics gives high sensitivity and specificity, recovers all species and serogroups and yields an isolate that can be matched to an environmental source. The urinary antigen test is highly accurate for Legionella pneumophila serogroup 1, and other methods are needed because other species and serogroups are pathogenic; direct fluorescent antibody and molecular methods supplement culture and give more rapid results (Pierre 2017). Pooled urinary antigen accuracy is covered in Bacterial Identification: Biochemical Tests, MALDI-TOF Mass Spectrometry, Sequencing and Rapid Molecular Panels.
Pasteurella, Capnocytophaga and the bite-wound flora
Bite wound infections contain a mixture of anaerobes and aerobes from the patient's skin and the animal's oral cavity, including Pasteurella, Streptococcus, Fusobacterium and Capnocytophaga species, and disseminated infection caused by Capnocytophaga canimorsus and Pasteurella multocida can produce septic shock, meningitis and endocarditis (Oehler 2009). Capnocytophaga canimorsus is a capnophilic gram-negative rod of the canine and feline oral flora, poses particular risk to patients with asplenia, cirrhosis or alcohol use disorder, and grows slowly on laboratory media, so isolation and identification are often delayed and nucleic acid amplification is the most reliable identification method (Zajkowska 2016).
Brucella, Francisella and Yersinia pestis in the clinical laboratory
Brucella species present an aerosol transmission risk in the clinical laboratory. In an investigation of two cases of laboratory-acquired brucellosis in microbiologists, 146 workers at two laboratories were found to have been exposed, and CDC recommended risk assessment for all exposed workers, postexposure prophylaxis for those at high risk, surveillance for symptoms and serologic follow-up (CDC 2008). Commercial mass spectrometry databases lacked reference spectra for Brucella, which prevented identification; a database constructed from 590 spectra of 84 strains allowed identification at genus level with no misidentification as the closely related and less pathogenic Ochrobactrum, and identification of B. melitensis, B. abortus and B. suis with accuracies of 100%, 92.9% and 100% (Mesureur 2018).
Yersinia pestis is a gram-negative obligate pathogen maintained in a flea-rodent cycle across a wide range of mammalian hosts, and its persistence in these reservoirs makes eradication unlikely (Perry 1997). Mass spectrometric identification of Y. pestis and Francisella tularensis depends on the database, and the in vitro diagnostic software misidentified 73.8% of Y. pestis extracts as Y. pseudotuberculosis (Rudrik 2017); the database limits are covered in Bacterial Identification: Biochemical Tests, MALDI-TOF Mass Spectrometry, Sequencing and Rapid Molecular Panels.
Bartonella, Streptobacillus and Chromobacterium
Bartonella species cause localized lymphadenopathy, bacteremia, endocarditis and tissue colonization with bacillary angiomatosis and peliosis hepatis; most human infection is caused by B. henselae, B. quintana and B. bacilliformis, and severity correlates with immune status (Angelakis 2014). The histologic workup of cat-scratch lymphadenitis is covered in Granulomatous Lymphadenitis (Cytology).
Rat bite fever caused by Streptobacillus moniliformis is a systemic illness of fever, rigors and polyarthralgia with 10% mortality when untreated, and a nonspecific initial presentation and difficulty culturing the organism delay the diagnosis (Elliott 2007). Chromobacterium violaceum is an environmental organism that rarely causes human disease and has a high fatality rate when it does; among 132 published cases from 1953 to 2020 the patients were predominantly male with a median age of 17.5 years. A third had immune deficiency or comorbidity, and the portal of entry was most often a wound of the leg or foot (28.0%) (Alisjahbana 2021).
Bacterial zoonoses and their laboratory considerations.
| Organism | Animal or vector source | Laboratory consideration | Source |
|---|---|---|---|
| Brucella species | Livestock and unpasteurized dairy products | Aerosol risk with laboratory-acquired infection; absent from standard mass spectrometry databases | CDC 2008; Mesureur 2018 |
| Francisella tularensis | Lagomorphs, rodents and arthropod vectors | Security-relevant database needed for mass spectrometry identification; see Bacterial Identification: Biochemical Tests, MALDI-TOF Mass Spectrometry, Sequencing and Rapid Molecular Panels | Rudrik 2017 |
| Yersinia pestis | Rodents and their fleas | Flea-rodent reservoir cycle; identification as for the other select agents | Rudrik 2017; Perry 1997 |
| Erysipelothrix rhusiopathiae | Swine, poultry, fish and soil | Gram-positive bacillus; occupational exposure; see Gram-Positive Bacteria and Anaerobes: Staphylococci, Streptococci, Enterococci, Gram-Positive Rods and Clostridioides difficile | Wang 2010 |
| Capnocytophaga canimorsus | Dog and cat oral flora | Slow growth; amplification for identification; asplenia as a risk factor | Zajkowska 2016 |
| Pasteurella multocida | Dog and cat bite wounds | Mixed aerobic and anaerobic wound flora | Oehler 2009 |
| Streptobacillus moniliformis | Rats and other rodents | Difficult to culture | Elliott 2007 |
| Bartonella henselae | Cats | Culture is difficult; serology and amplification are used; see Granulomatous Lymphadenitis (Cytology) | Angelakis 2014 |
| Chromobacterium violaceum | Soil and water exposure through a wound | Rare; high fatality; wound of the leg or foot as the usual portal of entry | Alisjahbana 2021 |
Mycobacteria, Nocardia, Spirochetes, Mycoplasma, Chlamydia and Other Intracellular Bacteria
Definition. These organisms share one laboratory property: routine aerobic bacterial culture does not detect them. Mycobacteria and the aerobic actinomycetes require acid-fast or modified acid-fast staining and dedicated media with prolonged incubation. The spirochetes, Mycoplasma, Chlamydia, Rickettsia, Coxiella, Ehrlichia, Anaplasma and Tropheryma whipplei are diagnosed by serology, nucleic acid amplification, direct microscopy or histologic methods, because they either cannot be cultured in the clinical laboratory or require specialized systems (Lewinsohn 2017; Papp 2024; Biggs 2016; Dolmans 2017).
Related page: Microbiology Specimens, Stains, Culture Media and Blood Cultures (acid-fast and modified acid-fast stains, mycobacterial media and broth systems, darkfield examination) Related page: Bacterial Identification: Biochemical Tests, MALDI-TOF Mass Spectrometry, Sequencing and Rapid Molecular Panels (sequence-based identification, mass spectrometry, molecular methods and antigen tests) Related page: Antimicrobial Susceptibility Testing, Breakpoints and Resistance Mechanisms (breakpoints, resistance mechanisms and phenotypic detection methods for conventional bacteria) Related page: Gram-Positive Bacteria and Anaerobes: Staphylococci, Streptococci, Enterococci, Gram-Positive Rods and Clostridioides difficile (Actinomyces, anaerobe culture and anaerobe susceptibility testing) Related page: Flow Cytometry, FISH, Microbiology and Electron Microscopy on Cytology Specimens (collection of aspirates for culture and Xpert MTB/RIF Ultra on cytology specimens) Related page: Granulomas and Sarcoidosis on Lung and EBUS FNA (limits of acid-fast morphology in tissue) Related page: Granulomatous Lymphadenitis (Cytology) (Xpert MTB/RIF Ultra on lymph node aspirates and cat-scratch disease) Related page: Respiratory Infections in Lung Cytology (filamentous bacteria in respiratory cytology) Related page: Stains in Cytology (special stains for fungi and mycobacteria in aspirates) Related page: Infections in Cerebrospinal Fluid Cytology (cerebrospinal fluid findings in tuberculous meningitis) Related page: Blood Donor Eligibility, Collection and Donor Infectious Disease Testing (donor screening for Treponema pallidum)
Mycobacterial species groups and the species that cause human disease
The genus comprises the Mycobacterium tuberculosis complex and more than 190 nontuberculous species and subspecies, divided by growth rate into slowly growing and rapidly growing organisms. The species that most often cause pulmonary disease are M. avium complex, M. kansasii and M. xenopi among the slow growers and M. abscessus among the rapid growers (Daley 2020). Many remaining species are unrecognized or misidentified in clinical practice (Tortoli 2014), and species distribution differs by United States region (Spaulding 2017). Mycobacterium chimaera caused a global heater-cooler-unit outbreak with latent presentation, intermittent bacteremia and high mortality (Kasperbauer 2019).
Runyon groups. Before sequence-based identification, the nontuberculous mycobacteria were grouped by growth rate and pigment production: group I photochromogens, which develop pigment only after light exposure (M. kansasii, M. marinum, M. simiae); group II scotochromogens, pigmented in the dark (M. scrofulaceum, M. szulgai, M. gordonae); group III nonphotochromogens (M. avium, M. intracellulare, M. xenopi, M. genavense); and group IV rapid growers (M. fortuitum, M. chelonae, M. abscessus) (Zykov 1967; Tomioka 1998). Mycobacterium leprae is noncultivable and falls outside the scheme, and current taxonomy is based on whole-genome sequencing (Turenne 2019).
Mycobacterial groups used in laboratory reporting.
| Group | Representative species | Laboratory features | Source |
|---|---|---|---|
| M. tuberculosis complex | M. tuberculosis, M. bovis | Slow growth; liquid and solid culture on every specimen; nucleic acid amplification on the initial respiratory specimen | Lewinsohn 2017 |
| Slowly growing nontuberculous mycobacteria | M. avium complex, M. kansasii, M. xenopi | Macrolide and amikacin testing for M. avium complex; rifampin and clarithromycin for M. kansasii; insufficient evidence for or against susceptibility-based treatment of M. xenopi | Daley 2020 |
| Rapidly growing nontuberculous mycobacteria | M. abscessus subspecies, M. chelonae, M. fortuitum | Visible growth within 7 days on agar; inducible macrolide resistance testing for M. abscessus | Set 2011; Daley 2020 |
| Temperature- and supplement-dependent species | M. haemophilum, M. marinum | M. haemophilum requires iron or hemin at 30 °C; cutaneous presentations | Franco-Paredes 2018; Tebruegge 2011 |
| Species of low pathogenicity | M. gordonae | Rarely causes human disease; an isolate is usually a contaminant, and disease is attributed only when the full criteria are met | Daley 2020 |
Specimen processing for acid-fast bacilli
Respiratory specimens are digested and decontaminated, because normal flora overgrows mycobacterial colonies on prolonged incubation. The N-acetyl-L-cysteine–sodium hydroxide method kills a large proportion of the organisms present: recovery averaged 20% for tuberculous and 11% for nontuberculous isolates (Thornton 1998). Sodium hydroxide concentration influences contamination rates (Piersimoni 2001), and the media and broth systems are covered in Microbiology Specimens, Stains, Culture Media and Blood Cultures. Centrifugation combined with any of several chemical methods raised smear yield over direct smears (Steingart 2006b). Specimens from sterile sites need no decontamination.
Acid-fast smear microscopy, smear grading and mycobacterial culture
Fluorescence microscopy is more sensitive than conventional light microscopy and is the standard method in high-income countries, with concern that specificity may be lower (Steingart 2006a). Same-day smear microscopy performs comparably to microscopy on specimens collected over separate days (Davis 2013). Acid-fast smear microscopy is performed on all patients with suspected pulmonary tuberculosis, and a negative smear does not exclude the disease (Lewinsohn 2017). The limits of acid-fast morphology in tissue are covered in Granulomas and Sarcoidosis on Lung and EBUS FNA.
Smears are graded semiquantitatively, and the categories differ between scales, so no single scale is universal. In one series the grades were zero, scanty (1–12 acid-fast bacilli), 1+, 2+ and 3+, and culture positivity rose with the grade from 42.9% at zero to 87.5% at 3+ (p < 0.001 for trend) (Mugusi 2025).
Liquid broth systems detect mycobacteria with a shorter mean time to detection than solid medium (Piersimoni 2001). Growth temperature and supplements distinguish several species: M. haemophilum requires iron or hemin for growth at 30 °C, which is within its 30 °C–32 °C optimum (Franco-Paredes 2018; Damato 1984; Saubolle 1996), and M. marinum causes nodular lymphangitic skin infection after water exposure (Tebruegge 2011).
Mycobacterium tuberculosis: biochemical identification and molecular diagnostics
Mycobacterium tuberculosis reduces nitrate very strongly compared with M. bovis and M. bovis BCG, and nitrate reductase with niacin accumulation separates M. tuberculosis from the other members of the complex and from the nontuberculous mycobacteria (Goh 2010). Mycobacterium simiae has a niacin-positive phenotype and is misdiagnosed as M. tuberculosis on that basis (Kamali Kakhki 2026), and some old laboratory M. bovis and BCG strains give a positive niacin reaction (Singh 2015). Mycobacterium bovis BCG is confirmed by absent nitrate reductase, a negative niacin test and resistance to pyrazinamide and cycloserine (Singh 2015). Mutations in pncA cause pyrazinamide resistance in naturally resistant M. bovis and in acquired-resistant M. tuberculosis (Scorpio 1996), and pncA analysis also separates the two species (Mohamed 2004).
Current guideline. The ATS/IDSA/CDC 2017 diagnosis guideline specifies (Lewinsohn 2017):
- Acid-fast smear microscopy on all patients with suspected pulmonary tuberculosis (strong recommendation).
- Both liquid and solid mycobacterial culture on every specimen (conditional recommendation).
- A diagnostic nucleic acid amplification test on the initial respiratory specimen (conditional recommendation); in smear-positive patients a negative result makes tuberculosis disease unlikely.
- Mycobacterial culture on specimens from suspected extrapulmonary sites (strong recommendation), with smear microscopy, amplification testing and histology as conditional recommendations.
- Submission of one isolate from every culture-positive patient to a regional genotyping laboratory (strong recommendation).
- Rapid molecular drug susceptibility testing for rifampin with or without isoniazid on respiratory specimens from patients who are acid-fast smear positive or positive by the Hologic Amplified Mycobacterium tuberculosis Direct test and who meet any of these criteria: previous treatment for tuberculosis; birth in or at least 1 year of residence in a foreign country with at least moderate tuberculosis incidence (20 or more per 100,000); residence in a country with high primary multidrug-resistant tuberculosis prevalence (2% or more); contact with a patient with multidrug-resistant tuberculosis; or HIV infection (strong recommendation). The recommendation is specific to that assay and does not apply to assays that themselves detect resistance, such as Xpert MTB/RIF.
Previous rule. The ATS/CDC Diagnostic Standards and Classification of Tuberculosis in Adults and Children predates routine initial nucleic acid amplification testing and the rapid molecular drug susceptibility framework above, and it remains the source of the tuberculin skin test interpretation groups cited in the 2017 guideline (ATS 2000).
The Xpert MTB/RIF Ultra assay had summary sensitivity 90.7% (95% CI 88.2–92.7) and specificity 94.8% (92.8–96.3) against culture for pulmonary tuberculosis, with sensitivity of 80.7% (75.4–85.0) in smear-negative culture-positive disease and lower sensitivity in people living with HIV and with a history of tuberculosis. For rifampin resistance, sensitivity was 95.8% and specificity 98.3%, and only 38.8% of trace-positive results were true positives (Horne 2025). Performance on lymph node aspirates is covered in Granulomatous Lymphadenitis (Cytology), and WHO module 3, 3rd edition, covers the WHO-recommended rapid diagnostics (WHO 2024).
Genotypic and phenotypic rifampin results disagree in a minority of isolates, most often because of borderline rpoB mutations in isolates that are phenotypically susceptible at MICs of 0.5 µg/mL or below, and rpoB sequencing resolves the discrepancy (He 2024). Pyrazinamide susceptibility testing in broth culture is unreliable: among 40 phenotypically resistant isolates, resistance was confirmed by mutations in pncA, rpsA or panD in 22 (55%) (Mok 2021).
The 1% critical proportion. In the agar proportion method an isolate is resistant when the colony count on drug-containing medium at the critical concentration is 1% or more of the count on the drug-free control (Siddiqi 1976). The method requires a fresh, well-dispersed suspension and accurate counts on both media, because the result is a percentage and not a growth or no-growth reading (Baba 1994).
Testing for Mycobacterium tuberculosis infection without disease
Current guideline. An interferon-γ release assay is recommended in preference to a tuberculin skin test in individuals 5 years or older who are likely to be infected, have low or intermediate risk of progression, warrant testing, and either have a history of BCG vaccination or are unlikely to return to have a skin test read (strong recommendation); a skin test is an acceptable alternative where an assay is unavailable, too costly or too burdensome. An assay is suggested in preference to a skin test in all other individuals 5 years or older who are likely to be infected and have low or intermediate risk of progression (conditional recommendation), and there are insufficient data to prefer either test at high risk of progression. A skin test is suggested in preference to an assay in healthy children younger than 5 years (conditional recommendation). Where testing is performed in individuals unlikely to be infected, a second test is suggested when the initial test is positive, and the person is considered infected only when both are positive. Neither test distinguishes infection from disease, so active tuberculosis is excluded before treatment for infection begins (Lewinsohn 2017).
Previous rules. The ATS/CDC diagnostic standards statement preceded interferon-γ release assays in routine use (ATS 2000), and the CDC 2010 guidelines set out the two assays then approved, whose antigens, methods and interpretation criteria differed from the earlier approved assay (Mazurek 2010).
TOOL CANDIDATE: Tuberculin skin test interpretation by risk group (CDC). Induration is read 48–72 hours after placement, and millimeters of induration are measured, not erythema.
| Cutoff | Groups considered positive | Source |
|---|---|---|
| 5 mm or more | HIV infection; recent contact with infectious tuberculosis; chest radiograph findings of previous tuberculosis; organ transplant recipients; other immunosuppression, including prolonged high-dose corticosteroids or TNF-α antagonists | CDC 2025b |
| 10 mm or more | Birth in a country where tuberculosis is common; drug or alcohol misuse; residence or work in high-risk congregate settings; mycobacteriology laboratory work; silicosis, diabetes, severe kidney disease, certain cancers or certain intestinal conditions; body weight below 90% of ideal; age under 5 years; exposure to adults in high-risk categories | CDC 2025b |
| 15 mm or more | People with no known risk factors for tuberculosis | CDC 2025b |
Two-step testing is used at baseline for people who will be retested periodically: when the first test is negative a second is placed 1–3 weeks later, and a positive second result is a boosted reaction that classifies the person as previously infected. BCG vaccination can cause a false-positive skin test that cannot be distinguished from infection, and it does not cause positive interferon-γ release assay results (CDC 2025b).
TOOL CANDIDATE: Interferon-γ release assay interpretation (CDC 2010).
| Assay | Positive | Negative | Indeterminate or borderline | Source |
|---|---|---|---|---|
| QuantiFERON-TB Gold In-Tube | Nil 8.0 IU/mL or less and TB response 0.35 IU/mL or more and 25% or more of nil | Nil 8.0 IU/mL or less, TB response below either threshold, mitogen 0.5 IU/mL or more | TB response below threshold with mitogen below 0.5 IU/mL, or nil above 8.0 IU/mL | Mazurek 2010 |
| T-SPOT.TB | Nil 10 spots or fewer and TB response 8 spots or more | Nil 10 spots or fewer and TB response 4 spots or fewer | Borderline at 5–7 spots; indeterminate when nil exceeds 10 spots, or TB response is below 5 spots with mitogen below 20 spots | Mazurek 2010 |
ESAT-6 and CFP-10 are absent from BCG strains and most nontuberculous mycobacteria and present in M. kansasii, M. szulgai and M. marinum, so sensitization to those species can produce false-positive results (Mazurek 2010).
Nontuberculous mycobacterial pulmonary disease and susceptibility testing
Current guideline. The ATS/ERS/ESCMID/IDSA 2020 guideline recommends the clinical, radiographic and microbiologic criteria from the 2007 statement (Daley 2020). Previous guideline: ATS/IDSA 2007 (Griffith 2007).
TOOL CANDIDATE: Diagnostic criteria for nontuberculous mycobacterial pulmonary disease (ATS/ERS/ESCMID/IDSA 2020).
| Criterion | Requirement | Status | Source |
|---|---|---|---|
| Clinical | Pulmonary or systemic symptoms | Required | Daley 2020 |
| Radiologic | Nodular or cavitary opacities on chest radiograph, or computed tomography showing bronchiectasis with multiple small nodules | Required | Daley 2020 |
| Exclusion | Appropriate exclusion of other diagnoses | Required | Daley 2020 |
| Microbiologic option 1 | Positive culture from at least two separate expectorated sputum samples collected a week or more apart, with the same species (or subspecies for M. abscessus) in both | One option required | Daley 2020 |
| Microbiologic option 2 | Positive culture from at least one bronchial wash or lavage | One option required | Daley 2020 |
| Microbiologic option 3 | Lung biopsy with granulomatous inflammation or acid-fast bacilli plus a positive culture, or such a biopsy plus one or more culture-positive sputum or bronchial washing specimens | One option required | Daley 2020 |
Susceptibility-based treatment is suggested over empiric treatment for macrolides and amikacin in M. avium complex and M. abscessus pulmonary disease, by broth microdilution. Testing covers the agents with documented correlation between in vitro activity and outcome: the macrolides and amikacin for those two organisms, and rifampin and clarithromycin for M. kansasii, in which rifampin resistance is defined by an MIC above 2 µg/mL and clarithromycin resistance by an MIC of 32 µg/mL or above. Acquired macrolide resistance in M. avium complex results from 23S rRNA (rrl) point mutations (Daley 2020).
Mycobacterium abscessus subsp. abscessus and subsp. bolletii carry the erythromycin resistance methylase gene erm(41), which confers inducible macrolide resistance; detection requires incubation of microdilution trays for up to 14 days or molecular characterization of the gene (Daley 2020). Time to detection varies with the erm(41) sequevar, and 82.7% of 104 isolates with inducible resistance were already resistant at day 7, which supports a day-7 read alongside the 14-day read (Christianson 2016). The gene is nonfunctional in subsp. massiliense and in some subsp. abscessus strains through a C in place of a T at nucleotide 28, which leaves those strains macrolide susceptible, and all three subspecies can acquire constitutive resistance through rrl mutations (Daley 2020; Rubio 2015).
Mycobacterium leprae
Mycobacterium leprae cannot be cultivated in vitro, so diagnosis uses histopathology with a stain for weakly acid-fast organisms, molecular testing and clinical findings (Reibel 2015). The Fite (modified Fite-Faraco) stain is used, because the organism is only weakly acid fast and is decolorized by the standard Ziehl-Neelsen method; fluorescent staining of the same sections was more sensitive in 40 biopsy-confirmed cases (67.5% versus 50%) (Kalagarla 2022).
Nocardia and the other aerobic actinomycetes
More than 30 Nocardia species are of human clinical significance, most often the N. nova complex, N. farcinica, N. cyriacigeorgica and N. brasiliensis, with variable drug susceptibility. Accurate identification requires a laboratory with molecular capability, because many newer species are genetically distinct while sharing few distinguishing phenotypic characteristics, and with the modified Kinyoun stain, which uses 1% sulfuric acid for decolorization, the nocardiae appear as partially acid-fast filamentous bacilli (Brown-Elliott 2006). Species-level identification by mass spectrometry depends on the database, with 16S rRNA and secA1 sequencing as the reference (Marín 2018). Among 765 isolates submitted to CDC over 1995–2004, 61% were resistant to sulfamethoxazole and 42% to trimethoprim-sulfamethoxazole (Uhde 2010).
Comparison of Nocardia and Actinomyces.
| Feature | Nocardia species | Actinomyces species | Source |
|---|---|---|---|
| Atmosphere | Aerobic | Anaerobic, with prolonged culture | Brown-Elliott 2006; Valour 2014 |
| Modified acid-fast stain | Positive (partially acid fast) | Negative | Brown-Elliott 2006; Valour 2014 |
| Identification | 16S rRNA and secA1 sequencing, or mass spectrometry | Anaerobic culture with mass spectrometry | Marín 2018; Alcalá 2021 |
| Susceptibility | Variable; 42% resistant to trimethoprim-sulfamethoxazole | Prolonged penicillin G or amoxicillin | Uhde 2010; Valour 2014 |
Cytologic appearance of both organisms in respiratory specimens is covered in Respiratory Infections in Lung Cytology, and the tissue findings of actinomycosis in Organisms in Cervical Cytology.
Rhodococcus, Tsukamurella and Gordonia are uncommon aerobic causes of lung cavitation and tuberculosis-like syndromes, and identification is difficult and determines both diagnosis and treatment (Savini 2012). Streptomyces, Nocardia and Actinomadura cause actinomycetoma, a chronic granulomatous disease of subcutaneous tissue, with Streptomyces predominating in Africa (Siddig 2021).
Treponema pallidum: direct detection, serologic algorithms and discordant results
Current recommendation. The CDC 2024 laboratory recommendations are the first CDC recommendations devoted to syphilis laboratory testing. Both the traditional algorithm, which begins with a nontreponemal (lipoidal antigen) test, and the reverse sequence algorithm, which begins with an automated treponemal immunoassay, are acceptable, and the choice depends on laboratory resources, test volume and the population served. A single reactive serologic test misclassifies syphilis status, both test types are used when the first test is reactive, and the two algorithms show about 99% concurrence. For discordant results, an additional treponemal test using a different assay type and target, such as T. pallidum particle agglutination (TP-PA), is recommended (Papp 2024). Previous rule. Among sera reactive on initial treponemal immunoassay screening at five laboratories during 2006–2010, 56.7% had a nonreactive rapid plasma reagin test, and 31.6% of those were also nonreactive by confirmatory treponemal testing (CDC 2011).
Nontreponemal tests are flocculation assays, so the prozone phenomenon can make a specimen with very high antibody concentration appear nonreactive. False-negative rapid plasma reagin results from a prozone were rare (below 0.85%) and occurred at all stages, most often in primary and secondary syphilis (4.7% and 1.8%), and the dilution needed to remove the prozone ranged from 1:8 to 1:512 across 36 sera. Because laboratorians typically do not know the patient's stage, the clinician requests an assessment for prozone when the patient has signs or symptoms of syphilis and the nontreponemal result is nonreactive (Papp 2024).
TOOL CANDIDATE: Syphilis serologic algorithm result interpretation (CDC 2024).
| Algorithm | Test sequence | Interpretation | Source |
|---|---|---|---|
| Traditional | Nontreponemal nonreactive | No serologic evidence; prozone assessed when signs or symptoms are present | Papp 2024 |
| Traditional | Nontreponemal reactive → treponemal reactive | Serologic evidence of syphilis; staging needs history | Papp 2024 |
| Traditional | Nontreponemal reactive → treponemal nonreactive | Biologic false-positive nontreponemal result | Papp 2024 |
| Reverse sequence | Treponemal immunoassay nonreactive | No serologic evidence of syphilis | Papp 2024 |
| Reverse sequence | Treponemal immunoassay reactive → nontreponemal reactive | Serologic evidence of syphilis; staging needs history | Papp 2024 |
| Reverse sequence | Treponemal immunoassay reactive → nontreponemal nonreactive → second treponemal test of a different type and target reactive | Treponemal antibody confirmed; past treated and untreated latent infection separated by history | Papp 2024 |
| Reverse sequence | Treponemal immunoassay reactive → nontreponemal nonreactive → second treponemal test nonreactive | False-positive initial immunoassay, proportionally more frequent in low-prevalence populations | Papp 2024 |
Laboratories that perform darkfield microscopy maintain it, and sexually transmitted disease clinics establish it where point-of-care detection of primary or secondary syphilis would allow earlier treatment. Reported sensitivity is 75%–100% for primary and 58%–71% for secondary lesions, with specificity of 94% or above, on serous fluid free of red blood cells. Darkfield examination is not recommended for oral lesions, because commensal oral treponemes can be misinterpreted, nor for cerebrospinal fluid or other body fluids. No FDA-cleared amplification test is available, and laboratory-developed assays target tp47 or polA, with sensitivity of 72%–95% on primary and 20%–86% on secondary lesion swabs (Papp 2024).
For congenital syphilis, treponemal testing of neonatal serum is not recommended, because passively transferred maternal antibody can give positive results for more than a year, and no IgM test is recommended. Quantitative nontreponemal tests are performed on neonatal serum and not on cord blood, and placenta and cord samples are tested with the immunohistochemistry avidin-biotin complex technique or indirect immunofluorescence and not with silver stain (Papp 2024). Donor screening is covered in Blood Donor Eligibility, Collection and Donor Infectious Disease Testing.
Borrelia and Leptospira: two-tier serology, the IgM rule and the microscopic agglutination test
Current recommendation. On July 29, 2019 the FDA cleared several Lyme disease serologic assays with new indications based on a modified two-test methodology (MTTT) that uses a second enzyme immunoassay in place of a western immunoblot, and CDC accepts such two-immunoassay formats as alternatives for the laboratory diagnosis of Lyme disease (Mead 2019). Previous rule. The 1995 CDC recommendation specified a sensitive enzyme immunoassay or immunofluorescence assay as the first test, followed by a standardized western immunoblot on specimens with positive or equivocal results (CDC 1995).
Under the 1995 criteria the IgM immunoblot is positive when two of the three bands 24 kDa (OspC), 39 kDa (BmpA) and 41 kDa (Fla) are present, and the IgG immunoblot is positive when five of the ten bands 18, 21 (OspC), 28, 30, 39 (BmpA), 41 (Fla), 45, 58, 66 and 93 kDa are present. Both procedures are used during the first 4 weeks of illness, and an IgM result alone is not recommended for determining active disease in illness of more than 1 month's duration (CDC 1995).
Antibody tests can be falsely negative in the first 4–6 weeks after infection, and titers remain elevated for months to years, so they do not confirm cure. Cross-reactions occur in relapsing fever, syphilis, rheumatoid arthritis and Epstein-Barr virus infection (CDC 2025a). The IDSA/AAN/ACR 2020 guideline covers prevention, diagnosis and treatment (Lantos 2021).
TOOL CANDIDATE: Two-tier Lyme disease serologic result interpretation (Mead 2019; CDC 2025a).
| First test (enzyme immunoassay) | Second test | Duration of illness at testing | Interpretation | Source |
|---|---|---|---|---|
| Negative | Not performed | Not applicable | Negative; no further testing | CDC 2025a |
| Positive or equivocal | Immunoblot or second immunoassay positive | Not applicable | Positive two-tier result | Mead 2019; CDC 2025a |
| Positive or equivocal | Immunoblot or second immunoassay negative | Not applicable | Negative two-tier result | CDC 2025a |
| Positive or equivocal | IgM reactive, IgG nonreactive | 30 days or less from onset | Positive, attributable to early infection | CDC 2025a |
| Positive or equivocal | IgM reactive, IgG nonreactive | More than 30 days | IgM disregarded; not interpreted as positive | CDC 2025a |
Borrelia miyamotoi is a relapsing fever group spirochete transmitted by the ixodid ticks that transmit the Lyme disease agents, first reported in humans in 2011, and severe disease including meningoencephalitis occurs (Krause 2015).
For leptospirosis, the microscopic agglutination test on paired sera remains the serologic reference standard, with pooled sensitivity 68% (95% credible interval 32–92) and specificity 75% (45–93) on paired sera, and sensitivity 14% (3–38) on single acute-phase samples (Valente 2024).
Mycoplasma, Ureaplasma and Chlamydia: amplification and resistance genotyping
Diagnosis of Mycoplasma pneumoniae infection has relied on serology, and PCR gave a summary sensitivity of 0.62 (95% CI 0.45–0.76) and specificity of 0.96 (0.93–0.98) relative to serologic reference standards (Zhang 2011).
Chlamydia pneumoniae. Detection of Chlamydia pneumoniae infection uses serology and culture or amplification of respiratory tract specimens. Serologic diagnosis requires a fourfold rise in IgG or IgA between acute and convalescent sera taken 4–6 weeks apart, so the result is retrospective and does not alter initial management. A single acute-phase IgM titer of 1:16 or higher depends on the time of collection, because a titer rise can be absent early in acute infection and in reinfection, and reliance on the acute specimen alone misses 25%–33% of infections. Antigens shared with other Chlamydia species limit specificity. Microimmunofluorescence is the serologic reference method, enzyme-linked immunosorbent assay is more objective to interpret, and complement fixation is not recommended because its sensitivity and specificity are limited. Amplification of respiratory specimens, including the multiplex respiratory panels, is the preferred method, and its specificity is limited by asymptomatic carriage and by persistent detection for weeks to months after symptoms resolve (Georgakopoulou 2024).
Mycoplasma genitalium grows slowly in vitro, so conventional susceptibility testing cannot be performed in clinical laboratories, and resistance-associated mutations in 23S rRNA and parC are detected instead (He 2023). Resistance-guided therapy and the specimen types used for amplification testing of M. genitalium, Chlamydia trachomatis and Neisseria gonorrhoeae follow the CDC 2021 sexually transmitted infections treatment guidelines (Workowski 2021). Genotyping of C. trachomatis in rectal specimens identifies the lymphogranuloma venereum genovars (Sánchez 2024). Ureaplasma species cause hyperammonemia without liver dysfunction after lung transplantation (Matson 2019).
Rickettsia, Ehrlichia, Anaplasma and Coxiella
Current recommendation. CDC recommends IgG indirect immunofluorescence antibody testing of at least two serum samples collected ideally 2–4 weeks apart for spotted fever group rickettsioses, the ehrlichioses and anaplasmosis. The assays are insensitive during the first week, sensitivity rises after about day 7 and is highest at 2–3 weeks, and diagnosis is confirmed by a fourfold or greater rise in titer between appropriately timed samples. A single reciprocal IgG titer of 64 or above in a compatible illness supports the diagnosis without confirming acute infection, and IgM alone is not diagnostic, because its specificity is lower (Biggs 2016).
Whole-blood PCR is particularly useful for confirming Ehrlichia chaffeensis, Anaplasma phagocytophilum and Ehrlichia ewingii infection, whereas PCR for Rickettsia rickettsii in whole blood is less sensitive because few organisms circulate early, and doxycycline lowers PCR sensitivity, so blood is drawn before therapy. Tissue is a more useful source of spotted fever group rickettsial DNA than acute blood, and an eschar biopsy, exudate swab or scab is suitable. Morulae on a routine blood smear provide presumptive early evidence, in monocytes in E. chaffeensis infection and in granulocytes in anaplasmosis and E. ewingii infection, and confirmatory testing is still required (Biggs 2016).
Coxiella burnetii is an obligate intracellular organism that proliferates only in an acidified lysosome-like vacuole and shows antigenic phase variation through modification of the membrane lipopolysaccharide. Transmission is most often by inhalation of aerosols from placental material. Diagnosis uses serology and direct methods such as culture or DNA detection, and the two presentations are acute disease and persistent focalized infection (España 2020; Tissot Dupont 1992).
Tropheryma whipplei and the diagnosis of Whipple disease
Whipple disease is fatal if untreated and is caused by Tropheryma whipplei, which routine culture does not recover. Periodic acid-Schiff staining of duodenal biopsy specimens was the former standard and has poor sensitivity and specificity, and molecular detection has improved diagnosis (Dolmans 2017; Marth 2016).
References
- Adeolu M, Alnajar S, Naushad S, Gupta RS. Genome-based phylogeny and taxonomy of the 'Enterobacteriales': proposal for Enterobacterales ord. nov. divided into the families Enterobacteriaceae, Erwiniaceae fam. nov., Pectobacteriaceae fam. nov., Yersiniaceae fam. nov., Hafniaceae fam. nov., Morganellaceae fam. nov., and Budviciaceae fam. nov. Int J Syst Evol Microbiol. 2016;66(12):5575–5599. doi:10.1099/ijsem.0.001485. PMID 27620848
- Adzitey F, Corry J. A Comparison between Hippurate Hydrolysis and Multiplex PCR for Differentiating Campylobacter coli and Campylobacter jejuni. Trop Life Sci Res. 2011;22(1):91-8. PMID 24575212
- Aggarwal VK, Higuera C, Deirmengian G, et al. Swab cultures are not as effective as tissue cultures for diagnosis of periprosthetic joint infection. Clin Orthop Relat Res. 2013;471(10):3196-203. doi:10.1007/s11999-013-2974-y. PMID 23568679
- Akoh JA. Relative sensitivity of blood and bone marrow cultures in typhoid fever. Trop Doct. 1991;21(4):174–176. doi:10.1177/004947559102100415. PMID 1746041
- Alcalá L, Marín M, Ruiz A, et al. Identifying Anaerobic Bacteria Using MALDI-TOF Mass Spectrometry: A Four-Year Experience. Front Cell Infect Microbiol. 2021;11:521014. doi:10.3389/fcimb.2021.521014. PMID 33968791
- Ali S, Fitzpatrick F. The lingering legacy of one letter in antimicrobial susceptibility testing. J Med Microbiol. 2025;74(10):002082. doi:10.1099/jmm.0.002082. PMID 41055491
- Alisjahbana B, Debora J, Susandi E, Darmawan G. Chromobacterium violaceum: A Review of an Unexpected Scourge. Int J Gen Med. 2021;14:3259–3270. doi:10.2147/IJGM.S272193. PMID 34267544
- Álvarez-Marín R, Lepe JA, Gasch-Blasi O, et al. Clinical characteristics and outcome of bacteraemia caused by Enterobacter cloacae and Klebsiella aerogenes: more similarities than differences. J Glob Antimicrob Resist. 2021;25:351–358. doi:10.1016/j.jgar.2021.04.008. PMID 33964492
- American College of Obstetricians and Gynecologists. Prevention of Group B Streptococcal Early-Onset Disease in Newborns: ACOG Committee Opinion, Number 797. Obstet Gynecol. 2020;135(2):e51–e72. doi:10.1097/AOG.0000000000003668. PMID 31977795 (ACOG 2020)
- American Thoracic Society, Centers for Disease Control and Prevention. Diagnostic Standards and Classification of Tuberculosis in Adults and Children. Am J Respir Crit Care Med. 2000;161(4 Pt 1):1376–1395. doi:10.1164/ajrccm.161.4.16141. PMID 10764337 (ATS 2000)
- Amsel R, Totten PA, Spiegel CA, et al. Nonspecific vaginitis. Diagnostic criteria and microbial and epidemiologic associations. Am J Med. 1983;74(1):14-22. doi:10.1016/0002-9343(83)91112-9. PMID 6600371
- Angelakis E, Raoult D. Pathogenicity and treatment of Bartonella infections. Int J Antimicrob Agents. 2014;44(1):16–25. doi:10.1016/j.ijantimicag.2014.04.006. PMID 24933445
- Atchade E, De Tymowski C, Grall N, Tanaka S, Montravers P. Toxic Shock Syndrome: A Literature Review. Antibiotics (Basel). 2024;13(1):96. doi:10.3390/antibiotics13010096. PMID 38247655
- Baba H. Studies on the problems of resistance to antituberculous drugs. II-2. Clinically significant critical concentration of streptomycin, isoniazid, kanamycin and ethambutol. Kekkaku. 1994;69(6):397–407. PMID 8041058
- Bamford C. Reporting of cumulative antimicrobial susceptibility testing data, including antibiograms. S Afr J Infect Dis. 2025;40(1):775. doi:10.4102/sajid.v40i1.775. PMID 41070166
- Banerjee R, Komarow L, Virk A, et al. Randomized Trial Evaluating Clinical Impact of RAPid IDentification and Susceptibility Testing for Gram-negative Bacteremia: RAPIDS-GN. Clin Infect Dis. 2021;73(1):e39-e46. doi:10.1093/cid/ciaa528. PMID 32374822
- Banerjee R, Teng CB, Cunningham SA, et al. Randomized Trial of Rapid Multiplex Polymerase Chain Reaction-Based Blood Culture Identification and Susceptibility Testing. Clin Infect Dis. 2015;61(7):1071-80. doi:10.1093/cid/civ447. PMID 26197846
- Barbee LA, Dombrowski JC, Kerani R, Golden MR. Effect of nucleic acid amplification testing on detection of extragenital gonorrhea and chlamydial infections in men who have sex with men sexually transmitted disease clinic patients. Sex Transm Dis. 2014;41(3):168–172. doi:10.1097/OLQ.0000000000000093. PMID 24521722
- Barbee LA, St Cyr SB. Management of Neisseria gonorrhoeae in the United States: Summary of Evidence From the Development of the 2020 Gonorrhea Treatment Recommendations and the 2021 Centers for Disease Control and Prevention Sexually Transmitted Infection Treatment Guidelines. Clin Infect Dis. 2022;74(Suppl 2):S95–S111. doi:10.1093/cid/ciac043. PMID 35416971
- Bauer AW, Kirby WM, Sherris JC, Turck M. Antibiotic susceptibility testing by a standardized single disk method. Am J Clin Pathol. 1966;45(4):493-496. PMID 5325707
- Bazzi AM, Al-Tawfiq JA, Rabaan AA. Misinterpretation of Gram stain from the stationary growth phase of positive blood cultures for Brucella and Acinetobacter species. Open Microbiol J. 2017;11:126-131. doi:10.2174/1874285801711010126. PMID 28839492
- Becker K, Heilmann C, Peters G. Coagulase-negative staphylococci. Clin Microbiol Rev. 2014;27(4):870–926. doi:10.1128/CMR.00109-13. PMID 25278577
- Becton Dickinson. BD BBL Chocolate II Agar (product 221267). https://www.bd.com/en-us/products-and-solutions/products/product-page.221267 (accessed November 10, 2026) (BD 2026a)
- Becton Dickinson. BD BBL Columbia CNA Agar with 5% Sheep Blood (product 221353). https://www.bd.com/en-us/products-and-solutions/products/product-page.221353 (accessed November 10, 2026) (BD 2026b)
- Becton Dickinson. Phenylethyl Alcohol Agar with 5% Sheep Blood (product 221277). https://www.bd.com/en-us/products-and-solutions/products/product-page.221277 (accessed November 10, 2026) (BD 2026c)
- Ben Saïd L, Diancourt L, Rabeau A, et al. Binary Enterotoxin Producing Clostridium perfringens Isolated in Blood Cultures: Case Report and Review of the Literature. Microorganisms. 2024;12(6):1095. doi:10.3390/microorganisms12061095. PMID 38930477
- Bernard K. The genus Corynebacterium and other medically relevant coryneform-like bacteria. J Clin Microbiol. 2012;50(10):3152–3158. doi:10.1128/JCM.00796-12. PMID 22837327
- Best LM, Takwoingi Y, Siddique S, et al. Non-invasive diagnostic tests for Helicobacter pylori infection. Cochrane Database Syst Rev. 2018;3(3):CD012080. doi:10.1002/14651858.CD012080.pub2. PMID 29543326
- Biggs HM, Behravesh CB, Bradley KK, et al. Diagnosis and Management of Tickborne Rickettsial Diseases: Rocky Mountain Spotted Fever and Other Spotted Fever Group Rickettsioses, Ehrlichioses, and Anaplasmosis: United States. MMWR Recomm Rep. 2016;65(2):1–44. doi:10.15585/mmwr.rr6502a1. PMID 27172113
- Blauwkamp TA, Thair S, Rosen MJ, et al. Analytical and clinical validation of a microbial cell-free DNA sequencing test for infectious disease. Nat Microbiol. 2019;4(4):663-674. doi:10.1038/s41564-018-0349-6. PMID 30742071
- Blot F, Nitenberg G, Chachaty E, et al. Diagnosis of catheter-related bacteraemia: a prospective comparison of the time to positivity of hub-blood versus peripheral-blood cultures. Lancet. 1999;354(9184):1071-7. doi:10.1016/s0140-6736(98)11134-0. PMID 10509498
- Boleij A, van Gelder MM, Swinkels DW, Tjalsma H. Clinical Importance of Streptococcus gallolyticus infection among colorectal cancer patients: systematic review and meta-analysis. Clin Infect Dis. 2011;53(9):870–878. doi:10.1093/cid/cir609. PMID 21960713
- Bottone EJ. Bacillus cereus, a volatile human pathogen. Clin Microbiol Rev. 2010;23(2):382–398. doi:10.1128/CMR.00073-09. PMID 20375358
- Brook I, Wexler HM, Goldstein EJ. Antianaerobic antimicrobials: spectrum and susceptibility testing. Clin Microbiol Rev. 2013;26(3):526–546. doi:10.1128/CMR.00086-12. PMID 23824372
- Brooke CJ, Riley TV. Erysipelothrix rhusiopathiae: bacteriology, epidemiology and clinical manifestations of an occupational pathogen. J Med Microbiol. 1999;48(9):789–799. doi:10.1099/00222615-48-9-789. PMID 10482289
- Brooke JS. Stenotrophomonas maltophilia: an emerging global opportunistic pathogen. Clin Microbiol Rev. 2012;25(1):2–41. doi:10.1128/CMR.00019-11. PMID 22232370
- Brown-Elliott BA, Brown JM, Conville PS, Wallace RJ. Clinical and laboratory features of the Nocardia spp. based on current molecular taxonomy. Clin Microbiol Rev. 2006;19(2):259–282. doi:10.1128/CMR.19.2.259-282.2006. PMID 16614249
- Burnham CA, Carroll KC. Diagnosis of Clostridium difficile infection: an ongoing conundrum for clinicians and for clinical laboratories. Clin Microbiol Rev. 2013;26(3):604–630. doi:10.1128/CMR.00016-13. PMID 23824374
- Bush K, Jacoby GA. Updated functional classification of beta-lactamases. Antimicrob Agents Chemother. 2010;54(3):969-76. doi:10.1128/AAC.01009-09. PMID 19995920
- Buss SN, Leber A, Chapin K, et al. Multicenter evaluation of the BioFire FilmArray gastrointestinal panel for etiologic diagnosis of infectious gastroenteritis. J Clin Microbiol. 2015;53(3):915-25. doi:10.1128/JCM.02674-14. PMID 25588652
- Campodónico VL, Ruelle J, Fitzgerald A, et al. Evaluation of long-read 16S rRNA next-generation sequencing for identification of bacterial isolates in a clinical diagnostic laboratory. J Clin Microbiol. 2025;63(5):e0167024. doi:10.1128/jcm.01670-24. PMID 40261041
- Cargill JS, Scott KS, Gascoyne-Binzi D, Sandoe JA. Granulicatella infection: diagnosis and management. J Med Microbiol. 2012;61(Pt 6):755–761. doi:10.1099/jmm.0.039693-0. PMID 22442291
- Castanheira M, Simner PJ, Bradford PA. Extended-spectrum β-lactamases: an update on their characteristics, epidemiology and detection. JAC Antimicrob Resist. 2021;3(3):dlab092. doi:10.1093/jacamr/dlab092. PMID 34286272
- Cattoir V, Giard JC. Antibiotic resistance in Enterococcus faecium clinical isolates. Expert Rev Anti Infect Ther. 2014;12(2):239–248. doi:10.1586/14787210.2014.870886. PMID 24392717
- Centers for Disease Control and Prevention. Biosafety in Microbiological and Biomedical Laboratories (BMBL) 6th Edition. Last updated March 18, 2026. https://www.cdc.gov/labs/bmbl/index.html (accessed November 10, 2026) (CDC 2026)
- Centers for Disease Control and Prevention. Discordant results from reverse sequence syphilis screening: five laboratories, United States, 2006–2010. MMWR Morb Mortal Wkly Rep. 2011;60(5):133–137. PMID 21307823 (CDC 2011)
- Centers for Disease Control and Prevention. Laboratory Response Network for Biological Threats (LRN-B). October 17, 2024. https://www.cdc.gov/laboratory-response-network/php/biological/index.html (accessed November 10, 2026) (CDC 2024)
- Centers for Disease Control and Prevention. Laboratory-acquired brucellosis: Indiana and Minnesota, 2006. MMWR Morb Mortal Wkly Rep. 2008;57(2):39–42. PMID 18199967 (CDC 2008)
- Centers for Disease Control and Prevention. Lyme disease: diagnosis and testing (for healthcare providers). https://www.cdc.gov/lyme/hcp/diagnosis-testing/index.html (accessed November 10, 2026) (CDC 2025a)
- Centers for Disease Control and Prevention. Recommendations for test performance and interpretation from the Second National Conference on Serologic Diagnosis of Lyme Disease. MMWR Morb Mortal Wkly Rep. 1995;44(31):590–591. PMID 7623762. https://www.cdc.gov/mmwr/preview/mmwrhtml/00038469.htm (CDC 1995)
- Centers for Disease Control and Prevention. Tuberculin skin test. https://www.cdc.gov/tb/hcp/testing-diagnosis/tuberculin-skin-test.html (accessed November 10, 2026) (CDC 2025b)
- Charlier C, Disson O, Lecuit M. Maternal-neonatal listeriosis. Virulence. 2020;11(1):391–397. doi:10.1080/21505594.2020.1759287. PMID 32363991
- Chatzigeorgiou KS, Sergentanis TN, Tsiodras S, et al. Phoenix 100 versus Vitek 2 in the identification of gram-positive and gram-negative bacteria: a comprehensive meta-analysis. J Clin Microbiol. 2011;49(9):3284-91. doi:10.1128/JCM.00182-11. PMID 21752980
- Chew SS, Lubowski DZ. Clostridium septicum and malignancy. ANZ J Surg. 2001;71(11):647–649. doi:10.1046/j.1445-1433.2001.02231.x. PMID 11736823
- Chey WD, Howden CW, Moss SF, et al. ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. Am J Gastroenterol. 2024;119(9):1730–1753. doi:10.14309/ajg.0000000000002968. PMID 39626064
- Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG Clinical Guideline: Treatment of Helicobacter pylori Infection. Am J Gastroenterol. 2017;112(2):212–239. doi:10.1038/ajg.2016.563. PMID 28071659
- Christianson S, Grierson W, Kein D, Tyler AD, Wolfe J, Sharma MK. Time-to-Detection of Inducible Macrolide Resistance in Mycobacterium abscessus Subspecies and Its Association with the Erm(41) Sequevar. PLoS One. 2016;11(8):e0158723. doi:10.1371/journal.pone.0158723. PMID 27490181
- Church DL, Cerutti L, Gürtler A, et al. Performance and Application of 16S rRNA Gene Cycle Sequencing for Routine Identification of Bacteria in the Clinical Microbiology Laboratory. Clin Microbiol Rev. 2020;33(4):e00053-19. doi:10.1128/CMR.00053-19. PMID 32907806
- Clark NC, Teixeira LM, Facklam RR, et al. Detection and differentiation of vanC-1, vanC-2, and vanC-3 glycopeptide resistance genes in enterococci. J Clin Microbiol. 1998;36(8):2294-7. doi:10.1128/JCM.36.8.2294-2297.1998. PMID 9666008
- Clinical and Laboratory Standards Institute. M100: Performance Standards for Antimicrobial Susceptibility Testing, 36th edition. Published January 26, 2026. https://clsi.org/shop/standards/m100/ (accessed November 10, 2026) (CLSI 2026)
- Cockerill FR 3rd, Wilson JW, Vetter EA, et al. Optimal testing parameters for blood cultures. Clin Infect Dis. 2004;38(12):1724-30. doi:10.1086/421087. PMID 15227618
- Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). Infect Control Hosp Epidemiol. 2010;31(5):431–455. doi:10.1086/651706. PMID 20307191
- Coyle MB, Carlson LC, Wallis CK, et al. Laboratory aspects of "Mycobacterium genavense," a proposed species isolated from AIDS patients. J Clin Microbiol. 1992;30(12):3206–3212. doi:10.1128/jcm.30.12.3206-3212.1992. PMID 1280652
- Croxen MA, Law RJ, Scholz R, Keeney KM, Wlodarska M, Finlay BB. Recent advances in understanding enteric pathogenic Escherichia coli. Clin Microbiol Rev. 2013;26(4):822–880. doi:10.1128/CMR.00022-13. PMID 24092857
- Daley CL, Iaccarino JM, Lange C, et al. Treatment of Nontuberculous Mycobacterial Pulmonary Disease: An Official ATS/ERS/ESCMID/IDSA Clinical Practice Guideline. Clin Infect Dis. 2020;71(4):e1–e36. doi:10.1093/cid/ciaa241. PMID 32628747
- Damato JJ, Collins MT. Radiometric studies with gas-liquid and thin-layer chromatography for rapid demonstration of hemin dependence and characterization of Mycobacterium haemophilum. J Clin Microbiol. 1984;20(3):515–518. doi:10.1128/jcm.20.3.515-518.1984. PMID 6436306
- Davis JL, Cattamanchi A, Cuevas LE, Hopewell PC, Steingart KR. Diagnostic accuracy of same-day microscopy versus standard microscopy for pulmonary tuberculosis: a systematic review and meta-analysis. Lancet Infect Dis. 2013;13(2):147–154. doi:10.1016/S1473-3099(12)70232-3. PMID 23099183
- Devanga Ragupathi NK, Muthuirulandi Sethuvel DP, Inbanathan FY, Veeraraghavan B. Accurate differentiation of Escherichia coli and Shigella serogroups: challenges and strategies. New Microbes New Infect. 2018;21:58–62. doi:10.1016/j.nmni.2017.09.003. PMID 29204286
- Dhavale SL, Patil HV, Patil SR. Carbapenemase Detection Methods in Clinical Microbiology: Conventional and Automated Approaches. Cureus. 2026;18(7):e112242. doi:10.7759/cureus.112242. PMID 42568830
- Djorić D, Little JL, Kristich CJ. Multiple Low-Reactivity Class B Penicillin-Binding Proteins Are Required for Cephalosporin Resistance in Enterococci. Antimicrob Agents Chemother. 2020;64(4):e02273-19. doi:10.1128/AAC.02273-19. PMID 32041714
- Dolmans RA, Boel CH, Lacle MM, Kusters JG. Clinical Manifestations, Treatment, and Diagnosis of Tropheryma whipplei Infections. Clin Microbiol Rev. 2017;30(2):529–555. doi:10.1128/CMR.00033-16. PMID 28298472
- Dortet L, Agathine A, Naas T, et al. Evaluation of the RAPIDEC® CARBA NP, the Rapid CARB Screen® and the Carba NP test for biochemical detection of carbapenemase-producing Enterobacteriaceae. J Antimicrob Chemother. 2015;70(11):3014-22. doi:10.1093/jac/dkv213. PMID 26260131
- Edelstein PH. Improved semiselective medium for isolation of Legionella pneumophila from contaminated clinical and environmental specimens. J Clin Microbiol. 1981;14(3):298-303. doi:10.1128/jcm.14.3.298-303.1981. PMID 7287886
- Efstratiou A, George RC. Laboratory guidelines for the diagnosis of infections caused by Corynebacterium diphtheriae and C. ulcerans. World Health Organization. Commun Dis Public Health. 1999;2(4):250–257. PMID 10598381
- Eisinger SW, Schwartz M, Dam L, et al. Evaluation of the BD Vacutainer Plus Urine C&S Preservative Tubes compared with nonpreservative urine samples stored at 4°C and room temperature. Am J Clin Pathol. 2013;140(3):306-13. doi:10.1309/AJCP5ON9JHXVNQOD. PMID 23955448
- Elliott SP. Rat bite fever and Streptobacillus moniliformis. Clin Microbiol Rev. 2007;20(1):13–22. doi:10.1128/CMR.00016-06. PMID 17223620
- Engler KH, Glushkevich T, Mazurova IK, George RC, Efstratiou A. A modified Elek test for detection of toxigenic corynebacteria in the diagnostic laboratory. J Clin Microbiol. 1997;35(2):495–498. doi:10.1128/jcm.35.2.495-498.1997. PMID 9003626
- España PP, Uranga A, Cillóniz C, Torres A. Q Fever (Coxiella burnetii). Semin Respir Crit Care Med. 2020;41(4):509–521. doi:10.1055/s-0040-1710594. PMID 32629489
- European Committee on Antimicrobial Susceptibility Testing. Clinical breakpoints, version 16.1, valid from June 24, 2026. https://www.eucast.org/clinical_breakpoints (accessed November 10, 2026) (EUCAST 2026)
- Fabre V, Hsu Y-J, Carroll KC, et al. Multicenter evaluation of blood culture contamination and blood cultures practices in US acute care hospitals: time for standardization. J Clin Microbiol. 2025;63(8):e0053025. doi:10.1128/jcm.00530-25. PMID 40643261
- Facklam R, Pigott N, Franklin R, et al. Evaluation of three disk tests for identification of enterococci, leuconostocs, and pediococci. J Clin Microbiol. 1995;33(4):885-7. doi:10.1128/jcm.33.4.885-887.1995. PMID 7790454
- Federal Select Agent Program. Select Agents and Toxins List. Last reviewed January 14, 2025. https://www.selectagents.gov/sat/list.htm (accessed November 10, 2026) (FSAP 2025)
- Fernández Guerrero ML, Robles I, Nogales MdelC, Nuevo D. Corynebacterium striatum: an emerging nosocomial drug-resistant endocardial pathogen. J Heart Valve Dis. 2013;22(3):428–430. PMID 24151771
- Ferroni A, Al Khoury H, Dana C, et al. Prospective survey of acute osteoarticular infections in a French paediatric orthopedic surgery unit. Clin Microbiol Infect. 2013;19(9):822–828. doi:10.1111/clm.12031. PMID 23957786
- Fiebelkorn KR, Crawford SA, McElmeel ML, et al. Practical disk diffusion method for detection of inducible clindamycin resistance in Staphylococcus aureus and coagulase-negative staphylococci. J Clin Microbiol. 2003;41(10):4740-4. doi:10.1128/JCM.41.10.4740-4744.2003. PMID 14532213
- Filkins L, Hauser JR, Robinson-Dunn B, Tibbetts R, Boyanton BL, Revell P. American Society for Microbiology Provides 2020 Guidelines for Detection and Identification of Group B Streptococcus [announcement of the ASM 2020 group B streptococcus laboratory guidelines]. J Clin Microbiol. 2020;59(1):e01230-20. doi:10.1128/JCM.01230-20. PMID 33115849
- Food and Drug Administration. Antibacterial Susceptibility Test Interpretive Criteria: Notices of Updates. Content current as of October 30, 2026. https://www.fda.gov/drugs/development-resources/notices-updates (accessed November 10, 2026) (FDA 2026)
- Fowler VG, Durack DT, Selton-Suty C, et al. The 2023 Duke-International Society for Cardiovascular Infectious Diseases Criteria for Infective Endocarditis: Updating the Modified Duke Criteria. Clin Infect Dis. 2023;77(4):518-526. doi:10.1093/cid/ciad271. PMID 37138445
- Franco-Paredes C, Marcos LA, Henao-Martínez AF, et al. Cutaneous Mycobacterial Infections. Clin Microbiol Rev. 2018;32(1):e00069-18. doi:10.1128/CMR.00069-18. PMID 30429139
- Frangiamore SJ, Saleh A, Grosso MJ, et al. Early Versus Late Culture Growth of Propionibacterium acnes in Revision Shoulder Arthroplasty. J Bone Joint Surg Am. 2015;97(14):1149–1158. doi:10.2106/JBJS.N.00881. PMID 26178890
- Frank KL, Del Pozo JL, Patel R. From clinical microbiology to infection pathogenesis: how daring to be different works for Staphylococcus lugdunensis. Clin Microbiol Rev. 2008;21(1):111–133. doi:10.1128/CMR.00036-07. PMID 18202439
- Friedemann M. Epidemiology of invasive neonatal Cronobacter (Enterobacter sakazakii) infections. Eur J Clin Microbiol Infect Dis. 2009;28(11):1297–1304. doi:10.1007/s10096-009-0779-4. PMID 19662446
- Funke G, von Graevenitz A, Clarridge JE, Bernard KA. Clinical microbiology of coryneform bacteria. Clin Microbiol Rev. 1997;10(1):125–159. doi:10.1128/CMR.10.1.125. PMID 8993861
- Gajdács M, Spengler G, Urbán E. Identification and Antimicrobial Susceptibility Testing of Anaerobic Bacteria: Rubik's Cube of Clinical Microbiology? Antibiotics (Basel). 2017;6(4):25. doi:10.3390/antibiotics6040025. PMID 29112122
- García-Álvarez L, Holden MT, Lindsay H, et al. Meticillin-resistant Staphylococcus aureus with a novel mecA homologue in human and bovine populations in the UK and Denmark: a descriptive study. Lancet Infect Dis. 2011;11(8):595-603. doi:10.1016/S1473-3099(11)70126-8. PMID 21641281
- Gassiep I, Armstrong M, Norton R. Human Melioidosis. Clin Microbiol Rev. 2020;33(2):e00006-19. doi:10.1128/CMR.00006-19. PMID 32161067
- Georgakopoulou VE, Lempesis IG, Tarantinos K, Sklapani P, Trakas N, Spandidos DA. Atypical pneumonia (Review). Exp Ther Med. 2024;28(5):424. doi:10.3892/etm.2024.12713. PMID 39301259
- Gogry FA, Siddiqui MT, Sultan I, et al. Current Update on Intrinsic and Acquired Colistin Resistance Mechanisms in Bacteria. Front Med (Lausanne). 2021;8:677720. doi:10.3389/fmed.2021.677720. PMID 34476235
- Goh KS, Rastogi N. Simple and rapid method for detection of nitrate reductase activity of Mycobacterium tuberculosis and Mycobacterium canettii grown in the Bactec MGIT960 system. J Microbiol Methods. 2010;81(2):208–210. doi:10.1016/j.mimet.2010.03.005. PMID 20298726
- Gopalsamy SN, Ramakrishnan A, Shariff MM, et al. Brucellosis Initially Misidentified as Ochrobactrum anthropi Bacteremia: A Case Report and Review of the Literature. Open Forum Infect Dis. 2021;8(10):ofab473. doi:10.1093/ofid/ofab473. PMID 34660837
- Gould LH, Bopp C, Strockbine N, et al. Recommendations for diagnosis of Shiga toxin-producing Escherichia coli infections by clinical laboratories. MMWR Recomm Rep. 2009;58(RR-12):1-14. PMID 19834454
- Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med. 2007;175(4):367–416. doi:10.1164/rccm.200604-571ST. PMID 17277290
- Guinet F, Carniel E, Leclercq A. Transfusion-transmitted Yersinia enterocolitica sepsis. Clin Infect Dis. 2011;53(6):583–591. doi:10.1093/cid/cir452. PMID 21865196
- Gupta R, Popli T, Ranchal P, et al. Corynebacterium jeikeium Endocarditis: A Review of the Literature. Cardiol Rev. 2021;29(5):259–262. doi:10.1097/CRD.0000000000000355. PMID 32976125
- Haldane DJ, Robart E. A comparison of calcofluor white, potassium hydroxide, and culture for the laboratory diagnosis of superficial fungal infection. Diagn Microbiol Infect Dis. 1990;13(4):337-9. doi:10.1016/0732-8893(90)90027-s. PMID 1706243
- Haq SM, Dayal HH. Chronic liver disease and consumption of raw oysters: a potentially lethal combination: a review of Vibrio vulnificus septicemia. Am J Gastroenterol. 2005;100(5):1195–1199. doi:10.1111/j.1572-0241.2005.40814.x. PMID 15842598
- Harju I, Lange C, Kostrzewa M, Maier T, Rantakokko-Jalava K, Haanperä M. Improved Differentiation of Streptococcus pneumoniae and Other S. mitis Group Streptococci by MALDI Biotyper Using an Improved MALDI Biotyper Database Content and a Novel Result Interpretation Algorithm. J Clin Microbiol. 2017;55(3):914–922. doi:10.1128/JCM.01990-16. PMID 28053215
- He G, Zheng Q, Wu J, et al. Discordant results between Xpert MTB/RIF assay and Bactec MGIT 960 culture system regarding the detection of rifampin-resistant Mycobacterium tuberculosis isolates in Wenzhou, China. Microbiol Spectr. 2024;12(6):e0385923. doi:10.1128/spectrum.03859-23. PMID 38738892
- He W, Yuan Y, Liang J, et al. Detection of macrolide and fluoroquinolone resistance-associated 23S rRNA and parC mutations in Mycoplasma genitalium by nested real-time PCR. Front Cell Infect Microbiol. 2023;13:1271392. doi:10.3389/fcimb.2023.1271392. PMID 37928183
- Higuchi R, Fockler C, Dollinger G, et al. Kinetic PCR analysis: real-time monitoring of DNA amplification reactions. Biotechnology (N Y). 1993;11(9):1026-30. doi:10.1038/nbt0993-1026. PMID 7764001
- Hooton TM, Roberts PL, Cox ME, et al. Voided midstream urine culture and acute cystitis in premenopausal women. N Engl J Med. 2013;369(20):1883-91. doi:10.1056/NEJMoa1302186. PMID 24224622
- Hördt A, López MG, Meier-Kolthoff JP, et al. Analysis of 1,000+ Type-Strain Genomes Substantially Improves Taxonomic Classification of Alphaproteobacteria. Front Microbiol. 2020;11:468. doi:10.3389/fmicb.2020.00468. PMID 32373076
- Horne DJ, Zifodya JS, Shapiro AE, et al. Xpert MTB/RIF Ultra assay for pulmonary tuberculosis and rifampicin resistance in adults and adolescents. Cochrane Database Syst Rev. 2025;7(7):CD009593. doi:10.1002/14651858.CD009593.pub6. PMID 40728034
- Howden BP, Davies JK, Johnson PD, et al. Reduced vancomycin susceptibility in Staphylococcus aureus, including vancomycin-intermediate and heterogeneous vancomycin-intermediate strains: resistance mechanisms, laboratory detection, and clinical implications. Clin Microbiol Rev. 2010;23(1):99-139. doi:10.1128/CMR.00042-09. PMID 20065327
- Huang Y, Cao Y, Zou M, et al. A Comparison of Tissue versus Swab Culturing of Infected Diabetic Foot Wounds. Int J Endocrinol. 2016;2016:8198714. doi:10.1155/2016/8198714. PMID 27123004
- Humphries R, Bobenchik AM, Hindler JA, et al. Overview of Changes to the Clinical and Laboratory Standards Institute Performance Standards for Antimicrobial Susceptibility Testing, M100, 31st Edition. J Clin Microbiol. 2021;59(12):e0021321. doi:10.1128/JCM.00213-21. PMID 34550809
- Humphries RM, Abbott AN, Hindler JA. Understanding and Addressing CLSI Breakpoint Revisions: a Primer for Clinical Laboratories. J Clin Microbiol. 2019;57(6):e00203-19. doi:10.1128/JCM.00203-19. PMID 30971460
- Ibrahim GM, Morin PM. Salmonella Serotyping Using Whole Genome Sequencing. Front Microbiol. 2018;9:2993. doi:10.3389/fmicb.2018.02993. PMID 30619114
- Idigoras P, Beristain X, Iturzaeta A, et al. Comparison of the automated nonradiometric Bactec MGIT 960 system with Löwenstein-Jensen, Coletsos, and Middlebrook 7H11 solid media for recovery of mycobacteria. Eur J Clin Microbiol Infect Dis. 2000;19(5):350-4. doi:10.1007/s100960050492. PMID 10898135
- Ikryannikova LN, Filimonova AV, Malakhova MV, et al. Discrimination between Streptococcus pneumoniae and Streptococcus mitis based on sorting of their MALDI mass spectra. Clin Microbiol Infect. 2013;19(11):1066-71. doi:10.1111/1469-0691.12113. PMID 23331578
- Ing J, Mason EO, Kaplan SL, et al. Characterization of nontypeable and atypical Streptococcus pneumoniae pediatric isolates from 1994 to 2010. J Clin Microbiol. 2012;50(4):1326-30. doi:10.1128/JCM.05182-11. PMID 22238440
- Jagtap PM, Dravid MN. Rapid identification of Escherichia coli in the diagnostic microbiology laboratory by the spot indole test. Indian J Pathol Microbiol. 1985;28(4):293-6. PMID 3914461
- Janda JM, Abbott SL. The genus Aeromonas: taxonomy, pathogenicity, and infection. Clin Microbiol Rev. 2010;23(1):35–73. doi:10.1128/CMR.00039-09. PMID 20065325
- Jo S, Kim SW, Kim JO, et al. Utility of the BioFire® FilmArray® Pneumonia Panel Using Bronchial Washing Specimens: A Comparative Study with Conventional Culture. Diagnostics (Basel). 2025;16(1):91. doi:10.3390/diagnostics16010091. PMID 41515586
- Johnson S, Lavergne V, Skinner AM, et al. Clinical Practice Guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 Focused Update Guidelines on Management of Clostridioides difficile Infection in Adults. Clin Infect Dis. 2021;73(5):e1029–e1044. doi:10.1093/cid/ciab549. PMID 34164674
- Jorgensen JH, Ferraro MJ. Antimicrobial susceptibility testing: a review of general principles and contemporary practices. Clin Infect Dis. 2009;49(11):1749-55. doi:10.1086/647952. PMID 19857164
- Kaakoush NO, Castaño-Rodríguez N, Mitchell HM, Man SM. Global Epidemiology of Campylobacter Infection. Clin Microbiol Rev. 2015;28(3):687–720. doi:10.1128/CMR.00006-15. PMID 26062576
- Kalagarla S, Alluri R, Saka S, et al. Efficacy of fluorescent microscopy versus modified Fite-Faraco stain in skin biopsy specimens of leprosy cases: a comparative study. Int J Dermatol. 2022;61(5):595–599. doi:10.1111/ijd.16046. PMID 35061916
- Kamali Kakhki R, Abavisani M, Ghazvini K, et al. Identification of a Novel Nucleic Acid Target for the Rapid and Specific Detection of Mycobacterium simiae Using Comparative Genomic Analysis. Avicenna J Med Biotechnol. 2026;18(2):157–166. doi:10.18502/ajmb.v18i2.21508. PMID 42466364
- Karadağ D, Ergon MC. Investigation of different methods in rapid microbial identification directly from positive blood culture bottles by MALDI-TOF MS. Microbiol Spectr. 2024;12(8):e0063824. doi:10.1128/spectrum.00638-24. PMID 38940589
- Kasperbauer SH, Daley CL. Mycobacterium chimaera Infections Related to the Heater-Cooler Unit Outbreak: A Guide to Diagnosis and Management. Clin Infect Dis. 2019;68(7):1244–1250. doi:10.1093/cid/ciy789. PMID 30371755
- Kawasaki T, Nakagawa N, Murata M, et al. Diagnostic accuracy of urinary antigen tests for legionellosis: A systematic review and meta-analysis. Respir Investig. 2022;60(2):205-214. doi:10.1016/j.resinv.2021.11.011. PMID 34972680
- Kaye KS, Shorr AF, Wunderink RG, et al. Efficacy and safety of sulbactam-durlobactam versus colistin for the treatment of patients with serious infections caused by Acinetobacter baumannii-calcoaceticus complex: a multicentre, randomised, active-controlled, phase 3, non-inferiority clinical trial (ATTACK). Lancet Infect Dis. 2023;23(9):1072-1084. doi:10.1016/S1473-3099(23)00184-6. PMID 37182534
- Kellogg JA, Manzella JP, Bankert DA. Frequency of low-level bacteremia in children from birth to fifteen years of age. J Clin Microbiol. 2000;38(6):2181-5. doi:10.1128/JCM.38.6.2181-2185.2000. PMID 10834973
- Kelly CR, Fischer M, Allegretti JR, et al. ACG Clinical Guidelines: Prevention, Diagnosis, and Treatment of Clostridioides difficile Infections. Am J Gastroenterol. 2021;116(6):1124–1147. doi:10.14309/ajg.0000000000001278. PMID 34003176
- Knorr L, Fox JD, Tilley PA, Ahmed-Bentley J. Evaluation of real-time PCR for diagnosis of Bordetella pertussis infection. BMC Infect Dis. 2006;6:62. doi:10.1186/1471-2334-6-62. PMID 16556317
- Koopmans MM, Brouwer MC, Vázquez-Boland JA, van de Beek D. Human Listeriosis. Clin Microbiol Rev. 2023;36(1):e0006019. doi:10.1128/cmr.00060-19. PMID 36475874
- Krause PJ, Fish D, Narasimhan S, Barbour AG. Borrelia miyamotoi infection in nature and in humans. Clin Microbiol Infect. 2015;21(7):631–639. doi:10.1016/j.cmi.2015.02.006. PMID 25700888
- Kuehn R, Rahden P, Hussain HS, et al. Enteric (typhoid and paratyphoid) fever. Lancet. 2025;406(10509):1283–1294. doi:10.1016/S0140-6736(25)01335-2. PMID 40914181
- Kuipers JE, Seidel L, Garnier NE, et al. Neisseria gonorrhoeae antimicrobial susceptibility testing: application of traditional agar dilution to a high-throughput 96-well microtiter assay. Microbiol Spectr. 2025;13(7):e0324924. doi:10.1128/spectrum.03249-24. PMID 40488602
- Lantos PM, Rumbaugh J, Bockenstedt LK, et al. Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA), American Academy of Neurology (AAN), and American College of Rheumatology (ACR): 2020 Guidelines for the Prevention, Diagnosis and Treatment of Lyme Disease. Clin Infect Dis. 2021;72(1):e1–e48. doi:10.1093/cid/ciaa1215. PMID 33417672
- Leber AL, Everhart K, Balada-Llasat JM, et al. Multicenter Evaluation of BioFire FilmArray Meningitis/Encephalitis Panel for Detection of Bacteria, Viruses, and Yeast in Cerebrospinal Fluid Specimens. J Clin Microbiol. 2016;54(9):2251-61. doi:10.1128/JCM.00730-16. PMID 27335149
- Lee A, Mirrett S, Reller LB, et al. Detection of bloodstream infections in adults: how many blood cultures are needed? J Clin Microbiol. 2007;45(11):3546-8. doi:10.1128/JCM.01555-07. PMID 17881544
- Lee WS, Jean SS, Chen FL, Hsieh SM, Hsueh PR. Lemierre's syndrome: A forgotten and re-emerging infection. J Microbiol Immunol Infect. 2020;53(4):513–517. doi:10.1016/j.jmii.2020.03.027. PMID 32303484
- Lewinsohn DM, Leonard MK, LoBue PA, et al. Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention Clinical Practice Guidelines: Diagnosis of Tuberculosis in Adults and Children. Clin Infect Dis. 2017;64(2):111–115. doi:10.1093/cid/ciw778. PMID 28052967
- Lewis JD, Salipante SJ. Development of advanced control material for reverse transcription-mediated bacterial nucleic acid amplification tests. J Clin Microbiol. 2024;62(5):e0024324. doi:10.1128/jcm.00243-24. PMID 38629844
- Li JS, Sexton DJ, Mick N, et al. Proposed modifications to the Duke criteria for the diagnosis of infective endocarditis. Clin Infect Dis. 2000;30(4):633-8. doi:10.1086/313753. PMID 10770721
- Lindberg H, Snygg-Martin U, Berge A, et al. Consequences of Excluding Enterococcus faecium as a Typical Endocarditis Pathogen in the Duke-ISCVID Criteria: Endocarditis Is Endocarditis Even if the Bacterium Is Uncommon. Clin Infect Dis. 2023;77(8):1216-1217. doi:10.1093/cid/ciad394. PMID 37384563
- Lindström M, Korkeala H. Laboratory diagnostics of botulism. Clin Microbiol Rev. 2006;19(2):298–314. doi:10.1128/CMR.19.2.298-314.2006. PMID 16614251
- Lineaweaver WC, Hill MK, Buncke GM, et al. Aeromonas hydrophila infections following use of medicinal leeches in replantation and flap surgery. Ann Plast Surg. 1992;29(3):238–244. doi:10.1097/00000637-199209000-00008. PMID 1524373
- Liu Y, Wu SY, Deng J, et al. Application of MALDI-TOF mass spectrometry for identification of Nocardia species. BMC Microbiol. 2024;24(1):358. doi:10.1186/s12866-024-03483-2. PMID 39304812
- Liu YY, Wang Y, Walsh TR, et al. Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. Lancet Infect Dis. 2016;16(2):161-8. doi:10.1016/S1473-3099(15)00424-7. PMID 26603172
- Lo CK, Schonhofer C, Mina N, et al. Erysipelothrix rhusiopathiae-associated bloodstream infection in a patient with systemic lupus erythematosus: a case report and literature review. Access Microbiol. 2024;6(11):000881.v3. doi:10.1099/acmi.0.000881.v3. PMID 39686969
- Long KS, Poehlsgaard J, Kehrenberg C, et al. The Cfr rRNA methyltransferase confers resistance to phenicols, lincosamides, oxazolidinones, pleuromutilins, and streptogramin A antibiotics. Antimicrob Agents Chemother. 2006;50(7):2500-2505. doi:10.1128/AAC.00131-06. PMID 16801432
- Lotz MJ, Tamplin ML, Rodrick GE. Thiosulfate-citrate-bile salts-sucrose agar and its selectivity for clinical and marine vibrio organisms. Ann Clin Lab Sci. 1983;13(1):45–48. PMID 6838150
- Lourtet-Hascoët J, Pilmis B, Mizrahi A, et al. Does prolonged blood culture incubation improve microbiological diagnosis of HACEK and slow-growing bacteria infective endocarditis? Eur J Clin Microbiol Infect Dis. 2019;38(5):989–990. doi:10.1007/s10096-019-03550-x. PMID 30937562
- Mahale RP, Darpan Sheth P, Murthy NS. Evaluating the sputum bacteriological profile of lower respiratory tract infections with Bartlett score analysis in a tertiary care hospital in Southern Karnataka. Cureus. 2024;16(6):e61924. doi:10.7759/cureus.61924. PMID 38978927
- Maki DG, Weise CE, Sarafin HW. A semiquantitative culture method for identifying intravenous-catheter-related infection. N Engl J Med. 1977;296(23):1305-9. doi:10.1056/NEJM197706092962301. PMID 323710
- Manoharan H, Lalitha AKV, Mariappan S, et al. Molecular Characterization of High-Level Aminoglycoside Resistance among Enterococcus Species. J Lab Physicians. 2022;14(3):290-294. doi:10.1055/s-0042-1742423. PMID 36119421
- Manuel C, Maynard R, Abbott A, et al. Evaluation of Piperacillin-Tazobactam Testing against Enterobacterales by the Phoenix, MicroScan, and Vitek2 Tests Using Updated Clinical and Laboratory Standards Institute Breakpoints. J Clin Microbiol. 2023;61(2):e0161722. doi:10.1128/jcm.01617-22. PMID 36719243
- March SB, Ratnam S. Sorbitol-MacConkey medium for detection of Escherichia coli O157:H7 associated with hemorrhagic colitis. J Clin Microbiol. 1986;23(5):869-72. doi:10.1128/jcm.23.5.869-872.1986. PMID 3519658
- Marín M, Ruiz A, Iglesias C, et al. Identification of Nocardia species from clinical isolates using MALDI-TOF mass spectrometry. Clin Microbiol Infect. 2018;24(12):1342.e5–1342.e8. doi:10.1016/j.cmi.2018.06.014. PMID 29933050
- Marrs ECL, Perry A, Perry JD. Evaluation of Three Culture Media for Isolation of Burkholderia cepacia Complex from Respiratory Samples of Patients with Cystic Fibrosis. Microorganisms. 2021;9(12):2604. doi:10.3390/microorganisms9122604. PMID 34946206
- Marth T, Moos V, Müller C, Biagi F, Schneider T. Tropheryma whipplei infection and Whipple's disease. Lancet Infect Dis. 2016;16(3):e13–e22. doi:10.1016/S1473-3099(15)00537-X. PMID 26856775
- Mateo M, Maestre JR, Aguilar L, et al. Genotypic versus phenotypic characterization, with respect to susceptibility and identification, of 17 clinical isolates of Staphylococcus lugdunensis. J Antimicrob Chemother. 2005;56(2):287-91. doi:10.1093/jac/dki227. PMID 15994248
- Matson KM, Sonetti DA. Successful treatment of Ureaplasma-induced hyperammonemia syndrome post-lung transplant. Transpl Infect Dis. 2019;21(1):e13022. doi:10.1111/tid.13022. PMID 30403322
- Mazurek GH, Jereb J, Vernon A, LoBue P, Goldberg S, Castro K. Updated guidelines for using Interferon Gamma Release Assays to detect Mycobacterium tuberculosis infection: United States, 2010. MMWR Recomm Rep. 2010;59(RR-5):1–25. PMID 20577159
- McDonald LC, Gerding DN, Johnson S, et al. Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clin Infect Dis. 2018;66(7):e1–e48. doi:10.1093/cid/cix1085. PMID 29462280
- Mead P, Petersen J, Hinckley A. Updated CDC Recommendation for Serologic Diagnosis of Lyme Disease. MMWR Morb Mortal Wkly Rep. 2019;68(32):703. doi:10.15585/mmwr.mm6832a4. PMID 31415492
- Merlino J, Koos G, Aitkens O, et al. Melioidosis: Burkholderia pseudomallei technical challenges in identification and susceptibility testing in a non-endemic area. Diagn Microbiol Infect Dis. 2026;116(1):117447. doi:10.1016/j.diagmicrobio.2026.117447. PMID 42105441
- Mesureur J, Arend S, Cellière B, et al. A MALDI-TOF MS database with broad genus coverage for species-level identification of Brucella. PLoS Negl Trop Dis. 2018;12(10):e0006874. doi:10.1371/journal.pntd.0006874. PMID 30335748
- Miller JM, Binnicker MJ, Campbell S, et al. A Guide to Utilization of the Microbiology Laboratory for Diagnosis of Infectious Diseases: 2018 Update by the Infectious Diseases Society of America and the American Society for Microbiology. Clin Infect Dis. 2018;67(6):e1-e94. doi:10.1093/cid/ciy381. PMID 29955859
- Miller JM, Binnicker MJ, Campbell S, et al. Guide to Utilization of the Microbiology Laboratory for Diagnosis of Infectious Diseases: 2024 Update by the Infectious Diseases Society of America (IDSA) and the American Society for Microbiology (ASM). Clin Infect Dis. Published online March 5, 2024. doi:10.1093/cid/ciae104. PMID 38442248
- Miyamoto H, Suzuki T, Murakami S, et al. Bacteriological characteristics of Arcanobacterium haemolyticum isolated from seven patients with skin and soft-tissue infections. J Med Microbiol. 2015;64(Pt 4):369–374. doi:10.1099/jmm.0.000038. PMID 25666838
- Mohamed AM, Bastola DR, Morlock GP, Cooksey RC, Hinrichs SH. Temperature-mediated heteroduplex analysis for detection of pncA mutations associated with pyrazinamide resistance and differentiation between Mycobacterium tuberculosis and Mycobacterium bovis by denaturing high-performance liquid chromatography. J Clin Microbiol. 2004;42(3):1016–1023. doi:10.1128/JCM.42.3.1016-1023.2004. PMID 15004047
- Mok S, Roycroft E, Flanagan PR, et al. Overcoming the Challenges of Pyrazinamide Susceptibility Testing in Clinical Mycobacterium tuberculosis Isolates. Antimicrob Agents Chemother. 2021;65(8):e0261720. doi:10.1128/AAC.02617-20. PMID 33972244
- Morgan DJ, Malani P, Diekema DJ. Diagnostic Stewardship-Leveraging the Laboratory to Improve Antimicrobial Use. JAMA. 2017;318(7):607-608. doi:10.1001/jama.2017.8531. PMID 28759678
- Mugusi S, Lema J, Ponsian P, et al. Diagnostic accuracy of sputum smear microscopy compared with culture in patients with tuberculosis confirmed by Xpert Mycobacterium tuberculosis/rifampicin assay in Tanzania: A cross-sectional study. J Int Med Res. 2025;53(10):3000605251390703. doi:10.1177/03000605251390703. PMID 41168107
- Murphy EC, Frick IM. Gram-positive anaerobic cocci: commensals and opportunistic pathogens. FEMS Microbiol Rev. 2013;37(4):520–553. doi:10.1111/1574-6976.12005. PMID 23030831
- Murray PR, Washington JA. Microscopic and baceriologic analysis of expectorated sputum. Mayo Clin Proc. 1975;50(6):339-44. PMID 1127999
- Naccache SN, Callan K, Burnham CA, et al. Evaluation of Oxacillin and Cefoxitin Disk Diffusion and Microbroth Dilution Methods for Detecting mecA-Mediated β-Lactam Resistance in Contemporary Staphylococcus epidermidis Isolates. J Clin Microbiol. 2019;57(12):e00961-19. doi:10.1128/JCM.00961-19. PMID 31462553
- Ng HY, Leung WK, Cheung KS. Antibiotic Resistance, Susceptibility Testing and Stewardship in Helicobacter pylori Infection. Int J Mol Sci. 2023;24(14):11708. doi:10.3390/ijms241411708. PMID 37511471
- Notomi T, Okayama H, Masubuchi H, et al. Loop-mediated isothermal amplification of DNA. Nucleic Acids Res. 2000;28(12):E63. doi:10.1093/nar/28.12.e63. PMID 10871386
- Nugent RP, Krohn MA, Hillier SL. Reliability of diagnosing bacterial vaginosis is improved by a standardized method of gram stain interpretation. J Clin Microbiol. 1991;29(2):297-301. doi:10.1128/jcm.29.2.297-301.1991. PMID 1706728
- Oehler RL, Velez AP, Mizrachi M, Lamarche J, Gompf S. Bite-related and septic syndromes caused by cats and dogs. Lancet Infect Dis. 2009;9(7):439–447. doi:10.1016/S1473-3099(09)70110-0. PMID 19555903
- Palavecino EL, Campodónico VL, She RC. Laboratory approaches to determining blood culture contamination rates: an ASM Laboratory Practices Subcommittee report. J Clin Microbiol. 2024;62(2):e0102823. doi:10.1128/jcm.01028-23. PMID 38051070
- Pancholi P, Carroll KC, Buchan BW, et al. Multicenter Evaluation of the Accelerate PhenoTest BC Kit for Rapid Identification and Phenotypic Antimicrobial Susceptibility Testing Using Morphokinetic Cellular Analysis. J Clin Microbiol. 2018;56(4):e01329-17. doi:10.1128/JCM.01329-17. PMID 29305546
- Papaparaskevas J, Houhoula DP, Papadimitriou M, Saroglou G, Legakis NJ, Zerva L. Ruling out Bacillus anthracis. Emerg Infect Dis. 2004;10(4):732–735. doi:10.3201/eid1004.030544. PMID 15200872
- Papp JR, Park IU, Fakile Y, et al. CDC Laboratory Recommendations for Syphilis Testing, United States, 2024. MMWR Recomm Rep. 2024;73(1):1-32. doi:10.15585/mmwr.rr7301a1. PMID 38319847
- Papp JR, Schachter J, Gaydos CA, Van Der Pol B. Recommendations for the laboratory-based detection of Chlamydia trachomatis and Neisseria gonorrhoeae: 2014. MMWR Recomm Rep. 2014;63(RR-02):1–19. PMID 24622331 (Papp 2014)
- Parmar R, Monari B, Potter E, et al. The Nugent score is an inappropriate diagnostic tool for neovaginal bacteria in transfeminine people. Commun Med (Lond). 2026;6(1):136. doi:10.1038/s43856-026-01410-2. PMID 41634193
- Patel R. MALDI-TOF MS for the diagnosis of infectious diseases. Clin Chem. 2015;61(1):100-11. doi:10.1373/clinchem.2014.221770. PMID 25278500
- Peel TN, Spelman T, Dylla BL, et al. Optimal Periprosthetic Tissue Specimen Number for Diagnosis of Prosthetic Joint Infection. J Clin Microbiol. 2017;55(1):234-243. doi:10.1128/JCM.01914-16. PMID 27807152
- Perry RD, Fetherston JD. Yersinia pestis: etiologic agent of plague. Clin Microbiol Rev. 1997;10(1):35–66. doi:10.1128/CMR.10.1.35. PMID 8993858
- Pierce VM, Bhowmick T, Simner PJ. Guiding antimicrobial stewardship through thoughtful antimicrobial susceptibility testing and reporting strategies: an updated approach in 2023. J Clin Microbiol. 2023;61(11):e0007422. doi:10.1128/jcm.00074-22. PMID 37768094
- Pierce VM, Simner PJ, Lonsway DR, et al. Modified Carbapenem Inactivation Method for Phenotypic Detection of Carbapenemase Production among Enterobacteriaceae. J Clin Microbiol. 2017;55(8):2321-2333. doi:10.1128/JCM.00193-17. PMID 28381609
- Pierre DM, Baron J, Yu VL, Stout JE. Diagnostic testing for Legionnaires' disease. Ann Clin Microbiol Antimicrob. 2017;16(1):59. doi:10.1186/s12941-017-0229-6. PMID 28851372
- Piersimoni C, Scarparo C, Callegaro A, et al. Comparison of MB/Bact Alert 3D system with radiometric BACTEC system and Löwenstein-Jensen medium for recovery and identification of mycobacteria from clinical specimens: a multicenter study. J Clin Microbiol. 2001;39(2):651–657. doi:10.1128/JCM.39.2.651-657.2001. PMID 11158124
- Pilarczyk-Zurek M, Sitkiewicz I, Koziel J. The Clinical View on Streptococcus anginosus Group: Opportunistic Pathogens Coming Out of Hiding. Front Microbiol. 2022;13:956677. doi:10.3389/fmicb.2022.956677. PMID 35898914
- Poirel L, Héritier C, Tolün V, et al. Emergence of oxacillinase-mediated resistance to imipenem in Klebsiella pneumoniae. Antimicrob Agents Chemother. 2004;48(1):15-22. doi:10.1128/AAC.48.1.15-22.2004. PMID 14693513
- Poyer F, Friesenbichler W, Hutter C, et al. Rothia mucilaginosa bacteremia: A 10-year experience of a pediatric tertiary care cancer center. Pediatr Blood Cancer. 2019;66(7):e27691. doi:10.1002/pbc.27691. PMID 30825249
- Prescott JF. Rhodococcus equi: an animal and human pathogen. Clin Microbiol Rev. 1991;4(1):20–34. doi:10.1128/CMR.4.1.20. PMID 2004346
- Putnam NE, Youn JH, Wallace MA, et al. Comparative Evaluation of Current Biochemical-, Sequencing-, and Proteomic-Based Identification Methods for the Streptococcus bovis Group. J Clin Microbiol. 2023;61(4):e0171222. doi:10.1128/jcm.01712-22. PMID 36912659
- Ray LC, Griffin PM, Wymore K, et al. Changing Diagnostic Testing Practices for Foodborne Pathogens, Foodborne Diseases Active Surveillance Network, 2012–2019. Open Forum Infect Dis. 2022;9(8):ofac344. doi:10.1093/ofid/ofac344. PMID 35928506
- Regan J, Lowe F. Enrichment medium for the isolation of Bordetella. J Clin Microbiol. 1977;6(3):303-9. doi:10.1128/jcm.6.3.303-309.1977. PMID 198430
- Reibel F, Cambau E, Aubry A. Update on the epidemiology, diagnosis, and treatment of leprosy. Med Mal Infect. 2015;45(9):383–393. doi:10.1016/j.medmal.2015.09.002. PMID 26428602
- Ren J, Xia J, Zhang M, et al. Automated identification of Salmonella serotype using MALDI-TOF mass spectrometry and machine learning techniques. J Clin Microbiol. 2025;63(7):e0003725. doi:10.1128/jcm.00037-25. PMID 40497731
- Rhoads DD, Pournaras S, Leber A, et al. Multicenter Evaluation of the BIOFIRE Blood Culture Identification 2 Panel for Detection of Bacteria, Yeasts, and Antimicrobial Resistance Genes in Positive Blood Culture Samples. J Clin Microbiol. 2023;61(6):e0189122. doi:10.1128/jcm.01891-22. PMID 37227281
- Richter SS, Dominguez EL, Hupp AA, et al. Evaluation of MicroScan and VITEK 2 systems for susceptibility testing of Enterobacterales with updated breakpoints. J Clin Microbiol. 2025;63(6):e0004825. doi:10.1128/jcm.00048-25. PMID 40304515
- Robinne S, Saad J, Morsli M, et al. Rapid Identification of Mycobacterium tuberculosis Complex Using Mass Spectrometry: A Proof of Concept. Front Microbiol. 2022;13:753969. doi:10.3389/fmicb.2022.753969. PMID 35432257
- Rouphael NG, Stephens DS. Neisseria meningitidis: biology, microbiology, and epidemiology. Methods Mol Biol. 2012;799:1–20. doi:10.1007/978-1-61779-346-2_1. PMID 21993636
- Rubio M, March F, Garrigó M, Moreno C, Español M, Coll P. Inducible and Acquired Clarithromycin Resistance in the Mycobacterium abscessus Complex. PLoS One. 2015;10(10):e0140166. doi:10.1371/journal.pone.0140166. PMID 26448181
- Rudrik JT, Soehnlen MK, Perry MJ, et al. Safety and Accuracy of Matrix-Assisted Laser Desorption Ionization-Time of Flight Mass Spectrometry for Identification of Highly Pathogenic Organisms. J Clin Microbiol. 2017;55(12):3513-3529. doi:10.1128/JCM.01023-17. PMID 29021156
- Rupp ME, Cavalieri RJ, Marolf C, et al. Reduction in Blood Culture Contamination Through Use of Initial Specimen Diversion Device. Clin Infect Dis. 2017;65(2):201-205. doi:10.1093/cid/cix304. PMID 28379370
- Russo TA, Marr CM. Hypervirulent Klebsiella pneumoniae. Clin Microbiol Rev. 2019;32(3):e00001-19. doi:10.1128/CMR.00001-19. PMID 31092506
- Saiki RK, Gelfand DH, Stoffel S, et al. Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. Science. 1988;239(4839):487-91. doi:10.1126/science.2448875. PMID 2448875
- Saiman L, Waters V, LiPuma JJ, et al. Practical Guidance for Clinical Microbiology Laboratories: Updated guidance for processing respiratory tract samples from people with cystic fibrosis. Clin Microbiol Rev. 2024;37(3):e0021521. doi:10.1128/cmr.00215-21. PMID 39158301
- Salminen MK, Rautelin H, Tynkkynen S, et al. Lactobacillus bacteremia, clinical significance, and patient outcome, with special focus on probiotic L. rhamnosus GG. Clin Infect Dis. 2004;38(1):62–69. doi:10.1086/380455. PMID 14679449
- Samuel LP, Balada-Llasat JM, Harrington A, et al. Multicenter Assessment of Gram Stain Error Rates. J Clin Microbiol. 2016;54(6):1442-1447. doi:10.1128/JCM.03066-15. PMID 26888900
- Sánchez D, Ferrer J, Giménez E, et al. Genotypic study of Chlamydia trachomatis for lymphogranuloma venereum diagnosis in rectal specimens from men who have sex with men: a cost-effectiveness analysis. BMC Infect Dis. 2024;24(1):298. doi:10.1186/s12879-024-09185-4. PMID 38454329
- Satlin MJ, Lewis JS, Weinstein MP, et al. Clinical and Laboratory Standards Institute and European Committee on Antimicrobial Susceptibility Testing Position Statements on Polymyxin B and Colistin Clinical Breakpoints. Clin Infect Dis. 2020;71(9):e523-e529. doi:10.1093/cid/ciaa121. PMID 32052041 (Satlin 2020b)
- Satlin MJ, Nicolau DP, Humphries RM, et al. Development of Daptomycin Susceptibility Breakpoints for Enterococcus faecium and Revision of the Breakpoints for Other Enterococcal Species by the Clinical and Laboratory Standards Institute. Clin Infect Dis. 2020;70(6):1240-1246. doi:10.1093/cid/ciz845. PMID 31504338 (Satlin 2020a)
- Saubolle MA, Kiehn TE, White MH, Rudinsky MF, Armstrong D. Mycobacterium haemophilum: microbiology and expanding clinical and geographic spectra of disease in humans. Clin Microbiol Rev. 1996;9(4):435–447. doi:10.1128/CMR.9.4.435. PMID 8894345
- Sautter RL, Parrott JS, Nachamkin I, et al. American Society for Microbiology evidence-based laboratory medicine practice guidelines to reduce blood culture contamination rates: a systematic review and meta-analysis. Clin Microbiol Rev. 2024;37(4):e0008724. doi:10.1128/cmr.00087-24. PMID 39495314
- Savini V, Fazii P, Favaro M, et al. Tuberculosis-like pneumonias by the aerobic actinomycetes Rhodococcus, Tsukamurella and Gordonia. Microbes Infect. 2012;14(5):401–410. doi:10.1016/j.micinf.2011.11.014. PMID 22192786
- Sayad E, Zeid CA, Hajjar RE, et al. The burden of Arcanobacterium haemolyticum pharyngitis: A systematic review and management algorithm. Int J Pediatr Otorhinolaryngol. 2021;146:110759. doi:10.1016/j.ijporl.2021.110759. PMID 34038812
- Schaffer JN, Pearson MM. Proteus mirabilis and Urinary Tract Infections. Microbiol Spectr. 2015;3(5). doi:10.1128/microbiolspec.UTI-0017-2013. PMID 26542036
- Schiemann DA. Synthesis of a selective agar medium for Yersinia enterocolitica. Can J Microbiol. 1979;25(11):1298-1304. doi:10.1139/m79-205. PMID 540256
- Scholte JB, van Dessel HA, Linssen CF, et al. Endotracheal aspirate and bronchoalveolar lavage fluid analysis: interchangeable diagnostic modalities in suspected ventilator-associated pneumonia? J Clin Microbiol. 2014;52(10):3597-604. doi:10.1128/JCM.01494-14. PMID 25078907
- Schuetz AN, Ferrell A, Hindler JA, et al. Overview of changes in the Clinical and Laboratory Standards Institute Performance Standards for Antimicrobial Susceptibility Testing: M100 32nd and 33rd editions. J Clin Microbiol. 2025;63(9):e0162323. doi:10.1128/jcm.01623-23. PMID 40772786
- Scorpio A, Zhang Y. Mutations in pncA, a gene encoding pyrazinamidase/nicotinamidase, cause resistance to the antituberculous drug pyrazinamide in tubercle bacillus. Nat Med. 1996;2(6):662–667. doi:10.1038/nm0696-662. PMID 8640557
- Scott TA, Baker KS, Trotter C, et al. Shigella sonnei: epidemiology, evolution, pathogenesis, resistance and host interactions. Nat Rev Microbiol. 2025;23(5):303–317. doi:10.1038/s41579-024-01126-x. PMID 39604656
- Sejvar JJ, Johnson D, Popovic T, et al. Assessing the risk of laboratory-acquired meningococcal disease. J Clin Microbiol. 2005;43(9):4811–4814. doi:10.1128/JCM.43.9.4811-4814.2005. PMID 16145146
- Set R, Shastri J. Laboratory aspects of clinically significant rapidly growing mycobacteria. Indian J Med Microbiol. 2011;29(4):343–352. doi:10.4103/0255-0857.90157. PMID 22120792 (Set 2011)
- Seyler L, Lalvani A, Collins L, et al. Safety and cost savings of an improved three-day rule for stool culture in hospitalised children and adults. J Hosp Infect. 2007;67(2):121-6. doi:10.1016/j.jhin.2007.07.010. PMID 17900758
- Sfeir MM, Hayden JA, Fauntleroy KA, et al. EDTA-Modified Carbapenem Inactivation Method: a Phenotypic Method for Detecting Metallo-β-Lactamase-Producing Enterobacteriaceae. J Clin Microbiol. 2019;57(5):e01757-18. doi:10.1128/JCM.01757-18. PMID 30867235
- Shahrizaila N, Lehmann HC, Kuwabara S. Guillain-Barré syndrome. Lancet. 2021;397(10280):1214–1228. doi:10.1016/S0140-6736(21)00517-1. PMID 33647239
- Sharma S, Acharya J, Banjara MR, et al. Comparison of acridine orange fluorescent microscopy and gram stain light microscopy for the rapid detection of bacteria in cerebrospinal fluid. BMC Res Notes. 2020;13(1):29. doi:10.1186/s13104-020-4895-7. PMID 31931859
- Shulman ST, Bisno AL, Clegg HW, et al. Clinical practice guideline for the diagnosis and management of group A streptococcal pharyngitis: 2012 update by the Infectious Diseases Society of America. Clin Infect Dis. 2012;55(10):e86–e102. doi:10.1093/cid/cis629. PMID 22965026
- Siddig EE, van de Sande WWJ, Fahal AH. Actinomycetoma laboratory-based diagnosis: a mini-review. Trans R Soc Trop Med Hyg. 2021;115(4):355–363. doi:10.1093/trstmh/traa176. PMID 33449118
- Siddiqi SH, Stauffer JC, Ali MA, Khan MA, Rahman A. Some bacteriologic aspects of the epidemiology of pulmonary and extrapulmonary tuberculosis. Am J Epidemiol. 1976;103(1):101–111. doi:10.1093/oxfordjournals.aje.a112198. PMID 1247006
- Sierra-Hoffman M, Watkins K, Jinadatha C, Fader R, Carpenter JL. Clinical significance of Aerococcus urinae: a retrospective review. Diagn Microbiol Infect Dis. 2005;53(4):289–292. doi:10.1016/j.diagmicrobio.2005.06.021. PMID 16269223
- Singh S, Kumar M, Singh P. Evolution of M. bovis BCG Vaccine: Is Niacin Production Still a Valid Biomarker? Tuberc Res Treat. 2015;2015:957519. doi:10.1155/2015/957519. PMID 25694828
- Smits WK, Lyras D, Lacy DB, Wilcox MH, Kuijper EJ. Clostridium difficile infection. Nat Rev Dis Primers. 2016;2:16020. doi:10.1038/nrdp.2016.20. PMID 27158839
- Snydman DR, Jacobus NV, McDermott LA, et al. Update on resistance of Bacteroides fragilis group and related species with special attention to carbapenems 2006–2009. Anaerobe. 2011;17(4):147–151. doi:10.1016/j.anaerobe.2011.05.014. PMID 21664469
- Soeters HM, Blain A, Pondo T, et al. Current Epidemiology and Trends in Invasive Haemophilus influenzae Disease: United States, 2009–2015. Clin Infect Dis. 2018;67(6):881–889. doi:10.1093/cid/ciy187. PMID 29509834
- Spaulding AB, Lai YL, Zelazny AM, et al. Geographic Distribution of Nontuberculous Mycobacterial Species Identified among Clinical Isolates in the United States, 2009–2013. Ann Am Thorac Soc. 2017;14(11):1655–1661. doi:10.1513/AnnalsATS.201611-860OC. PMID 28817307
- Spencer RC. Bacillus anthracis. J Clin Pathol. 2003;56(3):182–187. doi:10.1136/jcp.56.3.182. PMID 12610093
- Srinivasan S, Morgan MT, Liu C, et al. More than meets the eye: associations of vaginal bacteria with gram stain morphotypes using molecular phylogenetic analysis. PLoS One. 2013;8(10):e78633. doi:10.1371/journal.pone.0078633. PMID 24302980
- Stabler S, Titécat M, Duployez C, et al. Clinical relevance of Clostridium bacteremia: An 8-year retrospective study. Anaerobe. 2020;63:102202. doi:10.1016/j.anaerobe.2020.102202. PMID 32247000
- Steingart KR, Henry M, Ng V, et al. Fluorescence versus conventional sputum smear microscopy for tuberculosis: a systematic review. Lancet Infect Dis. 2006;6(9):570-81. doi:10.1016/S1473-3099(06)70578-3. PMID 16931408
- Steingart KR, Ng V, Henry M, et al. Sputum processing methods to improve the sensitivity of smear microscopy for tuberculosis: a systematic review. Lancet Infect Dis. 2006;6(10):664–674. doi:10.1016/S1473-3099(06)70602-8. PMID 17008175 (Steingart 2006b)
- Tamma PD, Bonomo RA, Heil EL, et al. Infectious Diseases Society of America 2026 Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections. Clin Infect Dis. 2026;:ciag481. doi:10.1093/cid/ciag481. PMID 42570093
- Tamma PD, Harris PNA, Mathers AJ, et al. Breaking Down the Breakpoints: Rationale for the 2022 Clinical and Laboratory Standards Institute Revised Piperacillin-Tazobactam Breakpoints Against Enterobacterales. Clin Infect Dis. 2023;77(11):1585-1590. doi:10.1093/cid/ciac688. PMID 36001445 (Tamma 2023a)
- Tamma PD, Harris PNA, Mathers AJ, et al. Deconstructing the 2023 Clinical and Laboratory Standards Institute Revised Piperacillin-Tazobactam Breakpoints Against Pseudomonas aeruginosa. Clin Infect Dis. 2023;76(10):1868-1870. doi:10.1093/cid/ciad012. PMID 36625154 (Tamma 2023b)
- Tamma PD, Heil EL, Justo JA, et al. Infectious Diseases Society of America 2024 Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections. Clin Infect Dis. 2024;:ciae403. doi:10.1093/cid/ciae403. PMID 39108079
- Taylor WI, Schelhart D. Isolation of Shigellae. 8. Comparison of xylose lysine deoxycholate agar, hektoen enteric agar, Salmonella-Shigella agar, and eosin methylene blue agar with stool specimens. Appl Microbiol. 1971;21(1):32-7. doi:10.1128/am.21.1.32-37.1971. PMID 5540672
- Tebbutt GM. Evaluation of some methods for the laboratory identification of Haemophilus influenzae. J Clin Pathol. 1983;36(9):991-5. doi:10.1136/jcp.36.9.991. PMID 6411774
- Tebruegge M, Curtis N. Mycobacterium marinum infection. Adv Exp Med Biol. 2011;719:201–210. doi:10.1007/978-1-4614-0204-6_17. PMID 22125046
- Thayer JD, Martin JE Jr. Improved medium selective for cultivation of N. gonorrhoeae and N. meningitidis. Public Health Rep (1896). 1966;81(6):559-62. PMID 4957043
- Thornton CG, MacLellan KM, Brink TL, Passen S. In vitro comparison of NALC-NaOH, Tween 80, and C18-carboxypropylbetaine for processing of specimens for recovery of mycobacteria. J Clin Microbiol. 1998;36(12):3558–3566. doi:10.1128/JCM.36.12.3558-3566.1998. PMID 9817873
- Tickler IA, Goering RV, Tenover FC. History and Evolution of the Hypervirulent Clostridioides difficile Ribotype 027 Lineage. Microorganisms. 2025;13(10):2376. doi:10.3390/microorganisms13102376. PMID 41156837
- Timbrook TT, Morton JB, McConeghy KW, et al. The Effect of Molecular Rapid Diagnostic Testing on Clinical Outcomes in Bloodstream Infections: A Systematic Review and Meta-analysis. Clin Infect Dis. 2017;64(1):15-23. doi:10.1093/cid/ciw649. PMID 27678085
- Tissot Dupont H, Raoult D, Brouqui P, et al. Epidemiologic features and clinical presentation of acute Q fever in hospitalized patients: 323 French cases. Am J Med. 1992;93(4):427–434. doi:10.1016/0002-9343(92)90173-9. PMID 1415306
- Tomioka H. Bacteriology of mycobacteria: taxonomic and morphological characteristics. Nihon Rinsho. 1998;56(12):3001–3007. PMID 9883600
- Tong SY, Davis JS, Eichenberger E, Holland TL, Fowler VG. Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management. Clin Microbiol Rev. 2015;28(3):603–661. doi:10.1128/CMR.00134-14. PMID 26016486
- Tortoli E. Microbiological features and clinical relevance of new species of the genus Mycobacterium. Clin Microbiol Rev. 2014;27(4):727–752. doi:10.1128/CMR.00035-14. PMID 25278573
- Trampuz A, Piper KE, Jacobson MJ, et al. Sonication of removed hip and knee prostheses for diagnosis of infection. N Engl J Med. 2007;357(7):654-63. doi:10.1056/NEJMoa061588. PMID 17699815
- Transport Canada. Shipping infectious substances. Date modified September 25, 2026. https://tc.canada.ca/en/dangerous-goods/shipping-infectious-substances (accessed November 10, 2026) (Transport Canada 2026)
- Tristram S, Jacobs MR, Appelbaum PC. Antimicrobial resistance in Haemophilus influenzae. Clin Microbiol Rev. 2007;20(2):368-89. doi:10.1128/CMR.00040-06. PMID 17428889
- Tron K, Cullerton C, Lupton J, et al. Four-day versus five-day blood culture incubation: a prospective study of diagnostic performance using the bioMérieux BACT/ALERT VIRTUO system. BMC Infect Dis. 2026;26(1):1745. doi:10.1186/s12879-026-13933-z. PMID 42414912
- Turenne CY. Nontuberculous mycobacteria: insights on taxonomy and evolution. Infect Genet Evol. 2019;72:159–168. doi:10.1016/j.meegid.2019.01.017. PMID 30654178
- Uhde KB, Pathak S, McCullum I, et al. Antimicrobial-resistant Nocardia isolates, United States, 1995–2004. Clin Infect Dis. 2010;51(12):1445–1448. doi:10.1086/657399. PMID 21058914
- Usuda D, Tanaka R, Suzuki M, et al. Obligate aerobic, gram-positive, weak acid-fast, nonmotile bacilli, Tsukamurella tyrosinosolvens: Minireview of a rare opportunistic pathogen. World J Clin Cases. 2022;10(24):8443–8449. doi:10.12998/wjcc.v10.i24.8443. PMID 36157836
- Valente M, Bramugy J, Keddie SH, et al. Diagnosis of human leptospirosis: systematic review and meta-analysis of the diagnostic accuracy of the Leptospira microscopic agglutination test, PCR targeting Lfb1, and IgM ELISA to Leptospira fainei serovar Hurstbridge. BMC Infect Dis. 2024;24(1):168. doi:10.1186/s12879-023-08935-0. PMID 38326762
- Valour F, Sénéchal A, Dupieux C, et al. Actinomycosis: etiology, clinical features, diagnosis, treatment, and management. Infect Drug Resist. 2014;7:183–197. doi:10.2147/IDR.S39601. PMID 25045274
- van den Beld MJC, Rossen JWA, Evers N, et al. MALDI-TOF MS Using a Custom-Made Database, Biomarker Assignment, or Mathematical Classifiers Does Not Differentiate Shigella spp. and Escherichia coli. Microorganisms. 2022;10(2):435. doi:10.3390/microorganisms10020435. PMID 35208889
- Vay C, Cittadini R, Barberis C, et al. Antimicrobial susceptibility of non-enterococcal intrinsic glycopeptide-resistant Gram-positive organisms. Diagn Microbiol Infect Dis. 2007;57(2):183–188. doi:10.1016/j.diagmicrobio.2006.08.014. PMID 17049799
- Verani JR, McGee L, Schrag SJ. Prevention of perinatal group B streptococcal disease: revised guidelines from CDC, 2010. MMWR Recomm Rep. 2010;59(RR-10):1–36. PMID 21088663
- Verduin CM, Hol C, Fleer A, van Dijk H, van Belkum A. Moraxella catarrhalis: from emerging to established pathogen. Clin Microbiol Rev. 2002;15(1):125–144. doi:10.1128/CMR.15.1.125-144.2002. PMID 11781271
- Vila A, Pagella H, Vera Bello G, et al. Brucella suis bacteremia misidentified as Ochrobactrum anthropi by the VITEK 2 system. J Infect Dev Ctries. 2016;10(4):432-6. doi:10.3855/jidc.7532. PMID 27131010
- Wagar E. Bioterrorism and the Role of the Clinical Microbiology Laboratory. Clin Microbiol Rev. 2016;29(1):175-89. doi:10.1128/CMR.00033-15. PMID 26656673
- Wagar EA, Mitchell MJ, Carroll KC, et al. A review of sentinel laboratory performance: identification and notification of bioterrorism agents. Arch Pathol Lab Med. 2010;134(10):1490–1503. doi:10.5858/2010-0098-CP.1. PMID 20923306
- Walsh TR, MacGowan AP, Bennett PM. Sequence analysis and enzyme kinetics of the L2 serine beta-lactamase from Stenotrophomonas maltophilia. Antimicrob Agents Chemother. 1997;41(7):1460-1464. doi:10.1128/AAC.41.7.1460. PMID 9210666
- Walters MS, Eggers P, Albrecht V, et al. Vancomycin-Resistant Staphylococcus aureus - Delaware, 2015. MMWR Morb Mortal Wkly Rep. 2015;64(37):1056. doi:10.15585/mmwr.mm6437a6. PMID 26402026
- Wang K, Tian J, Wu T, et al. Evaluation of eravacycline susceptibility testing by MIC test strip and disk diffusion against broth microdilution in carbapenem-resistant Enterobacterales. Front Cell Infect Microbiol. 2026;16:1932734. doi:10.3389/fcimb.2026.1932734. PMID 42827677
- Wang Q, Chang BJ, Riley TV. Erysipelothrix rhusiopathiae. Vet Microbiol. 2010;140(3–4):405–417. doi:10.1016/j.vetmic.2009.08.012. PMID 19733019
- Watthanaworawit W, Roberts T, Hopkins J, et al. A multi-country study using MALDI-TOF mass spectrometry for rapid identification of Burkholderia pseudomallei. BMC Microbiol. 2021;21(1):213. doi:10.1186/s12866-021-02276-1. PMID 34266382
- Weinstein MP, Klugman KP, Jones RN. Rationale for revised penicillin susceptibility breakpoints versus Streptococcus pneumoniae: coping with antimicrobial susceptibility in an era of resistance. Clin Infect Dis. 2009;48(11):1596-600. doi:10.1086/598975. PMID 19400744
- Weinstein MP, Towns ML, Quartey SM, et al. The clinical significance of positive blood cultures in the 1990s: a prospective comprehensive evaluation of the microbiology, epidemiology, and outcome of bacteremia and fungemia in adults. Clin Infect Dis. 1997;24(4):584-602. doi:10.1093/clind/24.4.584. PMID 9145732
- West PA, Russek E, Brayton PR, et al. Statistical evaluation of a quality control method for isolation of pathogenic Vibrio species on selected thiosulfate-citrate-bile salts-sucrose agars. J Clin Microbiol. 1982;16(6):1110-6. doi:10.1128/jcm.16.6.1110-1116.1982. PMID 6761362
- Wexler HM. Bacteroides: the good, the bad, and the nitty-gritty. Clin Microbiol Rev. 2007;20(4):593–621. doi:10.1128/CMR.00008-07. PMID 17934076
- Wilson MR, Sample HA, Zorn KC, et al. Clinical Metagenomic Sequencing for Diagnosis of Meningitis and Encephalitis. N Engl J Med. 2019;380(24):2327-2340. doi:10.1056/NEJMoa1803396. PMID 31189036
- Wong LK, Barry AL, Horgan SM. Comparison of six different criteria for judging the acceptability of sputum specimens. J Clin Microbiol. 1982;16(4):627-631. doi:10.1128/jcm.16.4.627-631.1982. PMID 7153311
- Workowski KA, Bachmann LH, Chan PA, et al. Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recomm Rep. 2021;70(4):1-187. doi:10.15585/mmwr.rr7004a1. PMID 34292926
- World Health Organization. WHO consolidated guidelines on tuberculosis. Module 3: diagnosis: rapid diagnostics for tuberculosis detection. 3rd ed. March 20, 2024. https://www.who.int/publications/i/item/9789240089488 (accessed November 10, 2026) (WHO 2024)
- Xie O, Davies MR, Tong SYC. Streptococcus dysgalactiae subsp. equisimilis infection and its intersection with Streptococcus pyogenes. Clin Microbiol Rev. 2024;37(3):e0017523. doi:10.1128/cmr.00175-23. PMID 38856686
- Yang Z, Liu W, Cui Q, et al. Prevalence and detection of Stenotrophomonas maltophilia carrying metallo-β-lactamase blaL1 in Beijing, China. Front Microbiol. 2014;5:692. doi:10.3389/fmicb.2014.00692. PMID 25538701
- Yasuo S, Murata M, Nakagawa N, et al. Diagnostic accuracy of urinary antigen tests for pneumococcal pneumonia among patients with acute respiratory failure suspected pneumonia: a systematic review and meta-analysis. BMJ Open. 2022;12(8):e057216. doi:10.1136/bmjopen-2021-057216. PMID 35953247
- Yigit H, Queenan AM, Anderson GJ, et al. Novel carbapenem-hydrolyzing beta-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae. Antimicrob Agents Chemother. 2001;45(4):1151-61. doi:10.1128/AAC.45.4.1151-1161.2001. PMID 11257029
- Yokoyama K, Okamoto A, Ohkusu M, et al. False-Positive Detection of Haemophilus influenzae by a Multiplex PCR Panel in a Neonate With Late-Onset Group B Streptococcal Bacteremia. Cureus. 2025;17(6):e86997. doi:10.7759/cureus.86997. PMID 40746816
- Yong D, Toleman MA, Giske CG, et al. Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India. Antimicrob Agents Chemother. 2009;53(12):5046-54. doi:10.1128/AAC.00774-09. PMID 19770275
- Zajkowska J, Król M, Falkowski D, Syed N, Kamieńska A. Capnocytophaga canimorsus: an underestimated danger after dog or cat bite: review of literature. Przegl Epidemiol. 2016;70(2):289–295. PMID 27837588
- Zhang L, Zong ZY, Liu YB, Ye H, Lv XJ. PCR versus serology for diagnosing Mycoplasma pneumoniae infection: a systematic review and meta-analysis. Indian J Med Res. 2011;134(3):270–280. PMID 21985809
- Zykov MP, Roulet H, Gaya N. Non-tuberculosis mycobacteria in Africa. 1. Isolation and identification. Bull World Health Organ. 1967;37(6):927–938. PMID 4872712